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1 INTRODUCTION 1 
1 Introduction 
1.1 Physiologic significance of Dopamine, Norepinephrine, and Serotonin 
The biogenic monoamines dopamine (DA), norepinephrine (NE), and serotonin (5-HT) are 
important neurotransmitters (Figure 1) which act in the human brain as well as in the periphery. 
 
Figure 1: Structures of dopamine, norepinephrine, and serotonin. 
However, this thesis will focus on the respective neural distribution and the functions of each 
of these monoamines (i.e. dopamine, norepinephrine, and serotonin): 
- Dopaminergic neurons are most abundant in the corpus striatum, but high 
concentrations can also be found in frontal cortex, limbic system, and hypothalamus. 
Due to the distribution of the dopaminergic neurons in mammalian brain different 
functions arise from dopamine neurotransmission.[1] Dopamine not only influences 
coordination of movements, cognitive functions (i.e. attention, learning, work memory, 
decision making, etc.), sexual and eating behavior, it is also responsible for the human 
reward system and as a consequence for addictive behavior.[2] 
- The highest concentration of norepinephrine neurons can be found in the locus 
coeruleus, which is located in the pons. It is also present in other parts of the brain, e.g. 
cortex, hippocampus, thalamus, hypothalamus, and cerebellum. The activation of the 
human fight-or-flight response induces a release of norepinephrine. It therefore 
increases vigilance, wakefulness, and attention. Next to these excitatory effects an 
activation of the respective adrenoreceptors, i.e. α1 receptors, norepinephrine is 
thought to be involved in motor activity, cognition, and anxiety.[1] 
- The serotonergic neurons are widespread in central nervous system (CNS), i.e. raphe 
nuclei, cortex, hippocampus, basal ganglia, limbic system, hypothalamus, cerebellum, 
medulla, and spinal cord.[1] Serotonin overlaps in its action with the previously 
described monoamines, e.g. regulation of eating and sexual behavior (DA), and anxiety 
(NE). Additionally, serotonin has specific functions, i.e. it controls aggression and 
impulse, sensory functions, and induces sleep.[1, 3] 
Figure 2 depicts neuronal functions of the aforementioned monoaminergic systems and also 
illustrates that dopamine, norepinephrine, and serotonin neurotransmitter systems have a 
common influence on mood. 
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Figure 2: Neuronal actions of the dopaminergic, noradrenergic, and serotonergic neurotransmitter systems 
(adopted from Guiard [4]). 
1.1.1 Neurotransmission 
To fulfill the described functions in mammalian CNS, the neurons responsible receive and 
transmit signals via a process called neurotransmission, which will be briefly explained below. 
After their biosynthesis, dopamine, norepinephrine, and serotonin are transported into vesicles 
via vesicular monoamine transporters (VMAT and VMAT2). The storage of the transmitters 
and the simultaneous increase in concentration has two reasons: first, the described 
monoamines are protected from degradation in cytosol, and secondly, a fast release of a high 
concentration is enabled (Figure 3, step 1).[5] The neurotransmitter release takes place in 
response of an arriving action potential in the nerve terminal and the associated influx of 
calcium ions at the terminal neuron. The resulting high intracellular concentration of calcium 
causes the vesicles to undergo an exocytosis with the plasma membrane releasing the stored 
monoamines (i.e. dopamine, norepinephrine, or serotonin) into the synaptic cleft (Figure 3, 
step 2). After their release into the synaptic cleft the neurotransmitters can bind to their 
respective receptors at the postsynaptic neuron which initiates a signal in this neuron (Figure 
3, step 3a). Two different types of monoamine neurotransmitter (i.e. dopamine, 
norepinephrine, and serotonin) receptors can be distinguished: 
- With one exception, all of these receptors belong to the family of G protein coupled 
receptors (GPCRs) which activate intracellular G proteins in response to ligand binding. 
These G proteins can then stimulate or inhibit two different intracellular signal 
pathways, i.e. the cyclic adenosine monophosphate (cAMP) and the 
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phosphatidylinositol signal pathway. Depending on the activated G protein, inhibitory 
as well as excitatory reactions in CNS are triggered. 
- Only one serotonin receptor, i.e. 5-HT3, is a ligand-gated sodium potassium cation 
channel, which upon activation leads to an excitatory response in neurons.  
Next to these postsynaptic receptors, some presynaptic receptors also exist, called 
autoreceptors which reduce a further release of DA, NE, and 5-HT via a negative feedback 
mechanism (Figure 3, step 3b).[6-9] But even if the further release is inhibited, the 
neurotransmitters released in the synaptic cleft have to be removed from the synaptic cleft 
either by enzymatic degradation or by reuptake to terminate the neurotransmitter signal. For 
the three monoaminergic neurotransmitters discussed here presynaptic transporters (see 
below, 1.2 Monoamine Transporters) which transport the monoamines back in the respective 
neurons (Figure 3, step 4) exist where they are stored again in the vesicles and can be reused 
later (Figure 3, step 5). 
 
Figure 3: Monoaminergic neurotransmission. Monoamines (i.e. dopamine, norepinephrine, and serotonin) are 
stored in vesicles (1) and released in response to an action potential (2). In the synaptic cleft, the released 
monoamines can interact with postsynaptic receptors (3a) and therefore transmit the signal to the next neuron, or 
activate presynaptic autoreceptors (3b), which inhibit a further neurotransmitter release (2). Presynaptic 
transporters terminate signals via transporting the monoamines back into the neurons (4), where the transported 
monoamines can be stored again in the vesicles (5). 
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1.1.2 Pathology and Therapy 
The physiological roles described above indicate that the monoamine neurotransmitter 
systems consisting of dopamine, norepinephrine, and serotonin (see 1.1 Physiological 
significance of Dopamine, Norepinephrine, and Serotonin) are associated with a series of 
mental disorders, such as depression, schizophrenia, obsessive-compulsive disorders, etc. 
This hypothesis was strengthened when in the 1950s and 1960s several links between clinical 
side effects of various drugs, namely an alleviation (e.g. iproniazid in treatment of tuberculosis) 
or induction (e.g. reserpine in treatment of hypertension) of symptoms of affective disorders, 
associated with the monoaminergic systems, were observed.[10] As a consequence, the so 
called ‘catecholamine hypothesis of affective disorders’,[11] and the ‘serotonin hypothesis’ [12] 
were formed explaining that depressions are a result of a functional deficit of norepinephrine 
and serotonin. Dopamine is today also assumed to be an important factor in the regulation of 
mood.[4] 
An enhancement of the respective monoamine neurotransmitter systems is therefore an 
obvious therapeutic approach for the treatment of depressions. This enhancement can 
generally be realized following different strategies:  
- Inhibition of enzymes catalyzing the degradation of monoamines: 
Inhibitors of catechol-O-methyltransferase (COMT) (e.g. entacapone and tolcapone) 
are only used in the therapy of Parkinson’s disease, while inhibitors of the monoamine 
oxidase (MAO) (e.g. tranylcypromine, moclobemide, etc.) are used in treatment of both, 
Parkinson’s disease and depressions. Since they cause adverse side effects and 
serious interactions MAO-inhibitors play a minor role as antidepressants today.[1] 
- Regulation of respective autoreceptors: 
A different strategy is the direct inhibition of respective autoreceptors. By the inhibition 
of the negative feedback mechanism, a further monoamine release out of the neuron 
into the synaptic cleft is enabled. Next to the adrenergic autoreceptors other receptors 
can also be inhibited via antagonists (e.g. mirtazapine, mianserin).[1] This type of drug 
enhances mainly the noradrenergic and serotonergic neurotransmitter systems. 
- Inhibition of reuptake: 
The mainstay in treatment of depression today is the inhibition of the responsible 
transporters, i.e. dopamine transporters (DAT), norepinephrine transporters (NET), and 
serotonin transporters (SERT), to effect a longer residence time of the monoamines in 
the synaptic cleft.[13]  
Diverse drug classes, namely tricyclic antidepressants (TCAs) as well as selective and 
dual reuptake inhibitors can realize an inhibition of the corresponding transporters. 
TCAs (e.g. clomipramine, desipramine, imipramine, etc.) were the first generation of 
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antidepressants, whose use started in the 1950s. The inhibition of NET and SERT is 
assumed to be the main mechanism of action. Unfortunately, TCAs are ‘dirty drugs’ 
since they do not possess a selective pharmacological profile. They not only inhibit 
reuptake, they also antagonize various serotonin, histamine, and muscarinic 
acetylcholine receptors, causing various side effects. The result of these adverse 
effects combined with the risk of an overdose brought about a replacement of TCAs in 
therapy by newer, safer antidepressants.[1, 10] 
The next generation of drugs, the so called selective serotonin reuptake inhibitors 
(SSRIs) (e.g. citalopram, fluoxetine, sertraline, etc.), was introduced in the 1980s [14] 
and remains until now the most frequently prescribed class of antidepressants.[15] Due 
to their selective inhibition of SERT, they show an improved side effect profile combined 
with an efficiency comparable to that of the TCAs in the treatment of depression (except 
in the treatment of severe depression).[1] Nevertheless, selective norepinephrine 
reuptake inhibitors (NRI) (e.g. reboxetine, nisoxetine) were also developed. Their 
therapeutic efficiency showed a further improvement compared to the one of TCAs and 
SSRIs. For example, reboxetine has demonstrated its long-term safety and 
effectiveness in treatment of SSRI resistant melancholia and severe depressions.[16] 
As a next step in the development of new antidepressants, the mode of action of SSRIs 
with the one of NRIs was combined. The result are dual reuptake inhibitors (SNRIs) 
(e.g. duloxetine, venlafaxine) enhancing both monoaminergic systems, i.e. 
noradrenergic and serotonergic. This new class is characterized by a safety profile 
comparable to that of the SSRIs and shows an improved clinical benefit comprising 
faster onset of action, a broader range of indications, and a higher efficacy.[15] It is worth 
to note that an authorized dual reuptake inhibitor inhibiting DAT and NET (NDRI), 
bupropion, also exists as an alternative in treatment of major depressions. Bupropion 
is the first antidepressant, which exhibits a dopaminergic component, [17, 18] and is also 
used for smoking cessation. 
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1.2 Monoamine Transporters 
Thanks to their outstanding role in therapy of depressions, the monoamine transporters remain 
the most important target for the development of new antidepressants. Different aspects of the 
monoamine transporters have been investigated in the last decades. The knowledge 
discovered in these studies concerning function, regulation, and structure of these highly 
important targets is discussed in the following part. 
The neurotransmitter transporters (NTTs) including monoamine transporters, Ȗ-aminobutyric 
acid transporters, and glycine transporters, are part of the solute carrier 6 (SLC6) gene family. 
These NTTs are also called ‘neurotransmitter-sodium-symporters’ (NSSs) or 
Na+/Cl- dependent transporters.[19] As the names indicate, this group of transporters mainly 
works using a transmembrane sodium gradient for the transport of the respective substrates 
against the concentration gradient from synaptic cleft into the pre-synaptic neuron. The 
respective stoichiometry of the monoamine transport for each transporter as well as other 
characteristics, i.e. turnover rates of the different substrate molecules per second and their 
affinities, are shown in Table 1: At least one sodium and one chloride ion are co-transported 
with the respective substrate. In case of DAT, two sodium ions are involved in the transport 
process, whereas in case of SERT, in addition a counter transport of a potassium ion takes 
place.[20] Comparable results for all three monoamine transporters have been found regarding 
the velocity of the transport process, having a turnover rate of one to three substrate molecules 
per second. The affinities (shown as inhibition constant Ki) and substrate selectivities of the 
monoamines heavily depend on the targeted transporter. The only really selective transporter 
is SERT. This is not surprising considering the difference of the structure of the substrate 
serotonin, compared to the structures of dopamine and the related norepinephrine (Figure 1). 
However, it is noteworthy that dopamine shows a higher affinity towards NET than the native 
substrate norepinephrine (Table 1). This might be easily explained by the fact that NET is also 
responsible for dopamine clearance in the synaptic cleft, primarily in dopaminergic brain 
regions exhibiting only a minimal DAT expression for example in the frontal cortex.[21] 
Table 1: Characteristics of the monoamine transporters DAT, NET, and SERT 
transporter 
substrate affinity 
Ki [µmol L-1]a  turnover rate [molecules s-1]b 
 
substrate-ion 
stoichiometry 
(substrate : Na+ : Cl-)b DA NE 5-HT   
DAT 6.40 ± 0.59 57.0 ± 13.0 549 ± 96.0  0.7 – 1.9  1 : 2 : 1 
NET 28.0 ± 11.0 160 ± 33.0 360 ± 71.0  1.7 – 2.5  1 : 1 : 1 
SERT 1,110 ± 180 1,470 ± 110 3.5 ± 1.2  1.0 – 3.1  1 : 1 : 1 : (1 K+ out) 
a
 Eshleman et al., 1999 [22]. b Kirstensen et al., 2011 [20] 
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1.2.1 Crystal Structures 
Unfortunately, no crystal structures of the human monoamine transporters are available as the 
crystallization of membrane-associated proteins is very difficult. The analogous crystal 
structures of two homologues are however available: of a prokaryotic leucine transporter 
LeuT [23-28] and of a eukaryotic monoamine transporter of Drosophila melanogaster (dDAT).[29] 
They are discussed in the following section. 
LeuT: 
In 2005 Yamashita et al. published a crystal structure of the leucine transporter of the 
hyperthermophilic bacterium Aquifex aeolicus (LeuTAa, in the following denoted as LeuT), 
which is a prokaryotic homologue of the eukaryotic NSS.[23] This structure confirmed the earlier 
predicted 12 transmembrane segments (TMs) of the NSS members, but revealed an 
unprecedented C2 pseudo-symmetry in the LeuT topology, where the subset of TM1-5 can be 
superimposed on TM6-10 by a rotation of 176.5° (Figure 4).  
 
Figure 4: Topology of LeuT showing the 12 TMs, several loops, the N-, and C-terminus. Colored triangles (rose and 
light blue) illustrate the structural repetition of TM 1-5 and TM 6-10, which can be superimposed by a rotation of 
176.5°. Bound substrate (yellow triangle) and two bound sodium ions (blue circles) are located in the core of the 
protein (adopted from Yamashita et al.[23]). 
This X-ray analysis also showed that the co-crystallized substrate, L-leucine, is located in the 
core of LeuT in a cavity that is mainly formed by TM1, TM3, TM6, and TM8.[23] A later study 
examined additional binding of different TCAs (clomipramine, desipramine, and imipramine) in 
presence of the substrate in LeuT.[24] In these experiments, Singh et al. co-crystallized LeuT 
with its substrate, L-leucine, and different TCAs. The crystallographic analysis of the 
LeuT-leucine-TCA complexes obtained in this way revealed that the TCAs do not bind in the 
known substrate binding pocket in the core of the transporter (termed S1), which was still 
occupied by L-leucine, but directly above in a so called extracellular vestibule (later also 
denoted as S2) (see also Figure 5).[24] In line with that result, in competitive experiments was 
found that the TCA clomipramine could not significantly displace [3H]leucine bound to the LeuT, 
indicating a noncompetitive inhibition of LeuT by clomipramine.[24] 
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Figure 5: Binding site for clomipramine (yellow spheres in the upper part) and L-leucine (yellow spheres in the 
middle part of the structure) in LeuT (adopted from Singh et al.[24]). 
The discovery of the existence of a second binding site S2 and in particular its potential 
function, is still controversially discussed by different groups. In 2008 Shi et al. postulated that 
not only noncompetitive inhibitors but also a second leucine molecule can bind in S2. It was 
proposed that this second substrate molecule in S2 allosterically triggers the release of the 
first bound leucine molecule bound in S1 into the cytoplasm.[26] This hypothesis of Shi et al. 
started a lively controversy about the postulated function of S2 for the transport process in 
LeuT.[26] In 2010 Piscitelli et al. examined the stoichiometry in substrate binding experiments 
revealing only one and not two high-affinity binding sites for L-leucine. It was suggested instead 
that S2 is a low-affinity binding site to which a second substrate can bind transiently. This 
conclusion contradicted the previously postulated transport mechanism of Shi et al..[28] The 
latest publication about this topic showed that conditions chosen (i.e. the employed 
concentration of the detergent) for the preparation of LeuT have a crucial influence on 
substrate binding in S2, which in the aforementioned study of Piscitelli et al. [28] falsified the 
results of the of S2 site.[27] 
Even though the actual function of S2 is still unclear the results demonstrated that two binding 
sites (i.e. S1 and S2) exist in LeuT. If both can be occupied by substrate molecules or if S2 is 
only a binding site for inhibitors remains uncertain so far. The existence of this second binding 
site (i.e. S2) in LeuT might however serve as explanation for an allosteric modulation site in 
the mammalian monoamine transporters which was discovered in the late 1990s.[30] At this 
time it was discovered that the binding of various inhibitors can affect the dissociation kinetics 
of rDAT-, rNET-, and rSERT-marker complexes to higher but also to lower values. As a 
consequence the affinity of the employed marker substances towards the respective target 
can also be changed to higher or lower values (for further information regarding this kind of 
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experiment, see below 1.3.2.2 Kinetic Studies).[30] According to this theory the employed 
inhibitor binds to a different binding site than the marker substance, i.e. S1, and this additional 
binding of the inhibitor affects the S1 binding site of the marker.[30] Plenge et al. called the 
addressed protein structure, which is responsible for this effect in the monoamine transporters, 
affinity-modulating site.[30] Different groups have confirmed the existence and relevance of this 
second binding site until now.[30-34] Nevertheless, as long as no crystal structure of a 
monoamine transporter with co-crystallized inhibitors occupying both binding sites is available, 
it will remain uncertain, whether this modulation site is equivalent to the S2 binding site in LeuT. 
However, it can be clearly concluded that monoamine transporters also have two binding sites, 
which can be addressed by different inhibitors.  
 
dDAT: 
Even though a large number of homology models based on LeuT have been developed for the 
monoamine transporters and have been found to provide data in good accord with 
experimental results,[35-37] many questions still remained unanswered. The limitation of these 
models are the result of the fact that with 20 – 24 % the sequence identity of LeuT and the 
monoamine transporters is quite low,[38] although the identity of the amino acids in the 
surrounding of the aforementioned S1 binding site is much higher, i.e. 76% comparing LeuT 
with hSERT.[39] Due to the differences and the fact that LeuT is a prokaryotic homologue we 
still lack many facts required for a complete understanding of the mammalian NSSs, i.e. 
occurrence of substrate selectivity, posttranslational modifications, the mechanism of inhibition 
by bound inhibitors, etc..[29] The results of Penmatsa et al. in 2013 were therefore a highlight 
in monoamine transporter research as they represent the first example of the crystal structure 
of an eukaryotic monoamine transporter, the dopamine transporter of Drosophila 
melanogaster, dDAT.[29] dDAT is a promising tool for further homology models for the 
mammalian NSSs, as it has a high sequence identity of 65 % compared to hDAT and hNET. 
Additionally, it is a pharmacologic hybrid of hDAT and hNET. That means that dDAT shows a 
substrate selectivity and transport kinetics more similar to hDAT than hNET in uptake 
experiments, but at the same time the rank order of potency for nonsubstrate inhibitors was 
found to be distinctly more similar with the one found for hNET than for hDAT.[40] 
The currently unique crystal structure revealed some new aspects which improves our 
understanding of monoamine transporters: 
First of all, the crystal structure of dDAT is in excellent accordance with the structure published 
for LeuT (see Figure 6a), exhibiting the same topology including C2 pseudo-symmetry 
observed for the latter (see also Figure 4).[29]  
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The most important new finding regarding monoamine transporters derives however from the 
way the co-crystallized TCA molecule, namely nortriptyline, is bound in dDAT. This provides 
completely new insights into the mechanism of inhibition when compared to that of LeuT.[29] 
Unlike the structures of LeuT-inhibitor complexes (see above), nortriptyline is not bound in the 
extracellular vestibules (S2), but in a cavity equivalent to the substrate binding pocket S1 of 
LeuT mainly formed by TM1, TM3, TM6, and TM8 as shown in Figure 6b. It is probable that 
the binding of nortriptyline sterically prevents a spatial approach of TM1 and TM6 to TM3 and 
TM8, which is supposed to be crucial for the transport process. A stabilization of the transporter 
in a so-called outwards-open state, which prohibits the transport of substrate molecules, by 
TCAs is therefore assumed as mode of action of inhibitors for the monoamine transporters.[29] 
 
Figure 6: a) Superposition of dDAT (dark blue) with LeuT (salmon, bound to sodium, PDB code 3F3A) showing an 
excellent accordance between these two crystal structures. The bound TCA, nortriptyline, is labelled by a red circle. 
b) Surface representation of dDAT with a nortriptyline molecule bound in S1. TMs showing interactions with 
nortriptyline are colored as follows: TM1 (red), TM3 (orange), TM6 (green), and TM 8 (cyan). Nortriptyline is shown 
in magenta in the middle of the model (adopted from Penmatsa et al.[29]). 
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1.3 Screening Tools in Drug Discovery 
The development of new, effective drug substances such as antibiotics, chemotherapeutics, 
etc., is a decisive factor in medicinal advance. While older substances, e.g. penicillin, were 
often found by chance, today the drug discovery process is well-organized and target-oriented. 
A representative scheme is shown in Figure 7. 
 
Figure 7: Simplified scheme of modern drug discovery process highlighting the application areas of binding assays 
below the respective stages (adopted from Cooper [41]). 
After a target structure is identified and validated for inducing or affecting a pharmacologic 
effect, the next question is how we can influence, i.e. inhibit or activate, this target? To trigger 
such an effect, a mediator is necessary, e.g. small molecules or an increasing number of 
proteins are also used nowadays for this purpose. These mediators have to interact with the 
chosen target structure to affect them. The first and therefore most important step is to ensure 
that this substance binds to the target of interest. 
Since the 1970s so called binding studies could be performed employing radioactively labelled 
ligands, also known as radioligand binding assays (for further information see below, 
1.3.1 Radioligand Binding Assays vs MS Binding Assays).[42] Even though radioligand binding 
assays were and still are a powerful tool in the drug discovery process, great efforts were made 
to develop other methods characterizing target-ligand interactions. Most research focused on 
finding ways to avoid the use of radioactivity in equivalent assays. This objective was achieved 
using optical sensors, measuring changes in the properties of light (e.g. due to absorption or 
fluorescence), as read-out, instead of radioactivity. Some of these approaches for the 
investigation of target-ligand interactions, e.g. fluorescence resonance energy transfer (FRET) 
and fluorescence polarization (FP), also require labelling either of the target structure and/or 
of the ligand.[43] One light based, nonlabelled method called surface plasmon resonance (SPR) 
was also developed.[41] 
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Though a large variety of techniques for the investigation of target-ligand binding exists, each 
has its disadvantages. Labelling, as required for radioligand binding and fluorescence assays 
(i.e. FRET and FP), is time consuming and expensive. Additionally, labelling can affect the 
affinity of the ligand towards the target, especially when sterically demanding 
fluorescence-labels are employed.[43] Even the nonlabelled SPR technique has disadvantages 
including high costs [43] and the employed targets have to be purified, a process that can be 
quite challenging in the case of membrane-bound proteins, and immobilized.[44] 
For these reasons our group developed a new method termed MS Binding Assays which 
employs a nonlabelled ligand and allows the application of membranous targets, while, at the 
same time, allowing a reasonable throughput at low costs per sample.[45-47] 
 
1.3.1 Radioligand Binding Assays vs MS Binding Assays 
The following chapter focuses on MS Binding Assays comparing them with the long 
established radioligand binding assays. Similarities, differences, advantages, and 
disadvantages are also discussed. 
As already described above, radioligand binding assays employ a radioactively labelled ligand, 
also called radioligand or simply marker. The labelling of the ligand is necessary to enable a 
reliable quantification even of very low concentrations of the formed target-marker complexes. 
Radioactivity can be quantified with high sensitivity via scintillation counting, which means that 
even targets being available in low concentrations, such as membrane associated proteins, 
can be investigated.  
The general procedure for radioligand binding assays is depicted below (Figure 8): 
A radioactively labelled substance, which is known to bind to the target, is incubated with some 
material containing the target for a defined period of time, the length of which is dependent on 
the aim of the experiment performed (for further information, see below 1.3.2 Types of Ligand 
Binding Assays). Native material of the respective organs, whole cells, or membrane fragments 
as well as purified, soluble targets (if they can be immobilized) can be employed as source for 
the target. In order to be able to quantify the amount of radioligand bound to the target, the 
formed target-marker complexes have to be separated from the incubation mixture (i.e. free 
radioligand). This can be achieved via filtration or centrifugation. The last step of the assay is 
the quantification of the fraction of bound radioligand via scintillation counting.[48]  
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Figure 8: Performance of a radioligand binding assay. Radioligand (orange spheres with radioactivity sign) are 
incubated with a target (blue, in this case membrane associated proteins) and separated via filtration. Finally, bound 
radioligands are quantified via scintillation (red ellipse). 
Unfortunately, this radioligand binding assays are accompanied by serious disadvantages as 
a consequence of the labelling. Radioactivity is dangerous both to the environment and 
humans, and strict legal regulations have to be followed when holding, working, and disposing 
radioactive substances and the resulting contaminated waste. MS Binding Assays offer a 
promising substitute for radioligand binding assays. This was made possible by the progress 
concerning throughput, selectivity, and sensitivity of modern mass spectrometry in the last 
decades.[49] Radioactive labelling of the employed marker has therefore become dispensable.  
The main difference between MS Binding Assays and conventional radioligand binding assays 
is the principle employed for detection. Mass spectrometry is employed instead of scintillation 
measurements. Other parameters, such as incubation system, incubation time, temperature, 
material containing the target, etc., can be adopted from respective radioligand binding assays. 
Sometimes an additional sample preparation step can be necessary to remove, e.g. insoluble 
cell fragments, which can clog the employed high-performance liquid chromatography (HPLC) 
column or the electrospray ionization (ESI) needle, but would not affect scintillation counting. 
However, MS Binding Assays can substitute all types of experiments (see below, 1.3.2 Types 
of Ligand Binding Assays), which have been realized employing radioligand binding assays to 
date, and offer some additional advantages: 
First, due to the fact that no labelling of the marker is required for MS Binding Assays, every 
native compound is suitable as marker substance as long as it binds with an appropriate affinity 
towards the target. The number of appropriate, commercially available marker substances for 
the target of interest is therefore significantly higher than for radioligand binding assays. 
Secondly, mass spectrometry allows the simultaneous detection and quantification of several 
compounds in one sample due to the differing monitored mass transitions (i.e. masses of the 
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respective [M+H]+ parent ions and the resulting fragment ions). It is therefore possible to 
employ different selective ligands for several target structures in one pot and reliably quantify 
each individual marker substance in the presence of the other employed marker substances.  
1.3.2 Types of Ligand Binding Assays 
Binding studies can be subclassified in three different types of experiments, i.e. saturation, 
kinetic studies, and competitive experiments. Each delivers unique information about the 
binding behavior of a ligand towards a specific target. 
The general workflow of all three types is as follows: 
The ligand is incubated with the respective target. Depending on the information sought and 
as a consequence of the type of experiment to be performed, incubation is terminated after a 
defined time period via a separation step, which separates the bound from the free ligand (see 
also 1.3.1 Radioligand Binding Assay vs MS Binding Assay). The amount of bound ligand is 
then quantified using the corresponding detection principle, i.e. scintillation counting or mass 
spectrometry.  
The performance and the resulting information of the individual experiment types is presented 
in the following chapters. 
1.3.2.1 Saturation Experiments 
Saturation experiments are the most fundamental binding experiments. Here the binding of a 
ligand to a target is monitored by directly measuring the amount of ligand that binds to the 
target. From the data obtained a saturation curve can be established that allows the 
determination of the binding affinity of that ligand as well as the target concentration. 
For this purpose, increasing concentrations of the ligand are incubated with a constant 
concentration of the target for a period sufficient to reach equilibrium state. The target-marker 
complexes are then separated by filtration or centrifugation and the amount of bound ligand is 
quantified. This quantified fraction represents the so-called total binding of the ligand, which is 
sum of the actual binding of the ligand to the target, called specific binding, and the binding of 
the ligand towards other binding sites, i.e. other protein structures or filter material, which is 
called nonspecific binding.[48, 50, 51] However, for the calculation of the affinity (equilibrium 
dissociation constant Kd) as well as the maximum amount of binding sites (Bmax), the 
concentration of specifically bound marker has to be determined, which can only be calculated 
by subtracting the nonspecific binding from the total binding. Whereas total binding can be 
obtained as described above, nonspecific binding has to be determined in a separate 
experiment. The only difference between this experiment and the determination of total binding 
is the presence of another ligand addressing the target in a vast excess. This new ligand should 
occupy the same binding sites at the target as the marker does. The quantified, remaining 
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binding of the marker is therefore a result of nonspecific binding to other binding sites. In the 
next step, specific binding can be calculated and plotted vs the employed nominal marker 
concentration (Figure 9a and 9b). Based on the data points for specific binding a saturation 
isotherm can be created, which provides certain information: The plateau of the specific binding 
isotherm indicates the maximum number of binding sites, also called Bmax, and the nominal 
concentration that produces an occupancy of 50 % of all relevant binding sites, is equal to the 
equilibrium dissociation constant, the Kd-value (Figure 9b).[50, 52] 
 
Figure 9: Typical saturation experiment. a) Quantified concentrations of total binding (green) and nonspecific binding 
(orange) are plotted vs the employed nominal concentration of the marker. b) Specific binding (blue) (difference of 
the shown total and nonspecific binding) is also plotted vs the employed nominal concentration of the marker, via 
nonlinear regression a saturation isotherm (blue line) can be created from which Kd (red) and Bmax (grey) can be 
deduced.  
There are several rules for the performance of such saturation experiments: 
First, the employed nominal marker concentrations should cover a wide range around the 
assumed affinity (Kd-value), but at least from 0.1 Kd to 10 Kd. Secondly, the constant target 
amount for incubation should have a maximal concentration of 0.1 Kd.[52]  
The latter is necessary to avoid an effect called marker depletion. This effect occurs when the 
concentration of the bound marker becomes a significant fraction of the employed nominal 
concentration. Since the applied calculation models are based on the free, unbound marker, 
the actual employed nominal concentration of the marker can only be used as substitute for 
the free marker concentration, if no marker depletion occurs. Otherwise the use of the 
calculation models leads to erroneous Kd- and Bmax-values.[52] 
 
1.3.2.2 Kinetic Studies 
Kinetic studies provide information about the time course of formation of target-marker 
complexes and their dissociation. This information can e.g. be used to estimate the incubation 
time required to reach equilibrium state in saturation experiments. 
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Two types of kinetic experiments can be distinguished: association and dissociation 
experiments. Dissociation experiments are used for the determination of the dissociation rate 
constant (koff) and half life of the target-marker complex (t1/2). A prerequisite of this type of 
experiments is the existence of an appropriate number of complexes that enables a reliable 
quantification of the remaining, non-dissociated complexes during the experiment. In most 
cases this is ensured by a pre-incubation of a constant target concentration with a constant 
marker concentration. The time dependent dissociation of these complexes is then 
investigated. This dissociation can be initiated by two ways: Either hand, a second ligand is 
added in a vast excess (i.e. displacer), which occupies vacant binding sites of the target-marker 
complexes after dissociation and thus prevents re-association of the marker. Or the formed 
target-marker complexes can be diluted, at least by factor of 30.[34] This extensive dilution 
should ensure that during dissociation the concentration of the free marker is negligible for a 
re-association.[52] Whichever approach is used to initiate the dissociation process, the 
experiments are stopped after defined time intervals via separation. In this case commonly 
only filtration can be used, because a centrifugation step would require too much time and it 
would not be possible to realize short time increments. The remaining amount of target-marker 
complexes is then quantified and plotted vs the time (Figure 10a). The half life (t1/2) and 
dissociation rate constant (koff) of the target-marker complex can be calculated via nonlinear 
regression from the dissociation curve.  
In contrast to koff the corresponding association rate constant (kon) cannot be determined 
directly, because the association does not proceed alone. There is always a parallel, inevitable 
dissociation of the formed target-marker complexes. It is therefore only possible to determine 
the so called observed rate constant (kobs), which can be used for calculation of kon according 
to the equation: kobs = kon x L + koff.[52] As this equation makes clear, kobs is dependent on the 
concentration of the ligand (L). For the determination of very fast association rates (e.g. due to 
high incubation temperatures) a marker concentration as low as possible is therefore 
preferable, as this reduces kobs. As in dissociation studies, a constant target concentration is 
incubated with a constant, preferably low concentration of the marker, but in this case 
incubation is terminated after defined time intervals via a separation step and the already 
formed amount of target-marker complexes is quantified and plotted vs the time (Figure 10b). 
Based on these data points, the employed marker concentration, and the previously 
determined dissociation rate constant (koff), the desired value for kon can be calculated 
according to the equation described above. 
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Figure 10: Typical kinetic studies. a) Dissociation experiment showing the time dependent decrease of total bound 
marker (red circles and dissociation curve) until the level of nonspecific binding (black line) is reached, and half life 
of the target-marker complex (t1/2, green). b) Association experiment (blue triangles and association curve) showing 
the formation of the target-marker complex with parallel dissociation, steady state phase (orange) indicates 
equilibrium state of both process.  
The results of such kinetic studies can be used to estimate a sufficient incubation time to reach 
equilibrium of the incubation system, which should be achieved after five times of the 
dissociation half life (t1/2) of the target-marker complex. The studies also provide information 
about the affinity of the marker substance towards the target according to the equation: 
Kd = koff / kon.[52]  
 
1.3.2.3 Competitive Experiments 
Competitive studies are one of the most important applications of binding assays and are used 
for the determination of affinities of unknown substances, also called competitors. It should be 
noted that this is an indirect approach for affinity characterization since it is not the binding of 
the competitor that is monitored, but the influence of this competitor on the binding of the 
employed marker at the target. A prerequisite for the performance of such competitive binding 
experiments is therefore a previous characterization of the employed marker regarding its 
Kd-value at the respective target but also regarding its kinetics to determine an incubation time, 
which ensures an equilibrium state of the incubation system. 
For competitive binding experiments increasing concentrations of a test compound are added 
to the incubation mixture (i.e. a constant target concentration and a constant marker 
concentration). The test compound and the marker are then competing for binding sites at the 
targets in the incubation mixture. After equilibrium of the system is reached, incubation is 
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stopped and the target protein including bound marker and bound competitor are separated 
from free marker/competitor, and the amount of bound marker is quantified. If the competitor 
addresses the same binding site as the marker, an increasing concentration of the competitor 
is accompanied by a reduction of the bound fraction of the marker. This is the result of the 
displacement of the marker at the binding sites by the competitor until the level of nonspecific 
binding of the marker substance is reached. As a last step, the specifically bound marker 
concentration, represented as a percentage of “total binding” (in this case termed as specific 
marker binding in absence of a competitor), is plotted vs the logarithmic concentration of the 
test compound for data analysis (Figure 11). The concentration of the competitor that reduces 
specifically bound marker to 50 % is called IC50-value and provides information about the 
inhibitory effect of the test compound on the marker binding, but does not represent an 
independent physical variable.  
 
Figure 11: Typical competition curve. The increasing concentration of the test compound is accompanied by a 
reduced specific binding of the marker, in which 100 % represents the specific binding in absence of any inhibitor 
(blue dashed line) and IC50 shows the concentration of the competitor (red solid line), which reduces specific marker 
binding to 50 % (red dashed line). 
But the IC50-value can be used to calculate the affinity, i.e. the inhibition constant Ki, according 
to the equation of Cheng-Prusoff:[53] 
�i =  IC501 +  [M]�d  
In this equation Ki is the inhibition constant, which represents the affinity of the test compound 
according to the law of mass action, [M] represents the free concentration of the marker, and 
Kd the equilibrium dissociation constant of the marker. However, it should be noted that the 
calculation models for the data analysis of such competitive experiments are also based on 
the free, unbound marker concentration (see equation above, [M]). As long as the marker 
depletion is negligible, which is typically ensured by a employed target concentration ≤ 0.1 Kd, 
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the actual employed nominal marker concentration can be used as substitute for the free 
marker concentration [M] (for further information see also 1.3.2.1 Saturation Experiments).  
Competitive binding experiments have two main advantages: The affinity of an unknown 
substance towards a target can be determined without individual quantification methods for 
each substance and without time consuming characterization of their Kd-values in separate 
saturation experiments. Additionally, a substantially wider range of concentrations for the test 
compound can be employed since the concentrations of bound marker are used as surrogate 
therefore.
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2 Aims and Scope 
Even though a large number of different antidepressants (1.1.2 Pathology and Therapy) exists, 
only approximately 65 % of depressive patients show a sufficient therapeutic response to 
medical treatment with antidepressants.[54] There is therefore a substantial need for new 
compounds acting as antidepressants.  
Binding studies are an indispensable tool for drug discovery (1.3 Screening Tools in Drug 
Discovery). Therefore, it was the aim of my research to develop a new binding assay which 
can be employed for binding studies addressing all three monoamine transporters (i.e. hDAT, 
hNET, and hSERT). The developed binding assay should serve as a screening tool for the 
identification of new inhibitors of one, two, or all three monoamine transporters, as their 
inhibition is considered today to represent the most promising approach in the treatment of 
depressions. The concept of MS Binding Assays recently used in our group for the 
development of binding assays for the murine Ȗ-aminobutyric acid transporter subtype 1 
(mGAT1)[47] and hSERT[45] was adapted for this purpose. MS Binding Assays have 
considerable advantages over the well-established radioligand binding assays, particularly 
with regard to safety of humans and the environment, since no radioactively labelled markers 
are needed. At the same time they offer all possibilities of radioligand binding assays with 
regard to the performance of the experiments and the resulting information. The general setup, 
i.e. incubation of target and marker, separation of formed target-marker complexes from the 
incubation system, and finally quantification of the bound marker, can be adopted from 
established radioligand binding assays. The main difference between these two types of 
binding assays is the method employed for quantification of the bound marker, which is mass 
spectrometry in MS Binding Assays but scintillation counting in radioligand binding assays (for 
further information see 1.3.1 Radioligand Binding Assays vs MS Binding Assays). As very low 
amounts of bound marker have to be determined in these two types of assays, a highly 
sensitive quantification method is needed. As a consequence, such a quantification method 
based on mass spectrometry is an essential prerequisite for the performance of MS Binding 
Assays. 
Two different strategies were conceivable for the intended MS Binding Assays addressing 
hDAT, hNET, and hSERT: 
- Employing one marker substance addressing all three targets which is only applicable 
if the individual targets are available in separate form (e.g. by heterologous 
expression), or 
- employing three different markers each with a selectivity for one target, which should 
allow an analysis of hDAT, hNET, and hSERT in one single experiment. 
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The application of one marker for all three targets can be considered as a more effective 
approach than the latter one, as the development of the above mentioned quantification 
method for the marker employed in MS Binding Assays can be considered as the most 
laborious and time consuming step when developing such assays.  
We therefore decided to follow the first approach. An essential prerequisite was now a source 
providing the target proteins for hDAT, hNET, and hSERT in individual form. Expressing the 
individual targets in heterologous systems was considered the best choice as it has substantial 
advantages: The presence of targets (e.g. receptors, other transporters, etc.) in samples 
resulting from such cell systems potentially interfering with the desired target-ligand binding is 
reduced and a higher concentration of the demanded target in the cell preparation than in 
native brain preparations can be achieved. For HEK293 cells stably expressing hSERT such 
an expression system was already available in our group,[55] but equivalent HEK293 cell lines 
stably expressing the other targets demanded, i.e. hDAT and hNET, had still to be established.  
Additionally, a native marker substance had to be found, which binds with a high affinity, ideally 
in the low nanomolar range, towards all three monoamine transporters (i.e. DAT, NET, and 
SERT). A highly sensitive MS based method for its quantification in biological matrices, as they 
result from respective binding samples, had to be developed as well. For quantitation a triple 
quadrupole mass spectrometer equipped with an ESI source for ionization was chosen as this 
system had already been successfully used for the marker quantification in formerly 
established MS Binding Assays.[45-47] However, ESI-MS/MS analysis is commonly prone to ion 
suppression, which is generally caused by components of the resulting biological matrix 
contained in the analytical sample. It was therefore intended to separate the matrix from the 
analyte (formerly bound marker) by high performance liquid chromatography (HPLC) 
connected upstream to the mass spectrometer. To compensate for uncontrolled sample loss 
or sample concentration and for any changes on the ionization efficiency an internal standard 
should be employed. To this end, a poly-deuterated analogue of the employed marker seemed 
most suitable. That way a reliable quantification even if the matrix might not be completely 
separated by HPLC should be amenable. The final method should be characterized by a short 
cycle time to enable a reasonable throughput of samples to remain competitive with 
comparable radioligand binding assays. To ensure the reliability and robustness of the method, 
it should be verified regarding its selectivity, the correctness of the calibration curve, lower limit 
of quantification (LLOQ), precision and accuracy according to the FDA guidance for 
bioanalytical method validation.[56] 
With the MS Binding Assays established in this way, the affinity of the selected marker towards 
hDAT, hNET, and hSERT should be determined in saturation experiments as well as the 
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affinities and selectivities of various known monoamine transporter inhibitors in competitive MS 
Binding Assays. 
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3 Results and Discussion 
3.1 Selection of the Native MS Marker–Indatraline 
Next to the availability of the desired targets, the second basic requirement for the development 
of MS Binding Assays is an appropriate marker substance, which ideally should have the 
following characteristics: 
First, it should exhibit an ideal level of affinity towards the relevant target. As a low koff and a 
long t1/2 are typically accompanied by a high affinity of marker substance towards the target 
the affinity should be high enough to enable filtration without affecting the fraction of bound 
marker due to uncontrolled dissociation of the target-marker complex (see 1.3.2.2 Kinetic 
studies). However, the affinity should not be too high to avoid that only very low target 
concentrations can be employed which might interfere with a reliable quantification of the 
bound marker (i.e. application of the target at a concentration ≤ 0.1 Kd and of the marker at 0.1 
to 10 Kd, for further information see 1.3.2.1 Saturation Experiments). The ideal affinity of a MS 
marker therefore lies in the low nanomolar range. 
Secondly, since the readout of the assay should be accomplished by means of mass 
spectrometry, preferably by electrospray ionization (ESI), the marker substance should 
possess physicochemical properties allowing a good atmospheric ionization to enable its 
highly sensitive quantification. 
Indatraline [rac-(1R,3S)-3-(3,4-dichlorophenyl)-1-methylamino-2,3-dihydro-1H-indene] has 
been identified as potential marker substance during extensive literature research, as it fulfills 
the first mentioned requirement, which means it is a highly affine triple reuptake inhibitor of 
DAT, NET, and SERT. Unfortunately, no data were available regarding indatraline’s mass 
spectrometric properties, i.e. ionization, fragmentation, etc., and its suitability towards a highly 
sensitive quantification via MS was therefore far from certain. Furthermore, indatraline 
possesses two stereogenic centers giving rise to four stereoisomers, of which only the two 
enantiomers with trans-configuration inhibit nonselectively all three monoamine transporters 
and are called indatraline (see Figure 12). The racemic form of the cis-configured diastereomer 
was however reported to be selective for SERT. Bogeso et al. found for the two enantiomers 
of indatraline an eudismic ratio of five, nine, and 51 for SERT, NET, and DAT, respectively, 
with (1R,3S)-indatraline being the eutomer for all three monoamine transporters.[57] The 
different pharmacological profiles found for the two enantiomers of indatraline at the three 
monoamine transporters prompted me to characterize the binding affinities of both individual 
enantiomers in the intended MS Binding Assays. While the racemic indatraline is commercially 
available its single enantiomers are not. Moreover, for the preparation of the pure enantiomers 
only one method based on resolution of the racemate via crystallization[57] and several 
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asymmetric synthesis applying chiral catalysts[58-63] or chiral functional group transfer 
reagents[64] had been described when this study was started. In addition, no efficient analytical 
method for the determination of the enantiopurities of the two enantiomers, i.e. (1R,3S)- and 
(1S,3R)-indatraline, was known then. The methods for the determination of the enantiomeric 
excess (ee) of (1R,3S)- and (1S,3R)-indatraline that had been published at that time, were 
based on polarimetry[57, 58] or 1H NMR spectroscopy employing a chiral shift reagent which 
allowed a quantification of ee up to 95 % only.[57]  
Figure 12: The four stereoisomers of 3-(3,4-dichlorophenyl)-1-methylamino-2,3-dihydro-1H-indene. 
It was therefore necessary to first develop an analytical method, which allows a reliable 
determination of the enantiopurity of (1R,3S)- and (1S,3R)-indatraline up to at least 99 % ee. 
Since I intended to gain access to the individual enantiomers by chiral resolution of the 
racemate via the crystallization of diastereomeric salts the analytical method for the 
determination of the enantiopurity was considered to be a useful tool to monitor the progress 
of the resolution process.  
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3.2 Summary of Published Results 
3.2.1 First Publication: 
Enantiopurity Determination of the Enantiomers of the Triple Reuptake 
Inhibitor Indatraline 
 
Indatraline is a compound of great pharmacological interest due to its high potency as inhibitor 
of all three monoamine transporters.[57] On the basis of the results of Bogeso et al., who found 
an eudismic ratio of five, nine, and 51 for SERT, NET, and DAT, respectively, with 
(1R,3S)-indatraline representing the eutomer,[57] especially the enantiomers, (1R,3S)- and 
(1S,3R)-indatraline, have been in the focus of research in medicinal chemistry in the last 
decade.[58-64] Unfortunately, no powerful and reliable analytical method existed then for the 
precise determination of the enantiopurity of the single enantiomers, which is essential if the 
pure enantiomers are to be characterized pharmacologically. 
Such a method had therefore to be developed. For sertraline, an analogue of indatraline, a 
method for the determination of the ee based on 1H NMR spectroscopy employing a chiral shift 
agent (CSA) is known from literature.[65] This approach served as a basis for the development 
of a method for the determination of the enantiopurity of the enantiomers of indatraline. To 
achieve this the influence of different CSAs and their stoichiometry ratios with regard to the 
analyte indatraline, the kind of solvent, and applied temperatures on the chemical shift 
difference between the signals of the diastereomeric indatraline-CSA complexes were 
investigated. The signal width, which also affects the signal resolution in the respective 1H NMR 
spectra, was examined as well. According to these findings, the best conditions for the 
determination of the enantiopurity of (1R,3S)-indatraline in 1H NMR are as follows: the use of 
the (S)-enantiomer of Mosher’s acid [(S)-(-)-α-methoxy-α-trifluoromethyl-phenylacetic acid] as 
CSA in a molar ratio of 1:1 with regard to the analyte, i.e. (1R,3S)-indatraline, and chloroform-d 
as sample solvent, with the measurement being performed at 25 °C. Applying this 1H NMR 
method to enantioenriched material, as it can be obtained from resolution via crystallization, 
allowed the determination of enantiopurities up to 98.9 % ee. 
To determine even higher enantiomeric excesses for indatraline’s enantiomers, a more 
sensitive method based on HPLC should be developed. The following aspects were 
investigated during the development of this method: the influence of buffer type, its 
concentration, the pH value of the aqueous fraction of the mobile phase, the kind and 
percentage of organic modifier, the temperature, the injection volume, and the sample milieu 
on chromatographic parameters (i.e. peak intensity, retention time, asymmetry factor, etc.) and 
the extent on the separation of the enantiomers (i.e. resolution). The final HPLC method 
consisted of a chiral stationary phase based on modified ȕ-cyclodextrins, a mobile phase 
composed of triethylammonium acetate (TEAA) (0.1 %, v/v) pH 4.0 and acetonitrile (85:15, 
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v/v) with the analysis being performed at a flow rate of 1.0 mL min-1 and at a temperature of 
20 °C. This method was successfully validated according to ICH guidance Q2(R1) regarding 
specificity, accuracy, precision, linearity, and quantitation limit. Not only is this the first HPLC 
quantitation method for indatraline described in literature so far, it also enabled a reliable 
determination of enantiopurities up to 99.75 % ee for (1R,3S)-indatraline and up to 99.67 % ee 
for (1S,3R)-indatraline. 
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ABSTRACT The present study describes the development of two approaches for the deter-
mination of the enantiopurity of both enantiomers of indatraline. Initially, a method was developed
using different chiral solvating agents (CSAs) for diastereomeric discrimination regarding signal
separation in 1H nuclear magnetic resonance (NMR) spectroscopy, revealing MTPA as a promising
choice for the differentiation of the indatraline enantiomers. This CSA was also tested for its ideal
molar ratio, temperature, and solvent. Optimized conditions could be achieved that made determina-
tion of enantiopurity for (1R,3S)-indatraline up to 98.9% enantiomeric excess (ee) possible. To quantify
even higher enantiopurities, a high-performance liquid chromatography (HPLC) method based on a
modiﬁed β-cyclodextrine phase was established. The inﬂuence of buffer type, concentration, pH
value, percentage and kind of organic modiﬁer, temperature, injection volume as well as
sample solvent on chromatographic parameters was investigated. Afterwards, the reliability
of the established HPLC method was demonstrated by validation according to the ICH
guideline Q2(R1) regarding speciﬁcity, accuracy, precision, linearity, and quantitation limit.
The developed method proved to be strictly linear within a concentration range of 1.25–1000
μM for the (1R,3S)-enantiomer and 1.25-750 μM for its mirror image that enables a reliable
determination of enantiopurities up to 99.75% ee for the (1R,3S)-enantiomer and up to 99.67% ee
for the (1S,3R)-enantiomer. Chirality 25:923–933, 2013. © 2013 Wiley Periodicals, Inc.
KEY WORDS: ICH Q2(R1); validation; HPLC; NMR; CSA; cyclodextrine; enantiomeric excess
INTRODUCTION
Indatraline [trans-3-(3,4-dichlorophenyl)-N-methyl-indan-1-
amine, rac-1], also known as Lu 19-005 (Fig. 1), was reported
for the ﬁrst time in 1982 in a study of K.P. Bøgesø1 that aimed
at the development of new psychopharmacologically active
drugs for the treatment of psychic disorders such as depression.
The trans-conﬁgured 3-phenyl-indan-1-amines with different
halogen substitution patterns that in addition to indatraline
(rac-1) had been studied as part of this project demonstrated
nonselective inhibition of the neurotransmitter transporters for
dopamine (DAT), norepinephrine (NET), and serotonin
(SERT), proteins that are responsible for signal termination
and recycling of the respective neurotransmitters, whereas most
of the cis-conﬁgured 3-phenyl-indan-1-amines selectively
inhibited SERT.2
Being trans-conﬁgured, indatraline (rac-1) also displayed
similar and also very low IC50 values in uptake experiments for
each of the three above-mentioned neurotransmitter transporters
based on rat synaptosomes [dopamine (DA)=0.99 nM,
norepinephrine (NE)= 0.26 nM, serotonin (5-HT)=0.48 nM].
Also for the single enantiomers of indatraline (rac-1), low to
negligible selectivities as inhibitors of these transporters (DAT,
NET, and SERT) were found, although one enantiomer, the
(1R,3S)-stereoisomer, appeared to be distinctly more potent than
its stereoisomeric counterpart. The eudismic ratio in favor of the
(1R,3S)-enantiomer ranged from 5 (5-HT) to 51 (DAT).2
The neuronal systems of DA, NE, and 5-HT are involved in
different mental disorders such as depression, Parkinson’s
disease, schizophrenia, and are also associated with drug
abuse. Dual (NE and 5-HT, or NE and DA, respectively) as
well as selective NE and selective 5-HT reuptake inhibitors
[e.g., sertraline (2), Zoloft, a cis-conﬁgured structural analog
of indatraline; see Fig. 1] are widely used in the treatment
of depression, but about 35% of patients with depression
do not or only partially respond to these agents.3 That’s
why current efforts include the development of triple reup-
take inhibitors, as so-called next-generation antidepres-
sants, for a faster onset and better efﬁciency in therapy.4
Due to its high and close afﬁnities to DAT, NET, and
SERT and its long-acting effect, indatraline (rac-1), and
especially its (1R,3S)-enantiomer, (1R,3S)-1, could serve
as a model substance to test the potential of this new class
of agents,5 e.g., for the treatment of depression6 or even
cocaine abuse.7
For the characterization of the pharmacological and
pharmacokinetic properties of the enantiomers of a chiral
compound, only highly enantioenriched samples should be
used, as the wrong isomer will falsify the data the more it is
present in the samples studied. In the study of the determination
of the eudismic ratio of neurotransmitter transporter inhibition
by the indatraline enantiomers, Bøgesø et al. used samples with
enantiopurities of ≥ 95%.2 The eudismic ratio for DAT inhibition of
indatraline enantiomers was found to be 51 [(1R,3S)- as compared
to the (1S,3R)-enantiomer]. But considering the enantiopurity
of the samples used, which in the worst case could still
contain 2.5% of the wrong enantiomer, the true eudismic ratio
of the indatraline enantiomers as DAT inhibitors might possi-
bly be distinctly higher than that. As can be seen from this
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example, there is a substantial need for analytical methods that
enable a reliable and precise determination of the enantiopurity
even of highly enantioenriched indatraline samples. Of course,
such methods will also be valuable tools for the preparation of
the indatraline enantiomers, independent of whether this is
accomplished by a resolution via crystallization (by formation
of diastereomers) as described by Bøgesø et al.,2 or by asym-
metric synthesis applying chiral catalysts8–13 or chiral functional
group transfer reagents.14
So far, only two methods for the characterization of the
enantiopurity of indatraline enantiomers have been described
in the literature. One is based on polarimetry,1,2,8 the other
on1H nuclear magnetic resonance NMR measurements
employing (R)-(-)-2,2,2-triﬂuoro-1-(9-anthryl)ethanol as shift
reagent.2 The latter represents the above-mentioned method
Bøgesø et al. used for the determination of the enantiopurity
of indatraline enantiomers which, however, allows the quantiﬁ-
cation of enantiomeric excesses (ee) of no higher than 95%.2
The aim of the present study was to develop a method
enabling the determination of enantiomeric excesses up to at
least 99% (ee) for the two indatraline enantiomers and to validate
this method to demonstrate its reliability.
MATERIALS AND METHODS
Synthesis of Indatraline ·HCl
The synthesis of indatraline · HCl (rac-1 · HCl) was accomplished in
ﬁve steps starting from commercially available 3,4-dichlorocinnamic acid
(see also Supporting Information). The latter was reacted with benzene in
the presence of AlCl3 to give 3-(3,4-dichlorophenyl)-3-phenylpropanoic
acid, which was transformed to the corresponding acid chloride utilizing
thionyl chloride and subsequently subjected to an intramolecular Friedel
Crafts acylation with AlCl3 to yield 3-(3,4-dichlorophenyl)indan-1-one
(93%). The following steps were performed according to Davies et al.8: re-
duction of the ketone with K-Selectride to afford the corresponding alco-
hol. In situ activation of the alcohol as mesilate followed by nucleophilic
substitution with methylamine provided indatraline as free base, which
was converted to its hydrochloride by treatment with aqueous HCl
followed by freeze-drying. All procedures for the synthesis of rac-1 as
well as the analytical data are shown in the Supporting Information.
Analytical data for the free base (rac-1), which is the test material for all
1H NMR experiments, is listed below.
1HNMR for rac-1 (chloroform-d, 500 MHz): δ = 2.24 (dt, J = 13.2/7.0 Hz,
1H, NCHCH2), 2.44 (ddd, J = 13.2/7.8/3.3 Hz, 1H, NCHCH2), 2.51 (s, 3H,
NCH3), 4.25 (dd, J = 6.8/3.2 Hz, 1H, CH2CH), 4.50 (t, J = 7.6 Hz, 1H,
NCH), 6.97 (m, 2H, Hindan), 7.22 (dd, J = 2.1 Hz, 1H, CHCCl),7.23-7.29
(m, 2H, Hindan), 7.35 (d, J = 8.2 Hz, 1H, CHCHCCl), 7.39 (dd, J = 8.2/2.1
Hz, 1H, CHCHCCl). 13C NMR (chloroform-d, 125 MHz): δ = 34.15,
43.21, 48.51, 63.64, 124.71, 125.25, 127.27, 127.45, 128.36, 129.88, 130.27,
130.44, 132.45, 144.74, 145.49, 145.53.
Infrared spectroscopy (IR) (ﬁlm):ev = 3326 cm-1, 3276, 3068, 3023, 2959,
2933, 2848,1469.
Mass spectrometry (MS): chemical ionization (CI, CH5
+); m/z (%): 292
(100) [M+H]+.
High-resolution mass spectrometry (HRMS): electron ionization (EI+):
M+· calcd. for C16H15NCl2: 291.0576; found: 291.0571 (error 1.7 ppm).
Chemicals
L-(+)-tartaric acid p.a. for the racemate resolution was provided by
Riedel de Haën.
HPLC-grade acetonitrile and methanol were purchased from VWR
International (Darmstadt, Germany). Water was obtained by distillation
and ﬁltration (0.45 μm ﬁlter) of demineralized water, prepared by a reverse
osmosis system.
Ammonium acetate (AAc) p.a. was purchased from Fluka
(Taufkirchen, Germany), acetic acid p.a. from VWR International, and
triethylamine (TEA) pure (≥ 99%), which was distilled prior to use, from
AppliChem (Darmstadt, Germany).
(S)-(-)-1,1´-bi-naphthyl-2,2´-diol for synthesis 99.8% (99.7% ee) (Merck,
Darmstadt, Germany), (S)-(+)-6-methoxy-α-methyl-2-naphthaleneacetic acid
98%, (S)-(+)-O-acetylmandelic acid 99% (98% ee) (both Sigma-Aldrich,
Steinheim, Germany), (R)-(+)-α-methoxy-α-triﬂuoromethylphenylacetic
acid 99% (Alfa Aesar, Karlsruhe, Germany), and (S)-(-)-α-methoxy-α-
triﬂuoromethylphenylacetic acid p.a. 99% (97% ee) (Fluka) were used as
purchased. The deuterated solvent benzene-d6 (99.6% D) was purchased from
Sigma-Aldrich, acetonitrile-d3 (99.8% D) from euriso top (Saarbrücken,
Germany), and chloroform-d (99.8% D) from Sigma-Aldrich, and euriso top.
Resolution of Indatraline Via Crystallization by Formation of
Diastereomers
The resolution of rac-1 was accomplished via crystallization
according to Bøgesø et al.,2 thereby the enantiopurity was monitored by
the developed 1H NMR or HPLCmethod, respectively. Contrary to Bøgesø
et al.,2 the tartaric acid salt was further transferred into the free base by
an alkaline ether extraction, then ﬁnally treated with an excess of
aqueous HCl (1 M) and subsequent freeze-drying of the resulting
residue yielded (1R,3S)-indatraline · HCl [(1R,3S)-1 · HCl], which was
recrystallized from ethyl acetate to give colorless crystals of distinctly
reduced hygroscopicity. The speciﬁc rotation of this product (melting point
172–173°C) amounted to α½ 21D +16.4 (c 0.39,methanol) using a Perkin Elmer
241 C polarimeter (Perkin Elmer, Rodgau, Germany).
1H NMR
Instrumentation. All 1H NMR spectra were recorded on a JNM
Eclipse +500 (500 MHz) NMR spectrometer from JEOL equipped with a
direct 5 mm broadband probe operating at 500.16 MHz. The sample
temperature was set to 25°C except for the investigations concerning
the inﬂuence of variable temperature (VT) on the enantiomeric chemical
shift differences (ΔΔδ). To achieve optimal results concerning peak
shape, a gradient shim was applied using the gradient shim tool provided
by the instrument operating software. The pulse angle was set to 45° and
a relaxation delay of 1.3 s was used. In all, 64 transients over a frequency
width of 7003 Hz were applied with 32 K data points, giving an overall
digital resolution of 0.21 Hz per points. The spectra were processed using
NMR software MestReNova v5.2.5-4119 provided by Mestrelab Research.
No line broadening was applied prior to Fourier transformation (FT). The
peak integration was performed manually with the integration tool
included in the software. The comparison of the effect of the different
solvents was made by measuring the chemical shift and the full width
at half maximum (FWHM) of each N-methyl proton signal. The chem-
ical shift was manually measured with MestReNova, and in contrast
the FWHM values were measured with delta v4.3.3 software (JEOL).
A 4 times zero-ﬁlling prior to FT was applied to obtain a reasonable
number of data points suitable for the determination of FWHM.
Signal-to-noise ratio (S/N) calculations were performed using the
S/N tool in root mean square (RMS) mode provided by the delta
v4.3.3 software (JEOL).
Preparation of the stock solutions for the
1
HNMR experiments and
method development. All 1H NMR experiments were measured using
a total sample volume of 700 μl. To obtain stock solutions with a deﬁned
concentration, rac-1 and the chiral solvating agents (CSAs) [(S)-(-)-1,1´-
Fig. 1. (1R,3S)-indatraline [(1R,3S)-1] and sertraline (1S,4S)-4-(3,4-
dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalen-1-amine) (2).
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binaphthyl-2,2´-diol (3), (S)-(+)-6-methoxy-α-methyl-2-naphthaleneacetic
acid (4), (S)-(+)-O-acetylmandelic acid (5), (S)-(-)-α-methoxy-α-
triﬂuoromethylphenylacetic acid ((S)-6), and (R)-(+)-α-methoxy-α-
triﬂuoromethylphenylacetic acid ((R)-6)] (Fig. 2) were dissolved in an
appropriate volume of the required deuterated solvent (chloroform-d,
benzene-d6, and acetonitrile-d3, respectively) to yield ﬁnal concentrations
of 0.1 M. The samples were prepared by mixing a deﬁned volume of a 0.1
M stock solution of rac-1 (free base) and various volumes of 0.1 M stock
solutions of the respective CSAs in a ﬁnal volume (700 μl) of the respective
deuterated solvent. When higher molar ratios (1:5 and 1:10, respectively) of
the CSA (S)-(-)-1,1´-binaphthyl-2,2´-diol (3) were examined, no addition of
the 0.1M stock solution of3was possible without changing the ﬁnal sample
volume. Due to the low solubility of 3 in the chosen deuterated solvents
(chloroform-d, benzene-d6, and acetonitrile-d3) the preparation of a higher
concentrated stock solution, e.g., 1 M, was also impossible. Therefore, the
required amount of3wasweighed and directly dissolved in the ﬁnal sample
volume (700 μl) already containing the deﬁned concentration of rac-1.
In the end, a 0.1 M stock solution of (1R,3S)-1 in chloroform-d was
made analogously to the rac-1 sample and analyzed under the conditions
established for the rac-1-CSA investigations.
UV-absorption measurements
The absorption spectrum of indatraline (rac-1 · HCl) was measured in a
96-well quartz UV plate (Hellma, Müllheim, Germany) by means of a
Spectra Max M2e plate reader (Molecular Devices, Ismaning, Germany).
Spectra were corrected for solvent absorption by subtraction of the
spectra of the pure solvents.
Chromatography
Instrumentation. An Agilent 1100 HPLC system consisting of an
vacuum degasser, quaternary pump, column oven, diode array detector
(Agilent, Waldbronn, Germany), and an SIL HTA Shimadzu autosampler
(Shimadzu, Duisburg, Germany) in combination with an Astec
Cyclobond I 2000 DM (25 cm x 4.6 mm; 5 μm) stationary phase
(Sigma-Aldrich) was used. Data analysis was performed by means of
Analyst 1.4.2 (Applied Biosystems, Darmstadt, Germany).
Preparation of stock solutions for the HPLC experiments. All
solutions and buffers were prepared in water unless stated otherwise.
For method development and validation we used 10 mM rac-1 · HCl stock
solutions. These stock solutions were prepared by dissolving rac-1 · HCl
in the appropriate volume of water or 7.3 mM TEAA (triethylammonium
acetate) pH 4.0, respectively. Analogously, a 10 mM stock solution of
(1R,3S)-1 · HCl in 7.3 mM TEAA pH 4.0 was prepared. All stock solutions
were frozen at -20°C, thawed on the day of the experiment, and ﬁnally
diluted in the corresponding sample solvent to obtain the samples for
method development and validation (calibration standards, QCs, spiked
samples).
HPLC method development, data analysis, and validation. For
each modiﬁcation in the development of the HPLC method, the samples
were measured in triplicates. Buffers (i.e., AAc and TEAA) were adjusted
to the required pH value by addition of glacial acetic acid.
Peak intensity during method development was deﬁned as peak height
[mAU] of the (1S,3R)-1 peak. Resolution (Rs) and asymmetry factors (As)
were calculated according to Kuss et al.15
For quantiﬁcation, peak areas (y) of both indatraline enantiomers as a
function of their concentration (x) were investigated. Linearity was
investigated by measurement of a series of calibration standards (13
concentration levels, i.e., 2.5, 5, 10, 25, 50, 75, 100, 250, 500, 750, 1000,
1500, 2000, and 3000 μM rac-1 · HCl).
The ﬁnal method based on a mobile phase composition of 7.3 mM
TEAA pH 4.0 and acetonitrile (85:15, v/v), at a ﬂow rate of 1.0 ml/min
and a temperature of 20°C, an injection volume of 50 μl, a sample solvent
of 7.3 mM TEAA pH 4.0 and a detection wavelength of 230 nm was
validated for speciﬁcity (comparison of a sample solvent blank with a
rac-1 · HCl sample at the expected retention time), linearity (described
above), accuracy (deﬁned as recovery obtained for QCs in ﬁve
concentrations each in ﬁve replicates), precision (calculated as RSD for
the same QCs used for accuracy), and quantitation limit (QL) according
to the ICH guidance Q2(R1).16 Validation of accuracy and precision was
extended to (1R,3S)-1 · HCl samples of high enantiopurity that were
spiked with deﬁned amounts of rac-1 · HCl as described above.
RESULTS AND DISCUSSION
1H NMR Method Development and Optimization
In 1985 Bøgesø et al. published an 1H NMR method based
on the use of a shift reagent that enabled the determination of
the enantiopurity of (1R,3S)- and (1S,3R)-1 up to 95% ee.2
Since this determination limit was not sufﬁcient for our
purpose, we intended to develop an alternative NMR method
that allows the determination of enantiomeric excesses (ee)
up to 99% and higher. To realize this method, we wanted to
make use of a technique recently published by Claridge
et al. which had distinctly improved the sensitivity for the
quantiﬁcation of diastereomeric excesses (de) by comparing
the integrals of the signals of the minor diastereomer with
the integral of 13C satellites of a suitable 1H NMR signal of
the major diastereomer.17 That way de of up to 99.8% could
be successfully determined.17 Our plan was to apply this
technique to the determination of ee of indatraline samples.
Actually, we considered this approach especially rewarding
as an 1H NMR-based method would, in addition, allow
detection of sample impurities, such as solvent remnants,
and recovery of the samples used.
Due to the fact that the N-methyl group gives rise to the
most intense signal in the 1H NMR spectrum of rac-1, it
was selected as the reference signal for the development of
the above-described 13C satellite method. As this secondary
methylamino moiety is directly attached to one of the two
chiral centers of 1, the chemical shift differentiation of this
group was expected to be especially sensitive to the different
nature of the diastereomeric ion pairs.
Various CSAs were tested to determine their effect on the
chemical shift differences between the signals of the
diastereomeric complexes of rac-1 in the respective 1H NMR
spectra.
As such, (S)-(-)-1,1´-binaphthyl-2,2´-diol (3) was selected as it
had been successfully applied to the determination of the
enantiopurity of the structurally closely related sertraline (2), a
method that had been established by Salsbury and Isbester18
(Fig. 1). Also, the well-established CSAs (S)-(+)-6-methoxy-α-
methyl-2-naphthaleneacetic acid (4), (S)-(+)-O-acetylmandelic
acid (5), (S)-(-)-α-methoxy-α-triﬂuoromethylphenylacetic acid
Fig. 2. Investigated CSAs for the
1
H NMR spectroscopic enantiomeric
discrimination.
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[(S)-6], and (R)-(+)-α-methoxy-α-triﬂuoromethylphenylacetic
acid [(R)-6] were studied. With these CSAs, a series of
experiments was performed in which the molar ratios (CSA :
rac-1, Table 1), solvents (Table 2), and temperature (Table 3)
were varied to identify the best-suited reagent and optimal
conditions for the determination of the enantiopurity of the
enantiomers of 1.
Regarding the molar ratios between the individual CSA and
indatraline (1), the optimal value was deﬁned as the ratio that
led to the largest enantiomeric chemical shift difference (ΔΔδ)
between the N-methyl signals of the diastereomeric complexes,
together with low line broadening of the respective signals,
which were measured as FWHM.
In brief, in chloroform-d at 25°C the best results were obtained
using CSA (S)-6 or (R)-6, at a molar ratio of 1:1 (Table 1 entries
14 and 20, respectively, 64 transients were taken) (Fig. 3). Under
these conditions, not only ΔΔδ values amounting to 0.046 to
0.047 ppm were very high, but also the FWHM values in the
range of 1.3–1.5 Hz were very low.
Due to the fact that the diastereomeric complex of 1 and
(S)-6 is the mirror image of 1 and (R)-6, the ΔΔδ and FWHM
values should be the same; the slight difference of entry 14
compared to entry 20 (Table 1) can be explained by different
enantiopurities of the purchased CSAs used and a determination
imprecision originating from manual measurements of both
parameters. Actually, for (S)-6 and (R)-6, the ΔΔδ had reached
their maximum when 1.0 equivalent of the CSA was employed
and decreased when the molar ratio of the CSA was further
increased (entries 15–17 and 21–13, Table 1), which at the same
time was accompanied by a worsening of the FWHM values. In
contrast, the ΔΔδ values either improved or reached a plateau
for the CSA 3-5 (see entries 7 and 8, Table 1) when the molar
ratios of the CSA as compared to rac-1 were increased. Using
(S)-6 and (R)-6 at a molar ratio of 1:1 (CSA : rac-1) gave the
highest ΔΔδ values for all tested CSAs in the respective molar
ratio range studied, except for CSA 3. Also, 3 when employed
in molar ratios of 2:1, 5:1, and 10:1, respectively (Table 1, entries
3-5) gave rise to ΔΔδ values reaching or even surpassing the
optimal results observed for (S)-6 and (R)-6, but this approach
suffered from two major disadvantages. First, an overlap of the
relevant N-methyl signals with a signal resulting from one of
the methylene protons of rac-1 occurred which complicated
the analysis of these signals, but also the line broadening
become distinctly worse. Thus, compound 3 appeared to be less
suitable than (S)-6 and (R)-6 for use as a CSA for the analysis of
the enantiopurity of the enantiomers of rac-1.
In further experiments the aprotic solvents acetonitrile-d3 and
benzene-d6 were also tested for their suitability in chemical shift
experiments with 3, 5, and (S)-6 as CSA, but clearly turned out
to be less appropriate than chloroform-d (Table 2). Finally,
varying temperature experiments were performed for the CSA
(S)-6 in chloroform-d. According to the results of these
experiments, a temperature of 25°C represents a good
compromise, yielding a reasonably high ΔΔδ together with an
adequately low FWHM value (entry 4, Table 3).
TABLE 1. Inﬂuence of different CSA and their molar ratio on
enantiomeric chemical shift difference (ΔΔδ) and
FWHM of rac-1
No. CSA Molar ratio
a
ΔΔδ [ppm]
b
FWHM
c
[Hz]
1 3 0.5 : 1 0.014 0.9 0.9
2 1 : 1 0.026 1.0 1.0
3 2 : 1 0.044 1.1 1.1
4 5 : 1 0.068 1.5 1.4
5 10 : 1 0.078 2.2 1.9
6 4 0.5 : 1 0.007 1.1 1.1
7 1 : 1 0.013 1.2 1.2
8 2 : 1 0.013 1.2 1.2
9 5 0.5 : 1 0.019 1.6 1.8
10 1 : 1 0.027 1.3 1.3
11 2 : 1 0.033 1.7 1.8
12 (S)-6 0.5 : 1 0.027 1.7 2.1
13 0.75 : 1 0.039 1.7 1.9
14 1 : 1 0.046 1.3 1.4
15 1.25 : 1 0.043 1.5 1.5
16 1.5 : 1 0.044 1.8 1.8
17 2 : 1 0.036 1.5 1.5
18 (R)-6 0.5 : 1 0.024 1.5 1.9
19 0.75 : 1 0.035 1.6 1.9
20 1 : 1 0.047 1.4 1.5
21 1.25 : 1 0.042 1.5 1.5
22 1.5 : 1 0.042 1.8 1.8
23 2 : 1 0.036 1.6 1.6
Standard conditions for these experiments were chloroform-d, at 25°C and 64
transients.
aMolar ratio CSA:rac-1.
bChemical shift difference between the N-methyl signal of the diastereomeric
enantiomer-CSA complexes.
cFirst value of the low frequency signal, second value of the high frequency
signal.
TABLE 2. Inﬂuence of benzene-d6 and acetonitrile-d3 as
solvent on enantiomeric chemical shift difference
(ΔΔδ) and FWHM
No. Solvent CSA
Molar
ratio
a
ΔΔδ
[ppm]
b
FWHM
c
[Hz]
1 benzene-d6 3 5 : 1 0.065 1.7 1.8
2 5 1 : 1 0.013 1.2 1.2
3 (S)-6 1 : 1 0.023 1.2 1.2
4 acetonitrile-d3 3 5 : 1 0.005 1.7 1.7
5 5 1 : 1 0.006 1.0 1.0
6 (S)-6 1 : 1 0.024 0.9 0.9
Standard conditions for these experiments were 25°C and 64 transients.
aMolar ratio CSA: rac-1.
bChemical shift difference between the N-methyl signal of the diastereomeric
enantiomer-CSA complexes.
cFirst value of the low frequency signal, second value of the high frequency
signal.
TABLE 3. Inﬂuence of the temperature on enantiomeric
chemical shift difference (ΔΔδ) and FWHM using rac-1
and (S)-6 (1:1)
No. T [°C] ΔΔδ [ppm]
a
FWHM
b
[Hz]
1 - 50 0.076 6.0 11.5
2 - 25 0.064 2.4 3.3
3 0 0.055 1.7 2.0
4 25 0.045 1.2 1.4
5 50 0.037 1.2 1.3
Standard conditions for these experiments were chloroform-d and 64
transients.
aChemical shift difference between the N-methyl signal of the diastereomeric
enantiomer-CSA complexes.
bFirst value of the low frequency signal, second value of the high frequency
signal.
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In the end, the optimized method was subjected to testing
at a sample that had been obtained from multiple resolution
via crystallization of the racemic compound rac-1, which
was expected to be of exceptional high ee. Corresponding to
Parker and Taylor,19 the size of the ΔΔδ values in general
varies depending on the enantiomeric composition of the
analyte and the absolute conﬁguration of the CSA employed.
Hence, differing ΔΔδ values had to be expected for this highly
enantioenriched sample depending on the enantiomer of the
CSA used [(S)-6 or (R)-6]. Therefore, the (1R,3S)-1 obtained
by resolution of rac-1 via crystallization (see Materials and
Methods) was analyzed by means of the optimized 1H NMR
method using (S)-6 and (R)-6 as CSA as well. The spectra
resulting from these studies revealed that (S)-6 is better
suited for the analysis of the enantiopurity of (1R,3S)-1, as
this CSA enantiomer gives higher values for ΔΔδ (0.080
ppm compared to 0.050 ppm for (R)-6). Moreover, when
(R)-6 was used as CSA the N-methyl signals of the two
enantiomers of 1 were overlapping, severely impeding their
separate integration. According to Claridge et al.,17
theoretically diastereomeric excesses of up to 99.8% de can
be determined provided an acceptable S/N ratio is reached.
Unfortunately, we were not able to reliably quantitate the
N-methyl signal of the (1S,3R)-enantiomer with 64
transients, as its integral was substantially lower than that
of the 13C satellite signal of the respective N-methyl signal
of the major isomer the (1R,3S)-1. Although an S/N of 12:1
was found for one 13C satellite which did fulﬁll our key
criterion of S/N≥10:1 for accurate quantiﬁcation, the N-methyl
signal of the minor isomer almost vanished in the signal noise
for this real sample with high enantiopurity. Therefore, an S/N
ratio optimization was performed by incrementally increasing
the number of transients (128, 512, 2048, and 8192). But even
with 8192 transients [S/N 66:1 for one 13C satellite of the
N-methyl group of (1R,3S)-1], the enantiopurity of this
highly enantioenriched material of (1R,3S)-1 could not be
analyzed accurately, as slight changes of phase correction
performance had signiﬁcant effects on the integration
values. To overcome this obstacle, more concentrated
solutions could be used. But as we intended, for practical
reasons, to employ only low amounts of enantioenriched
samples obtained during the racemic resolution of rac-1,
this opportunity was rejected. Nevertheless, as the integral
of the N-methyl signal of the minor enantiomer was in any
case unequivocally lower than the integral of one of the 13C
satellite signals of theN-methyl signal of the major enantiomer,
it can be stated that the ee of the analyzed sample must have
been higher than 98.9%. The ee being ≥ 98.9%, follows from
the fact that the natural occurrence of 13C amounts to 1.108%,
and for this reason the ratio between the integrals of the 12C-1H
NMR signal and a single 13C satellite signal is 178.5:1,17 which
compares to an integral of 0.56% (= major signal, equivalent to
100%, divided by 178.5) for a 13C satellite signal in relation to
the parent signal. Accordingly, for theoretical reasons, the ee must
amount to≥ 98.9% if the integral of the 12C-1H NMR signal of the
minor isomer is less than the integral of the 13C satellite signal of
the major isomer.
In any case, the above-described method represents a
simple and quick tool for the analysis of the progress of
racemic resolutions of indatraline (1) up to even very high
enantiomeric excesses of ee≤ 98.9%.
HPLC Method Development and Optimization
With the aim of developing an analytical method suitable
for determination of ee≥ 99% for both indatraline enantiomers,
we tried next to beneﬁt from the capabilities of a chiral stationary
phase.
The method described by Rao et al.20 for the separation and
quantitation of stereoisomers and related enantiomeric impurities
of sertraline (2) by means of a dimethylated β-cyclodextrine
material as stationary phase was considered a suitable starting
point. The column employed in this study, an Astec Cylcobond I
2000 DM, seemed to be promising for our purpose due to the
structural analogy of indatraline (1) compared to sertraline (2).
The described mobile phase, however, employing 0.4% (v/v)
triﬂuoroacetic acid (TFA) at pH 3.020 can be considered relatively
harsh and possibly destructive for the stationary phase as these
conditions are at or even not within the manufacturer’s advice
Fig. 3. Excerpt of the 1H NMR spectrum of rac-1 with (S)-6 in a molar ratio of 1:1 measured in chloroform-d at 25°C with 64 transients. Separated N-methyl sig-
nals for the determination of ΔΔδ as well as FWHM values are labeled.
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for handling of the Astec Cylcobond I 2000 DM. Additionally, for
TFA amemory effect was found by Ye et al.21whichwas assumed
to impair a rapid switching between different kinds of buffers.
Hence, a gentle but powerful HPLCmethod avoiding TFA should
be developed for this stationary phase. First, in order to select an
appropriate wavelength for analyte detection, an absorption
spectrum of rac-1 ·HCl was recorded. Figure 4 shows the
absorption spectrum of a 25 μM aqueous solution of rac-
1 · HCl. It reveals a weak maximum at 265 nm and a steep
increase of absorption at a wavelength <240 nm with a
slight shoulder at about 230 nm.
Further spectra recorded in possible mobile phases such as
10 mM AAc pH 4.0, 7.3 mM TEAA pH 4.0, or 7.3 mM TEAA
pH 4.0 and acetonitrile (85:15, v/v), employing different
concentrations of rac-1 · HCl and varying pH values of the
buffers used as solvent (pH 3.0–7.0) covering the suggested
operation range of the Astec Cyclobond I 2000 DM conﬁrmed
these absorption characteristics. These spectra were also
similar to those of 2 reported by Mandrioli et al.,22 who
identiﬁed absorption maxima at 208 nm and 275 nm
(conditions not speciﬁed), respectively. For the present
study, we decided to use 230 nm as the detection wavelength
for the HPLC analysis, just as Mandrioli et al.22 had done in
the case of 2, as it provides high analytical sensitivity and at
the same time is still sufﬁciently distant from the cutoff of
the mobile phase.
To develop the required HPLC separation method for the
enantiomers of indatraline (1) based on the selected Astec
Cylcobond I 2000 DM column, we started with the
chromatographic conditions suggested by the manufacturer
for separation of racemic hydrobenzoine. When these were
employed [i.e., 10 mM AAc buffer pH 4.0 and acetonitrile
90:10 (v/v)] injecting 10 μl of a 1 mM aqueous solution of
rac-1 · HCl, at a ﬂow rate of 1.0 ml/min and a temperature
of 20°C, a reasonable separation for the two enantiomers of
indatraline (Rs = 3.95) was obtained (see Table 4a, entry 2).
As discrimination of enantiomers by means of cyclodextrine
phases is known to depend on the nature of the buffer, its
concentration and pH value, on the organic modiﬁer as well
as on temperature,23 we investigated the inﬂuence of these
parameters on separation, run time, peak symmetry, and
peak intensity [deﬁned as peak height of (1S,3R)-1]. Regarding
the latter, the peak resulting from the (1S,3R)-1 enantiomer
was considered to be crucial due to its longer retention time
and broader peak width.
Several trends can be recognized from the results obtained
when varying the chromatographic conditions, which are shown
in Table 4a and 4b. First, the resolution of the enantiomers
appeared to be sufﬁcient for all conditions investigated (Rs≥3,
allentriesTable4aand4b).Second,forbothbuffers(AAcandTEAA)
a decrease in buffer concentration led to shorter retention times
(Table 4a and 4b, entries 1–3, respectively) associated with
increased intensities (at least for AAc, Table 4a entries 1–3) and
lower peak widths (data not shown). Third, the opposite effect
(i.e., longer retention time associated with decreased intensities
and broader peaks) was observed when the pH value was
increased(Table4aand4b,entries2and4–6, respectively).Fourth,
enhanced amounts of acetonitrile resulted in shorter retention
times, higher intensities, and improved peak shapes (i.e., lower As
Table 4a and 4b, entries 2 and 7–8, respectively). Fifth, decreased
temperatures caused a conspicuous peak broadening (data not
shown) and a marked loss of intensity due to longer retention
times (Table 4a and 4b, entries 2 and 9–11, respectively). Finally,
it should be mentioned that substitution of acetonitrile for
methanol led to markedly worse results regarding intensity,
resolution, run time, and peak shape (data not shown).
Based on the conditions of entry 8 (Table 4b, i.e., 7.3 mM
TEAA pH 4.0 with acetonitrile in a ratio of 85:15 (v/v), ﬂow
rate of 1.0 ml/min, temperature of 20°C) that were
considered a good compromise regarding intensity (at the
same noise level compared to AAc), resolution, and peak
shape, the effect of enhanced injection volumes was
investigated. Thus, to gain higher intensities, the original
injection volume of 10 μl of the 1 mM sample solution of
rac-1 · HCl in water was raised to 50 μl.
The results shown in Table 5 document a proportional
increase of intensities in relation to the injection volume at
acceptable resolution and asymmetry factors for both
enantiomers (Table 5, entries 1–3) the highest intensity thus
being observed for the injection volume of 50 μl. But as peak
splitting of the (1S,3R)-1 peak of rac-1 ·HCl samples in water
and in the mobile phase with concentrations> 1 mM occurred,
additional experiments to optimize the sample solvent were
performed. We found that by using 7.3 mM TEAA pH 4.0 as
sample solvent the situation distinctly improved, giving higher
intensities for (1S,3R)-1 and better peak shape for (1R,3S)-1
(Table 5, entry 4), with the remaining analytical characteristics
unchanged. Thus, in this way, peak splitting of the (1S,3R)-
enantiomer could be suppressed up to concentrations of 1.5
mM of rac-1 ·HCl. A representative chromatogram recorded
after injection of 50 μl of a 1 mM rac-1 ·HCl sample in 7.3 mM
TEAA pH 4.0 under these optimized conditions is shown in
Figure 5a. The chromatographic parameters calculated for this
sample are shown in Table 5.
These results were considered appropriate for a reliable
quantitation of high enantiomeric excesses (i.e., >99% ee)
for both enantiomers of indatraline. Therefore, we intended
to verify the validity of the method used based on an Astec
Cyclobond I 2000 DM as stationary phase (25 x 4.6 cm, 5 μm),
a mobile phase composition of 7.3 mM TEAA pH 4.0, and
acetonitrile (85:15, v/v) at a ﬂow rate of 1.0 ml/min at 20°C
and an injection volume of 50 μl of the samples dissolved in
7.3 mM TEAA pH 4.0 in the next step.
Validation
When a single enantiomer is selected for development as a
new drug, the other enantiomer, i.e., the minor isomer,
should be analyzed in the same manner as required for other
Fig. 4. Absorption spectrum, corrected by subtraction of the correspond-
ing absorption spectrum of the sample solvent, of rac-1 · HCl (25 μM in water)
in the range from 200–300 nm with an enlargement of the slight shoulder at
about 230 nm.
GRIMM ET AL.928
Chirality DOI 10.1002/chir
deﬁned impurities.24 The ICH Q2(R1) guidance,16 which
addresses this topic, recommends quite generally “to
demonstrate that it (i.e., the developed method) is suitable
for its intended purpose.” However, the ICH Q2(R1) guidance
contains almost no exactly deﬁned (i.e., quantitative)
requirements regarding validation parameters for methods
to determine enantiopurity. For the intended purpose of the
described method it is mandatory for the accurate and precise
TABLE 4a. Effect of concentration and pH value of ammonium acetate buffer, organic modiﬁer and temperature on intensity, reso-
lution, retention times, and asymmetry factors of the indatraline enantiomers
tR [min] As
No. Conditions
a
Peak height
b
[mAU] Rs 1R,3S 1S,3R 1R,3S 1S,3R
Buffer conc. [mM]
1 5 135.00 3.51 7.64 9.55 2.43 2.40
2 *10 93.83 3.95 11.00 13.90 2.32 2.40
3 15 78.10 4.24 13.33 16.97 2.22 2.72
pH
4 3.5 115.33 3.87 9.53 11.94 1.71 1.59
2 *4.0 93.83 3.95 11.00 13.90 2.32 2.40
5 4.5 89.00 3.99 12.40 15.70 2.60 2.74
6 5.0 70.33 4.06 15.10 19.23 2.96 3.03
A : B ratio
c
7 95:5 37.80 4.57 19.30 26.33 3.31 2.94
2 *90:10 93.83 3.95 11.00 13.90 2.32 2.40
8 85:15 148.33 3.17 6.96 8.20 1.69 1.62
T [°C]
9 5 63.83 3.90 12.33 16.14 2.19 1.88
10 10 60.30 3.98 12.43 16.13 2.33 2.23
11 15 79.27 4.02 11.53 14.80 2.38 2.14
2 *20 93.83 3.95 11.00 13.90 2.32 2.40
Highlighted entries represent starting conditions, during variation of each parameter (e.g., concentration, pH, A : B ratio, temperature) the three remaining
parameters were kept constant.
a10 μl of an aqueous 1 mM rac-1 · HCl solution injected on an Astec Cyclobond I 2000 DM (25 cm x 4.6 mm, 5 μm).
b(1S,3R)-1.
cAmmonium acetate buffer (A):acetonitrile (B) (v/v).
TABLE 4b. Effect of concentration and pH value of triethylammonium acetate buffer, organic modiﬁer and temperature on intensity,
resolution, retention times, and asymmetry factors of the indatraline enantiomers
tR [min] As
No. Conditions
a
Peak height
b
[mAU] Rs 1R,3S 1S,3R 1R,3S 1S,3R
Buffer conc. [mM]
d
1 3.65 133.00 3.28 6.94 8.65 2.20 2.16
2 *7.30 134.67 3.66 8.66 10.87 2.49 2.50
3 14.60 105.33 4.08 12.63 16.2 2.63 2.63
pH
4 3.5 135.33 3.68 8.18 10.30 1.86 1.89
2 *4.0 134.67 3.66 8.66 10.87 2.49 2.50
5 4.5 101.67 3.78 10.57 13.47 2.58 2.88
6 5.0 80.20 3.82 13.00 16.60 2.87 2.94
A: B ratio
c
7 95:5 58.40 3.99 15.33 20.90 4.00 4.40
2 *90:10 134.67 3.66 8.66 10.87 2.49 2.50
8 85:15 176.33 3.00 5.97 7.03 2.25 2.07
T [°C]
9 5 85.17 3.72 10.37 13.63 2.44 2.47
10 10 116.00 3.68 9.94 12.90 2.67 2.70
11 15 126.67 3.67 9.64 12.37 2.60 2.78
2 *20 134.67 3.66 8.66 10.87 2.49 2.50
Highlighted entries represent starting conditions, during variation of each parameter (e.g., concentration, pH, A : B ratio, temperature) the three remaining
parameters were kept constant.
a10 μl of an aqueous 1 mM rac-1 · HCl solution injected on an Astec Cyclobond I 2000 DM (25 cm x 4.6 mm, 5 μm).
b(1S,3R)-1.
cTriethylammonium acetate buffer (A):acetonitrile (B) (v/v).
dPreparation of triethylammonium acetate buffer by diluting triethylamine in water and pH adjustment using glacial acetic acid (7.3 mM are equivalent to 0.1% (v/v)
triethylamine in water).
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TABLE 5. Effect of the injection volume on intensity, resolution, retention time, and asymmetry factors of the indatraline enantio-
mers based on the chromatographic conditions of entry 8 table 4b*
No.
Sample
solvent
Injection
volume
a
Peak
height
b
[mAU]
Rs
tR [min] As
1R,3S 1S,3R 1R,3S 1S,3R
1 water 10 μl 176.33 3.00 5.97 7.03 2.25 2.07
2 water 20 μl 338.67 2.95 5.95 6.99 2.75 2.09
3 water 50 μl 778.67 2.74 5.91 6.90 3.28 2.81
4 7.3 mM TEAA 50 μl 934.83 2.69 5.72 6.64 1.81 3.18
a1 mM rac-1 · HCl injected.
b(1S,3R)-1.
*7.3 mM triethylammonium acetate pH 4.0 and acetonitrile (85:15, v/v) as mobile phase, at a ﬂow rate of 1.0 ml/min at 20°C using an Astec Cylclobond I 2000 DM
(25 cm x 4.6 mm, 5 μm) as stationary phase.
Fig. 5. Chromatograms of (a) 1 mM rac-1 · HCl, (b) sample solvent blank (7.3 mM triethylammonium acetate pH 4.0, (c) 500 μM of (1R,3S)-1 · HCl
(obtained by racemate resolution, see Materials and Methods), an asterisk denotes tR of the (1S,3R)-enantiomer. All chromatograms were recorded
employing a mobile phase of 7.3 mM triethylammonium acetate pH 4.0 and acetonitrile (85:15, v/v), at a ﬂow rate of 1.0 ml/min at 20°C on an Astec
Cylclobond I 2000 DM (25 cm x 4.6 mm, 5 μm).
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determination of both enantiomers – even if one is present
in vast excess – that the range covered by the method is
as large as possible. Following these considerations, we
tried to demonstrate the performance of the established
method for both indatraline enantiomers examining rele-
vant validation parameters [i.e., range, quantitation limit
(QL), linearity, precision, i.e., repeatability, accuracy, i.e.,
recovery, speciﬁcity] for both indatraline enantiomers by
investigation of rac-1 · HCl samples (due to the fact that
no certiﬁed enantiopure material was available) over a
broad concentration range.
Speciﬁcity. Injection of a blank sample (i.e., 7.3 mM TEAA
pH 4.0) led to the chromatogram shown in Figure 5b. The
absence of peaks at the retention times expected for the
indatraline enantiomers indicates that there are no
substances interfering with the indatraline enantiomers.
Also, the resolution for the separation of the enantiomers
(Rs = 2.69, see Fig. 5a) could be considered sufﬁcient, thus
demonstrating that this method is speciﬁc for both
enantiomers.
Quantitation limit (QL). The S/N recorded for ﬁve 2.5 μM
calibration standards of rac-1 · HCl was calculated by means
of Analyst 1.4.2 software. It was found to be ≥ 23 for (1R,3S)-1
and≥ 18 (1S,3R)-1,. This means that the ICH recommendation
regarding QL (S/N >10) is fulﬁlled for both enantiomers at a
concentration of 1.25 μM.
Linearity – range. From the resulting peak areas obtained for
both enantiomers, calibration functions were generated by
means of linear regression. Employing a 1/x2 weighting to the
calibration functions gave best results regarding a concentration
range as broad as possible. In this way, a calibration function of
y =29.55x - 1.731 was found for the (1R,3S)-1 (r2= 0.9995 and a
negligible y-intercept corresponding to 4.38% of the area obtained
at QL complywith the requirements for linearity 25) for a range of
1.25–1000 μM(i.e., 2.5–2000 μM rac-1 ·HCl). For (1S,3R)-1, this
led to y=29.63x – 1.623 (r2=0.9999, y-intercept corresponds to
4.62% of the area obtained at QL) as calibration curve for a range
of 1.25–750 μM (i.e., 2.5–1500 μM rac-1 ·HCl). Regarding the
upper concentrations of the range, it should be recalled that for
(1S,3R)-1 a tendency to peak splitting had been observed when
samples of rac-1 ·HCl with concentrations ≥2000 μM had been
injected (see above). Furthermore, the injection of calibration stan-
dards containing 3000 μM rac-1 ·HCl (see above) appeared to
overload the column, resulting in peak broadening and
decreased resolution.
Accuracy – precision. Accuracy (i.e., recovery) and precision
(i.e., repeatability) were examined for quality control samples
(QCs) at ﬁve concentration levels (i.e., 2.5, 10, 50, 500, and
1500 μM) of rac-1 · HCl, each in replicates of ﬁve. Table 6
shows the recovery (ratio of experimentally determined
concentration to nominal concentration ± conﬁdence interval,
α = 0.05) and the repeatability (given as relative standard
deviation, RSD) calculated from the experimentally obtained
areas by means of the respective calibration functions. The
developed method yielded accurate and precise results with
recoveries between 98.6 ± 0.4% and 101.0 ± 1.0% and RSDs
between 0.3% and 1.4% for (1R,3S)-1, and recoveries of
98.9 ± 0.3% to 100.5 ± 1.0% with RSDs of 0.2% to 1.1% for
(1S,3R)-1. As all recoveries and RSDs are distinctly within
the commonly accepted limits (recovery: 98.0%–102.0%, RSD
≤ 2.0%25), the established method is clearly in agreement with
the ICH recommendations for accuracy (i.e., recovery) and
precision (i.e., repeatability).
Considering the results of the validation based on rac-1 ·HCl
samples, characterization of enantiopurities up to 99.75% ee [i.e.,
1000 μM (1R,3S)-1 in presence of 1.25 μM (1S,3R)-1] for
(1R,3S)-1 and 99.67% ee [i.e., 750 μM (1S,3R)-1 in presence of
1.25 μM (1R,3S)-1] for (1S,3R)-1 should be possible, when
enantioenriched samples are analyzed at the upper concentration
of the enantiomer representing the major isomer of the sample.
In the next step, we employed this method to study a
sample of (1R,3S)-1, that was expected to possess an
extremely high enantiopurity in the range of the analytical
limit of the aforementioned method that had become
available to us by resolution of rac-1 via crystallization using
L-(+)-tartaric acid as auxiliary reagent (see Materials and
Methods) (chromatogram shown in Fig. 5c). As a (1R,3S)-1
reference standard was still not available, the obtained
(1R,3S)-1 · HCl material was analyzed employing the
calibration function established for rac-1 · HCl.
The (1R,3S)-1 ·HCl samples were investigated in a nominal
concentration of 1000 μM in ﬁve replicates. The concentrations
of both enantiomers calculated by means of the aforementioned
calibration functions were 979 μM for (1R,3S)-1 and 2.28 μM for
(1S,3R)-1, indicating an ee of 99.5%. The concentrations obtained
in this experiment indicated a recovery of 98.1 ± 0.3%
(mean ± conﬁdence interval, α = 0.05) related to the sum of
both enantiomers. The small but nevertheless distinctly
lower recovery determined for the (1R,3S)-1 · HCl sample
in comparison to the total recoveries of rac-1 · HCl samples
[e.g., 98.8% for 1500 μM rac-1 · HCl, i.e., 98.6% for 750 μM
(1R,3S)-1 and 98.9% 750 μM (1S,3R)-1, see Table 6] is
presumably due to a small amount of ethyl acetate present
TABLE 6. Validation results (mean values, n =5) regarding accuracy (recovery ± conﬁdence interval, CI, α=0.05) and precision
(relative standard deviation, RSD) for ﬁve different QC levels of Indatraline
Concentration [μM]
Found Recovery [%] ±CI RSD [%]
Nominal 1R,3S 1S,3R 1R,3S 1S,3R 1R,3S 1S,3R
1.25 1.26 1.26 101.0 ± 1.0 100.5 ± 1.0 1.1 1.1
5 5.04 5.02 100.9 ± 1.3 100.3 ± 0.3 1.4 0.32
25 25.1 25.0 100.3 ± 0.3 100.0 ± 0.3 0.29 0.28
250 252 251 100.8 ± 0.2 100.5 ± 0.2 0.25 0.19
750 740 742 98.6 ± 0.4 98.9 ± 0.3 0.46 0.34
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in the respective (1R,3S)-1 · HCl material. Unfortunately,
this small amount of ethyl acetate — unambiguously
identiﬁed by 1H NMR (≤1.0%) in the respective (1R,3S)-1 ·HCl
sample— could not be completely removed even after intensive
high-vacuum treatment. That EtOAc has been found in this
sample, of (1R,3S)-1 ·HCl, but not in those of rac-1 ·HCl is
certainly a result of the different procedures used for the
preparation of these compounds, (1R,3S)-1 · HCl having
been recrystallized from EtOAc, whereas rac-1 · HCl has
been isolated by freeze-drying of an aqueous solution in the
ﬁnal step (see Materials and Methods).
Since validation was initially based on rac-1 ·HCl samples, we
additionally tried to validate accuracy (i.e., recovery) and
precision (i.e., repeatability) of the method for their application
to highly enantioenriched (1R,3S)-1 ·HCl samples by means of
spiking experiments, which should ensure that even slight
changes in the ee of highly enriched (1R,3S)-1 ·HCl samples
can be reliably quantiﬁed. To this end, we spiked the above-
mentioned 981 μM (1R,3S)-1 ·HCl sample of 99.5% ee [979 μM
(1R,3S)-1 and 2.28 μM (1S,3R)-1], with different volumes of a 1
mM rac-1 ·HCl solution in replicates of ﬁve and determined
the resulting concentrations of (1R,3S)-1 and (1S,3R)-1, by
means of the calibration functions established for the racemic
sample. The results from this experiment are shown in Table 7.
For both of the spiked samples the expected concentrations
calculated from the concentrations of the original solutions [977
μM and 975 μM for (1R,3S)-1 and 4.77 μM and 6.26 μM for
(1S,3R)-1] matched those found experimentally almost exactly
[970 μM and 967 μM for (1R,3S)-1 and 4.72 μM and 6.21 μM
for (1S,3R)-1]. To this end, the found recoveries of ≥99.0% and
RSDs≤1.1% are also within the commonly accepted limits
(recovery: 98.0%–102.0%, RSD ≤2.0%) 25; additionally, a perfect
agreement between expected and found enantiomeric excesses
could be deduced from the performed spiking experiments. As
consequence, the developed method can be considered reliable
for the enantiopurity determination of the triple reuptake
inhibitor (1R,3S)-indatraline.
CONCLUSION
Even though enantiodiscrimination by 1H NMR spectroscopy
is a well-established approach, this work demonstrates its limits
for indatraline concerning the determination of low amounts of
the minor enantiomer in samples containing the major enantio-
mer in large excess. Nevertheless, the established 1H NMR
method may serve as tool to monitor the progress of a resolution
of indatraline enantiomers. For a more precise and sensitive
analysis of highly enantioenriched samples, an HPLC method
was developed that could be shown to enable accurate and pre-
cise quantitation of ee up to 99.75% for the (1R,3S)-enantiomer
of indatraline (eutomer) and 99.67% for the (1S,3R)-enantiomer
(distomer). Additionally, the results of HPLC method develop-
ment show that ESI-MS detection employing a mobile phase
based on ammonium acetate buffer is possible as well. The reli-
ability of the established method was conﬁrmed by validation
according to the ICH guideline Q2(R1). As indatraline is a prom-
ising triple reuptake inhibitor, it is worth mentioning that the
presented HPLC method represents a prerequisite for a correct
pharmacological characterization of the pure enantiomers of
indatraline and their possible use as pharmacological tools.
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1. Synthesis of Indatraline hydrochloride (rac-1.HCl) 
 
OH
O
Cl
Cl
OH
O
Cl
Cl
Cl
O
Cl
Cl
Cl
Cl
O OH
Cl
Cl
NH
Cl
Cl
CH3
a b
c d
e
98% quant.
89% 95%
75%
cis-(±)-3-(3,4-dichlorophenyl)indan-1-ol* 
rac-1 . HCl*
.
 HCl
 
 
 
 
a) AlCl3 (2 equiv.), benzene, rt., 20 h. b) SOCl2 (3 equiv.), DMF (1.8 equiv.), DCM, rt., 
45 h. c) AlCl3 (3 equiv.), benzene, 90 °C, 3 h. d) K-Selectride® (1.1 equiv.), THF, 
-10 °C, 20 h. e) 1. methanesulfonyl chloride (2 equiv.), NEt3 (4 equiv.), THF, -15 °C, 
1 h; 2. NH2CH3 (2 M, 20 equiv.), 0 °C to rt, 20 h, 3. aqueous HCl (1 M). 
 
*Depicted compounds are racemic although only one enantiomer is shown. 
2. General Methods 
Benzene, THF and NEt3 were distilled from sodium and CH2Cl2 was distilled from 
CaH2 under nitrogen. SOCl2 (Fluka), DMF (Acros) and methanesulfonyl chloride 
Fluka) were used without further purification. All other chemical reagents were used 
from bulk without further purification. Common solvents for recrystallization, column 
chromatography were distilled before use. TLC plates were made from silica gel 60 
F254 on aluminium sheets (Merck). Compounds were first stained with I2 on silica 
then with 5% (NH4)6Mo7O24·4H2O, 0.2% Ce(SO4)2·4H2O and 5% conc. H2SO4. If 
nothing else is stated, Merck silica gel (mesh 230–400) was used as stationary phase 
for flash chromatography (CC). Melting points: m.p. (uncorrected) were determined 
with an Electrothermal IA9100MK1 Melting Point apparatus. IR spectroscopy: FT-IR 
Spectrometer 1600 and Paragon 1000 (Perkin Elmer), oils were measured as film, 
solid samples as KBr pellets for measurements. Mass spectrometry: EI and CI, Mass 
Spectrometer 5989 A with 59980 B particle beam LC/MS interface (Hewlett Packard); 
ESI, API 2000 (Applied Biosystems). NMR spectroscopy: NMR spectra were recorded 
on JNMR-GX (Jeol, 500 MHz) with TMS as internal standard and integrated with the 
program of NMR-software Nuts (2D Version 5.097, Acorn NMR, 1995).   
 
3. 3-(3,4-dichlorophenyl)-3-phenylpropanoic acid1 
 
OH
O
Cl
Cl
 
 
To a stirred solution of (E)-3-(3,4-dichlorophenyl)acrylic acid (2.06 g, 9.50 mmol) in 
benzene (40 mL) was added AlCl3 (2.53 g, 19.0 mmol) at r.t. After stirring for 23 h the 
reaction mixture was poured into phosphate buffer (pH 5.5, 1 M, 70 mL) and the 
aqueous phase was extracted with EtOAc (5 x 80 mL). The combined organic layers 
were washed with saturated K-Na-tartrate solution (40 mL) then dried (MgSO4) and 
filtered. The solvent was removed in vacuo. The resulting material was not subjected 
to a further purification step. Colorless oil (2.76 g, 98 %): 
                                                 
1 Bøgesø KP, Christensen AV, Hyttel J, Liljefors T. 3-Phenyl-1-indanamines. Potential Antidepressant Activity and Potent 
Inhibition of Dopamine, Norepinephrine, and Serotonin Uptake. J Med Chem 1985; 28: 1817-1828. 
1H NMR (500 MHz, CD2Cl2): δ = 3.06 (dd, J = 16.2/8.2 Hz, 1 H, CH2), 3.10 (dd, J = 
16.2/7.7 Hz, 1 H, CH2), 4.47 (t, J = 7.9 Hz, 1 H CH2CH), 7.11 (dd, J = 8.3/2.1 Hz, 1 H, 
CCHCHCCl), 7.18–7.23 (m, 3 H, Har), 7.27–7.33 (m, 2 H, Har), 7.34 (d, J = 2.1 Hz, 1 
H, CCHCCl), 7.34 (d, J = 8.3 Hz, 1 H, CCHCHCCl). 13C NMR (125 MHz, CD2Cl2): δ = 
39.9, 46.0, 127.2, 127.4, 127.6, 128.7, 129.0, 129.8, 130.7, 142.3, 144.0, 177.2. IR 
(film): v~  = 3087 cm-1, 3062, 3092, 2920, 2671, 1713, 1471. MS (CI, CH5+): m/z (%): 
295 (4) [M+H]+, 149 (100). HRMS (EI): m/z [M]+ cacld. for C15H12O235Cl2: 294.0214, 
found: 294.0210. 
 
 
4. 3-(3,4-dichlorophenyl)-3-phenylpropanoyl chloride 
 
Cl
O
Cl
Cl
 
 
To a stirred solution of 3-(3,4-dichlorophenyl)-3-phenylpropanoic acid (11.4 g, 38.6 
mmol) in CH2Cl2 (100 mL) was added SOCl2 (8.41 mL, 116 mmol) and DMF (5.38 
mL, 69.5 mmol) at 0 °C. The ice bath was removed and the reaction mixture was 
stirred at r.t. for 20 h. CCl4 (200 mL) was added and the solvent was removed in 
vacuo. The resulting product was not subjected to a further purification step. 
Colorless oil (12.1 g, 100 %): 
1H NMR (500 MHz, CD2Cl2): δ = 3.62 (dd, J = 18.0/7.9 Hz, 1 H, CH2), 3.66 (dd, J = 
16.2/7.7 Hz, 1 H, CH2), 4.55 (t, J = 7.7 Hz, 1 H CH2CH), 7.11 (dd, J = 8.3/2.2 Hz, 1 H, 
CCHCHCCl), 7.18–7.23 (m, 2 H, Har), 7.23-7.38 (m, 1 H, Har), 7.31–7.36 (m, 3 H, 2 x 
Har, CCHCCl), 7.61 (td, J = 7.5/1.3 Hz, 1 H, CCHCH), 7.77 (ddt, J = 7.7/1.2/0.6 Hz, 1 
H, ) 13C NMR (125 MHz, CD2Cl2): δ = 41.8, 47.8, 122.7, 123.0, 124.6, 125.2, 126.3, 
126.5, 128.2, 136.4, 138.0, 144.0, 167.3. IR (film): v~  = 3087 cm-1, 3062, 3029, 2922, 
1799, 1471. MS (EI): m/z (%): 312 (10) [M]+, 235 (100). HRMS (EI): m/z [M]+ cacld. 
for C15H11O35Cl3: 311.9876, found: 311.9882. 
 
 
 
5. 3-(3,4-dichlorophenyl)indan-1-one1,2 
 
Cl
Cl
O
 
 
To a stirred solution of 3-(3,4-dichlorophenyl)-3-phenylpropanoyl chloride (2.94 g, 
0.94 mmol) in benzene (36 mL) was added AlCl3 (3.71g, 27.8 mmol) at r.t. and then 
refluxed for 3 h. After cooling to r.t. the reaction mixture was poured into H2O (150 
mL) followed by extraction with EtOAc (6 x 60 mL). The combined organic layers 
were washed with saturated K-Na-tartrate solution (40 mL) then dried (MgSO4) and 
filtered. The solvent was removed in vacuo. The resulting crude product was purified 
by flash chromatography (heptane/EtOAc = 85:15). Colorless solid (2.25 g, 89%): 
m.p. 104-105 °C (Lit.1 113-15 °C). 1H NMR (500 MHz, CD2Cl2): δ = 2.59 (dd, J = 
19.1/3.9 Hz, 1 H, CH2), 3.20 (dd, J = 19.1/8.2 Hz, 1 H, CH2), 4.57 (dd, J = 8.2/3.9 Hz, 
1 H, CH2CH), 7.00 (dd, J = 8.3/2.2 Hz, 1 H, CCHCHCCl), 7.24 (d, J = 2.1 Hz, 1 H, 
CCHCCl), 7.27 (dq, J = 7.8/0.9 Hz, 1 H, C(=O)CCCH), 7.40 (d, J = 8.3 Hz, 1 H, 
CCHCHCCl), 7.46 (ddt, J = 8.0/7.5/0.9 Hz, 1 H, C(=O)CCHCH), 7.61 (td, J = 7.5/1.3 
Hz, 1 H,  C(=O)CCCHCH), , 7.77 (ddt, J = 7.5/1.2/0.6 Hz, 1 H, C(=O)CCH) . 13C 
NMR (125 MHz, CD2Cl2): δ = 43.6, 46.4, 123.4, 126.8, 127.4, 128.3, 129.7, 130.79, 
130.83, 132.7, 135.3, 136.9, 144.5, 156.6, 204.6. IR (KBr): v~  = 3050 cm-1, 3014, 
2947, 2914, 1699, 1471, 764. MS (CI, CH5+): m/z (%): 277 (100) [M+H]+. HRMS (EI): 
m/z [M]+ cacld. for C15H10O35Cl2: 276.0109, found: 276.0108. 
 
 
 
                                                 
2 Davies HML, Gregg TM. Asymmetric synthesis of (+)-indatraline using rhodium-catalyzed C-H activation. Tetrahedron Lett 
2002; 43: 4951-4953.. 
6. cis-(±)-3-(3,4-dichlorophenyl)indan-1-ol1,2 
 
OH
Cl
Cl
 
 
To a stirred solution of 3-(3,4-dichlorophenyl)indan-1-one (1.18 g, 4.27 mmol) in THF 
(40 mL) was added a solution of K-Selectride® in THF (1 M, 4.70 mL, 4.70 mmol) at 
-10 °C. After stirring for 20 h the reaction mixture was poured into and then refluxed 
for 3 h. After cooling to r.t. the reaction mixture was poured into a saturated K-Na-
tartrate solution (100 mL) followed by extraction with EtOAc (5 x 90 mL). The 
combined organic layers were dried (MgSO4), filtered and the solvent was removed 
in vacuo. The resulting crude product was purified by flash chromatography 
(heptane/EtOAc = 80:20). Colorless solid (1.15g, 97%): m.p. 73-74 °C (Lit.1 90-91 
°C). 1H NMR (500 MHz, CD2Cl2): 1.86 (ddd, J = 12.9/8.8/7.2 Hz, 1 H, CH2), 2.98 
(ddd, J = 12.9/7.8/7.0 Hz, 1 H, CH2), 4.17 (t, J = 8.3 Hz, 1 H, CH2CH), 5.27 (q, J = 6.5 
Hz, 1 H, CHOH), 6.92 (dq, J = 7.7/1.0 Hz, 1 H, CH(OH)CCCH), 7.11 (dd, J = 8.3/2.1 
Hz, 1 H, CCHCHCCl), 7.25 (tt, J = 7.4/0.9 Hz, 1 H, CH(OH)CHCH), 7.31 (tt, J = 
7.5/1.1 Hz, 1 H, CH(OH)CCCHCH), 7.35 (d, J = 2.1 Hz, 1 H, CCHCCl) 7.40 (d, J = 
8.3 Hz, 1 H, CCHCHCCl), 7.46 (dq, J = 7.5/0.9 Hz, 1 H, CH(OH)CCH). 13C NMR (125 
MHz, CD2Cl2): δ = 46.7, 47.7, 74.9, 121.9, 122.8, 125.5, 125.9, 126.5, 128.20, 128.4, 
128.5, 120.3, 142.6, 143.2, 143.5. IR (KBr): v~  = 3334 cm-1, 3070, 3026, 2964, 2927, 
2862, 1469, 744. MS (EI) m/z (%): 278 (53) [M]+, 105 (100). HRMS (EI): m/z [M]+ 
cacld. for C15H12O35Cl2: 278.0265, found: 276.0281. 
 
 
7. Indatraline hydrochloride (rac-1.HCl)1,2 
 
NH
Cl
Cl
CH3
. HCl
 
 
To a stirred solution of cis-(±)-3-(3,4-dichlorophenyl)indan-1-ol (1.60 g, 5.73 mmol) in 
THF (40 mL) was added NEt3 (3.19 mL, 22.9 mmol) at -15 °C and methanesulfonyl 
chloride (679 µL, 8.60 mmol). After 1 h the reaction mixture was warmed to 0 °C and 
gaseous methylamine was introduced for 15 min with a syringe from a second vessel 
containing a large excess of a stirred mixture (1:1) of KOH and methylamine 
hydrochloride. The reaction mixture was allowed to warm slowly to r.t. over 10 h. The 
resulting orange solution was poured into saturated NaHCO3 solution (50 mL) 
followed by extraction with EtOAc (6 x 70 mL). The combined organic layers were 
dried (MgSO4), filtered and the solvent was removed in vacuo. The resulting crude 
product was purified by flash chromatography (heptane/EtOAc = 85:15 + 1% 
N,N-dimethylethylamine). The resulting colorless oil was dissolved in dioxane (1 mL), 
treated with aqueous HCl (1 M, 10 mL) and freeze dried. The resulting product was 
recrystallized from EtOAc (15 mL) to yield colorless crystals (1.41 g, 75%): m.p. 120-
123 °C (Lit.1: 183-185 °C). 1H NMR (500 MHz, D2O): 2.28 (dt, J = 15.2/8.0 Hz, 1 H, 
CH2), 2.63 (s, 3 H, CH3), 2.66 (ddd, J = 15.2/7.6/2.1 Hz, 1 H, CH2), 4.55 (t, J = 7.9 
Hz, 1 H, CH2CH), 4.82 (d, J = 7.8 Hz, 1 H, CHNCH3), 6.84 (d, J = 7.6 Hz, 1 H, 
CH(OH)CCCH), 6.91 (dd, J = 8.3/2.1 Hz, 1 H, CCHCHCCl), 7.15 (d, J = 2.1 Hz, 1 H, 
CCHCCl),  7.32–7.18 (m, 3 H, CH(NCH3)CHCH),  CH(NCH3)CCCHCH, CCHCHCCl), 
7.53 (d, J = 7.6 Hz,  1 H, CH(NCH3)CCH). 13C NMR (125 MHz, D2O): δ = 28.26, 36.4, 
45.9, 60.7, 123.8, 124.0, 125.9, 126.2, 127.8, 128.3, 128.7, 128.9, 130.1, 134.5, 
142.3, 145.3. IR (KBr): v~  = 3406 cm-1, 3963, 2712, 2479, 2444, 1590, 1486, 760. MS 
(CI, CH5+) m/z (%): 292 (100) [M+H-HCl]+. HRMS (EI): m/z [M-HCl]+ cacld. for 
C16H15N35Cl2: 291.0582, found: 291.0570. 
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3.2.2 Second Publication: 
Development and validation of an LC-ESI-MS/MS method for triple reuptake 
inhibitor indatraline enabling its quantification in MS Binding Assays  
 
Binding assays which characterize the affinity of a ligand to a defined target are an 
indispensable tool in the drug discovery process. Next to the well-established radioligand 
binding assays a concept called MS Binding Assays was recently introduced.[45-47] A basic 
prerequisite for both types of assays is a reliable and highly sensitive quantification of the 
employed marker substance in biological matrices. In radioligand binding assays quantitation 
is accomplished by the scintillation measurement, a highly sensitive method, of radioactively 
labelled markers, i.e. radioligands. MS Binding Assays are based on a quantification of a 
native, i.e. nonlabelled marker via LC-MS.  
To develop MS Binding Assays addressing the human monoamine transporter (i.e. dopamine 
transporter, norepinephrine transporter, and serotonin transporter) an LC-MS quantification 
method for the chosen marker substance, i.e. the high affine triple reuptake inhibitor 
indatraline, had to be established. First of all, the previously unknown ESI-MS/MS mass 
transitions of indatraline and of the intended internal standard (2H7)-indatraline were 
investigated. Next, an LC method was developed which should allow a fast, reliable, and highly 
sensitive quantification of indatraline in binding samples. Different parameters concerning the 
LC such as composition of mobile phase, size of injection volume, composition of sample 
milieu, etc., but also concerning the generation of the matrix, i.e. filter material, incubation and 
washing buffer, as well as eluent for liberation of bound marker, were examined for their effect 
on signal intensity of the analyte as well as signal-to-noise ratio. The final HPLC method for 
quantification of indatraline [YMC Triart C18 column (50 mm x 2.0 mm, 3 µm) with a YMC Triart 
C18 precolumn (10 mm x 2.0 mm, 3 µm) as stationary phase, a mixture of acetonitrile and 
ammonium bicarbonate buffer (5 mmol L-1, pH 10.0) in a ratio of 90:10 (v/v) as mobile phase, 
a mixture of acetonitrile and ammonium bicarbonate buffer (5 mmol L-1, pH 10.0) in a ratio of 
75:25 (v/v) as sample milieu, at a temperature of 20 °C, a flow rate of 600 µL min-1, and an 
injection volume of 45 µL] was then validated according to the FDA guidance for bioanalytical 
method validation[56] regarding selectivity, calibration standard curve in a range from 5 pmol L-1 
(LLOQ) to 5 nmol L-1, accuracy, and precision. The developed LC-ESI-MS/MS method was 
used not only for the quantification of indatraline but also for its cis-configured diastereomer in 
biological matrices. It is also worth stressing that the developed method is the most sensitive 
quantification method for indatraline described in literature so far.  
Finally, as proof of concept this method was applied to MS Binding Assays characterizing the 
affinity of (1R,3S)-indatraline towards hNET in saturation experiments and of desipramine in 
competitive experiments employing (1R,3S)-indatraline as marker. Both results, i.e. found 
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affinity of (1R,3S)-indatraline and desipramine towards hNET, demonstrated the efficiency of 
the developed MS Binding Assays and its suitability as substitute for conventional radioligand 
binding assays addressing NET. 
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Abstract We herein present the first LC-MS/MS quantifica-
tion method for indatraline, a highly potent nonselective in-
hibitor of the three monoamine transporters (for dopamine,
DAT; norepinephrine, NET; serotonin, SERT), and its appli-
cation toMSBinding Assays. For HPLC, an R18 columnwith
a mobile phase composed of acetonitrile and ammonium
bicarbonate buffer (5 mmol L-1, pH 10.0) in a ratio of 90:10
(v/v) at a flow rate of 600 μL min-1 was used. Recording
indatraline at m/z 292.2/261.0 and (2H7)-indatraline,
employed as internal standard, at m/z 299.2/268.0 allowed
reliable quantification from 5 pmol L−1 (LLOQ) to 5 nmol
L−1 in biological matrices without additional sample prepara-
tion. Validation of the developed quantification method
showed that selectivity, calibration standard curve, accuracy,
as well as precision meet the criteria of the CDER guideline.
Applying this method to mass spectrometry (MS) Binding
Assays, a label-free MS-based alternative to conventional
radioligand binding assays, binding of indatraline’s eutomer,
(1R,3S)-indatraline, towards NET could be characterized di-
rectly for the first time, revealing an equilibrium dissociation
constant (Kd) of 805 pmol L
−1. Additionally, it could be shown
that the established MS Binding Assays enable characterization
of test compounds in competition experiments. As the
established setup is based on a 96-well format and an LC MS/
MS method with a short chromatographic cycle time (1.5 min),
the developedMSBinding Assays enable considerable through-
put and are therefore well suited as substitute for corresponding
radioligand binding assays.
Keywords Indatraline . hNET . Validation . Binding .
LC-MS
Introduction
Since the catechol hypothesis was published in the 1960s as
an explanation for the genesis of depressions [1, 2], the
neuronal systems of dopamine (DA), norepinephrine (NE),
and serotonin (5-HT) are in focus for drug development.
Inhibition of the corresponding transporters [dopamine trans-
porter (DAT), norepinephrine transporter (NET), and seroto-
nin transporter (SERT)], which terminate the signals that
originate from these monoamines at their receptors by
transporting them out of the synaptic cleft back into neurons,
represent the mainstay for the treatment of major depression
[3]. Nowadays, selective inhibitors for a single monoamine
transporter type (SERT or NET) as well as dual reuptake
inhibitors, which inhibit two of the monoamine transporters
(SERTand NETor NETand DAT), are primarily employed to
achieve this task. As currently only 65 % of the depressive
patients treated with corresponding monoamine transporter
inhibitors are showing a sufficient therapeutic response, there
is still a substantial need for the development of new antide-
pressants with an improved therapeutic profile [4].
The identification of new drug candidates addressing
monoamine transporters (or other targets aiming at the therapy
of depression) requires suitable screening tools. Therefore, a
broad spectrum of techniques providing information regard-
ing affinity or functional activity is available. Competitive
binding assays based on a reporter ligand, with high affinity
for the target of interest, represent an efficient approach for
affinity determination of test compounds. A prerequisite for
this approach is a highly sensitive quantification of the report-
er ligand. Commonly, this task is achieved by employing a
ligand labelled with a radioisotope. Despite the extraordinarily
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high sensitivity of this detection principle, the use of
radioligands is associated with considerable disadvantages
such as severe legal restrictions in the handling of these
hazardous compounds and problems with the resulting radio-
active waste. Mass spectrometry (MS) developed to be a
promising detection technique to monitor binding of native
ligands to defined targets in the last decades, either directly at
the level of the target-ligand complexes or at the level of the
ligands interacting with the targets. As it is beyond the scope
of this introduction to give an overview over MS-based
screening techniques, the interested reader is referred to liter-
ature [5–10]. A simple but very efficient strategy to avoid the
drawbacks of radioligands in binding assays is the concept of
MS Binding Assays recently developed in our group [11, 12].
It is based on nonlabelled reporter ligands, in this case termed
MS marker, native marker, or simply marker, that can be
quantified by means of mass spectrometry. MS Binding As-
says follow the conventional setup of radioligand binding
assays but offer all of their possibilities and are therefore a
promising substitute for radioligand binding assays.
It was the aim of the present study to establish an LC-MS/
MSmethod for anMSmarker that can be employed to address
DAT, NET, and even SERT in MS Binding Assays. As in this
case the conditions of the intended binding experiments can
be adopted from known radioligand binding and transport
assays, the development of a highly sensitive, reliable, robust,
and fast quantification method for the selectedMSmarker can
be considered by far as the most time-consuming step in the
process to set up corresponding MS Binding Assays. There-
fore, selection of a marker, which can be used to address all of
the three targets (DAT, NET, and SERT), can be considered as
a particularly efficient approach, as the development of a
suitable quantification method causes only a single effort. In
this context, it should be mentioned that this approach is only
feasible when the individual targets are individually accessi-
ble, as this is the case when heterologous expression systems
are employed. According to this idea, we intended to benefit
from indatraline [(1RS,3SR)-3-(3,4-dichlorophenyl)-1-
methylamino-2,3-dihydro-1H-indene], also known as Lu 19-
005 [13], that inhibits all three monoamine transporters (DAT,
NET, SERT) with high potency and is therefore referred to as a
triple reuptake inhibitor. For the MS Binding Assays to be
established, we aimed to employ the eutomer, (1R,3S)-
indatraline, as MS marker (Fig. 1).
So far, neither (1R,3S)-indatraline nor (1S,3R)-indatraline
has been characterized in binding assays towards DAT, NET,
or SERT. However, both enantiomers of indatraline have been
investigated in uptake assays for their inhibitory potencies,
revealing low nanomolar to subnanomolar IC50 values and a
eudismic ratio of 5 (SERT) to 51 (DAT) in favor of (1R,3S)-
indatraline [13]. Assessing the significance of these data re-
garding potency and selectivity of (1R,3S)-indatraline for our
intended binding assays addressing DAT, NET, and SERT, we
had to consider the conditions under which these uptake
assays had been performed [13]. As Bogeso et al. employed
indatraline enantiomers with a moderate enantiopurity (≥95%
ee) in the uptake experiments [13], the true potencies of the
enantiomers may differ to some extent to those determined in
this study. Furthermore, Bogeso et al. used crude animal (rat)
brain preparations in their uptake experiments [13], which do
not represent an appropriate target source for selective char-
acterization of the individual monoamine transporters in up-
take assays, as the substrates employed (in this case [3H]DA,
[3H]NE, and [3H]5-HT) could also interact with other targets
present in the preparation. Thus, the data may be falsified to
some extent. Distinctly more information is available from
radioligand binding experiments at monoamine transporters
regarding the racemic compound. Indatraline’s affinity (i.e.,
inhibition constants, Ki) employing different radioligands
such as [125I]RTI-55 [14–16] or [3H]WIN-35,428 [17–19]
for DAT, [125I]RTI-55 [16] and [3H]nisoxetine [15, 20] for
NET, and [125I]RTI-55 [14, 16, 21], [3H]citalopram [15],
[3H](S)-citalopram [22, 23], [3H]DASB [23], [125I]EINT
[24], or [3H]paroxetine [25] for SERT in binding assays (see
Electronic SupplementaryMaterial (ESM) Fig. S1) was found
to be in the low nanomolar to subnanomolar concentration
range. Again, most of the corresponding data were generated
employing crude membrane preparations [except for [16, 22,
23] employing human embryonic kidney (HEK) membrane
preparations]. Based on all the information available, (1R,3S)-
indatraline’s equilibrium dissociation constant (Kd) in binding
experiments addressing DAT, NET, or SERT can only be
assumed to be in the range from low nanomolar down to
picomolar concentrations, but is not exactly known. There-
from, the following consequences are arising.
At first and foremost, the quantification method for
indatraline to be applied in the corresponding MS Binding
Assays has to be extremely sensitive. An estimation for the
required sensitivity can be derived from the expectedKd value
of (1R,3S)-indatraline towards hDAT, hNET, or hSERT (low
nanomolar down to picomolar range, see above) in combina-
tion with the rules generally accepted for saturation experi-
ments in radioligand binding assays. These are nominal
Fig. 1 (1R,3S)-indatraline [(1R,3S)-3-(3,4-dichlorophenyl)-1-
methylamino-2,3-dihydro-1H-indene] (black) and (2H7)-indatraline
[(1RS,3SR)-3-(3,4-dichloro(2,5,6-2H3)phenyl)-1-methylamino-2,3-
dihydro(4,5,6,7-2H4)-1H-indene] (red)
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marker concentrations in a range from at least 0.1 Kd to 10 Kd
and target concentrations in a magnitude of up to 0.1 Kd that
have to be employed to avoid a marker depletion [26]. It has to
be mentioned that target concentrations distinctly below 0.1
Kdwill further increase the challenge ofmarker quantification.
For our intended hDAT, hNET, or hSERT saturation experi-
ments following these recommendations, the concentration of
the boundmarker could be assumed to be in the low picomolar
perhaps even in the femtomolar range for binding samples
containing nominal (1R,3S)-indatraline concentrations in the
low ormiddle picomolar range. As a consequence, our aspired
lower limit of quantification (LLOQ) should be as low as
possible but at least in the very low picomolar range. Such a
highly sensitive method to quantify indatraline has—to the
best of our knowledge—not been described so far. The only
LCmethod known for indatraline employs UV detection [27].
Therefore, we started to establish a new LC-ESI-MS/MS
quantification method employing indatraline in its racemic
form, which is commercially available. Secondly, as ESI-
MS/MS is prone to ion suppression that may in our case result
from the matrix of the binding samples, it was our intention to
make use of (2H7)-indatraline [(1RS ,3SR)-3-(3,4-
d ich loro(2 ,5 ,6-2H 3 )phenyl ) -1-methylamino-2 ,3-
dihydro(4,5,6,7-2H4)-1H-indene] (Fig. 1) that was synthe-
sized recently in our group to serve as internal standard [28].
Thirdly, to assure reliable results in MS Binding Assays, this
LC-ESI-MS/MS quantification method should be validated
according to generally accepted criteria for bioanalytical
methods before its application. Furthermore, the LC-ESI-
MS/MS method to be developed for quantification of
indatraline should also be investigated for its capability to
enable quantification of the cis-configured diastereomer of
indatraline in MS Binding Assays, which is known as a SERT
selective monoamine transport inhibitor [13, 16].
As an MS Binding Assay addressing hSERT [29] was
already available in our group, the development of new MS
Binding Assays employing (1R,3S)-indatraline as marker was
focused on hDAT and hNET. Due to the fact that HEK cells
stably expressing hNETwere obtained first, we intended to set
up saturation and competition experiments for this transporter
as a proof of concept.
Materials and methods
Chemicals
All LC-MS grade solvents (acetonitrile, water) as well as HPLC
grademethanol were purchased fromVWRProlabo (Darmstadt,
Germany). Water for incubation and wash buffer was obtained
in-house by distillation of demineralized water (prepared by
reverse osmosis) and subsequent filtration using 0.45 μm filter
material. Additives for LC-MS (ammonium bicarbonate,
ammonium hydroxide solution ≥25 %, ammonium formate,
and formic acid), all of LC-MS quality, were bought from Fluka
(Taufkirchen, Germany). Ammonium acetate (HPLC grade) and
HEPES (2-[4-(hydroxyethyl)piperazin-1-yl]ethanesulfonic acid)
were purchased from VWR Prolabo (Darmstadt, Germany).
Inda t r a l i ne hydroch lo r ide , ( 2H 7 ) - inda t r a l i ne
deuterochloride, and the hydrochloride of the cis-configured
diastereomer of indatraline were synthesized in-house. For
(1R,3S)-indatraline hydrochloride employed in this study, an
enantiopurity of >99.75% eewas determined according to the
method previously described [27]. [3H]MPP+ acetate (80–
85 Ci mmol−1) for uptake experiments was bought from
BIOTREND (Cologne, Germany). Nonlabelled MPP+ iodide
and desipramine hydrochloride were from Sigma-Aldrich
(Steinheim, Germany).
Dulbecco’s modified Eagle’s medium (DMEM) was
bought from Sigma-Aldrich, and fetal bovine serum, penicil-
lin, streptomycin, and geneticin were bought from PAA
(Cölbe, Germany). HEK293 cells were purchased fromAmer-
ican Type Culture Collection (LGC Standards GmbH, Wesel,
Germany).
Unless otherwise indicated, all percentages and ratios are
specified (v/v).
Preparation of standards and quality controls
For the preparation of stock solutions, the hydrochlorides of
indatraline, (1R,3S)-indatraline, and the cis-configured diaste-
reomer of indatraline as well as the deuterochloride of (2H7)-
indatraline, respectively, were dissolved in an appropriate
volume of water, resulting in a concentration of
10 mmol L−1 in each case. (2H7)-Indatraline stock solution
was diluted with water, yielding a 1 μmol L−1 working solu-
tion, and indatraline, (1R,3S)-indatraline, and cis-configured
diastereomer stock solutions were diluted in the same way,
obtaining working solutions of 1µmol L-1, 100, and
10 nmol L−1. All solutions were stored at room temperature.
On the day of the assay, respective working solutions were
diluted with acetonitrile to yield the required concentrations
for the preparation ofmatrix-based calibration standards, qual-
ity controls (QC), and zero samples. Generation of matrix
samples was performed as described for binding samples
(“MS Binding Assay—standard setup”; see below). After
filtration and drying, the filter plates were eluted with 3×
75 μL of a solution, containing analyte and internal standard,
or just the internal standard, in acetonitrile as required, to
obtain calibration standards, QCs, and zero samples, or ace-
tonitrile to obtain matrix blanks. Finally, 75 μL of a
5 mmol L−1 ammonium bicarbonate buffer (pH 10.0) was
added to each well, obtaining the desired concentrations (see
“Method validation”) of (2H7)-indatraline and indatraline for
calibration standards and QCs (the same procedure was
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applied to obtain corresponding standards and QCs for the cis-
configured diastereomer).
LC-ESI-MS/MS
LC-MS instrumentation
Preliminary experiments for HPLC method development and
post column infusion experiments were performed on an API
2000 triple quadrupole mass spectrometer (Applied
Biosystems, Darmstadt, Germany) coupled to an Agilent
1100 HPLC system (Agilent vacuum degasser, quaternary
pump, column oven; Agilent, Waldbronn, Germany) and a
Shimadzu SIL-10 autosampler (Shimadzu, Duisburg, Germa-
ny). For further method development, validation, and binding
experiments, an API 5000 triple quadrupole mass spectrome-
ter with a Turbo V ion source coupled to an Agilent 1200
HPLC system (Agilent vacuum degasser, binary pump, col-
umn oven) and anHTS-PAL autosampler (50μL sample loop,
50 μL syringe, CTC Analytics, Zwingen, Switzerland) was
used. Direct infusion experiments at the API 5000 were per-
formed using a syringe pump (model 11 Plus MA 170-2208,
Harvard Apparatus Inc., Holliston, MA, USA). For all MS-
based investigations, Q1 and Q3 were operated with unit
resolution.
For HPLC, a YMC Triart C18 (50×2.0 mm, 3 μm; YMC
Europe GmbH, Dinslaken, Germany) with a YMC Triart C18
precolumn (10×2.0 mm, 3 μm) was employed. For routine
MS Binding Assays, the column was additionally protected
with two IDEX frits (Wertheim-Monfeld, Germany) of 0.5
and 0.2 μm porosity, respectively, and the first 0.6 min of the
eluents was sent to waste. For all experiments, the column
temperature was set to 20 °C.
Method development
Optimization of compound-dependent parameters for the pre-
cursor and the product ions of indatraline and (2H7)-
indatraline was performed by direct infusion of a
1 μmol L−1 solution (API 2000) or a 20 nmol L−1 solution
(API 5000), which were prepared in methanol/0.1 % formic
acid at a ratio of 50:50, using the Analyst 1.4.2 Quantitative
Optimization tool.
For the examination of the influence of the pH value on
chromatography, matrix samples were generated by elution of
hNET matrix (“MS Binding Assays—standard setup”; see
below) with 3×100 μL methanol, drying overnight at 50 °C,
and, finally, reconstitution of the dried sample residues in
300 μL of the respective mobile phase. The capacity factor
(k) calculation was based on a total void volume comprised of
the experimentally determined system void volume and the
column void volume calculated to 131.95 mm3 according to
[30].
Using the flow injection analysis (FIA) option of the An-
alyst 1.4.2 Quantitative Optimization tool, 10 μL of a
500 pmol L−1 indatraline solution, dissolved in the mobile
phase, was injected to determine the most appropriate source-
dependent parameters for the final HPLC method.
Method validation
The validation was based on six different sample series (each
including blank samples, zero samples, calibration standards,
and QCs, all in the presence of the matrix obtained from hNET
binding samples) investigated on different days using different
batches of membrane preparation (“MS Binding Assays—
standard setup”; see below).
Linearity was determined for calibration standards at ten
different concentration levels (i.e., 5 pmol L−1–5 nmol L−1),
which were prepared in triplicates, except for 5 pmol L−1
(LLOQ, six replicates). Obtained area ratios (y) of indatraline
vs (2H7)-indatraline were plotted against the concentration of
indatraline (x). A linear regression with a weighting of 1/x2
was applied to all calibration data sets. QC samples at five
different concentration levels (i.e., 10, 25, 100, 500 pmol L−1
and 1 nmol L−1), each consisting of six replicates, were used
to evaluate intra- and inter-batch accuracy as well as precision.
The LLOQ was defined as the lowest concentration of
indatraline, which had at least a signal-to-noise ratio of 5:1,
an accuracy of 80–120 %, and a precision of a relative stan-
dard deviation (RSD) ≤20 %. Acceptance limits for accuracy
were 85–115 % (except LLOQ) and for precision an RSD
≤15 % (except LLOQ).
Stability of the aqueous stock solutions of indatraline was
investigated by comparing 1 nmol L−1 solvent standards (sup-
plemented with 1 nmol L−1 internal standard, n=6) prepared
from a fresh indatraline stock solution or an 8-month-old
indatraline stock solution stored at room temperature, respec-
tively, employing in both cases an 8-month-old stock solution
of (2H7)-indatraline.
Analogously, the cis-configured diastereomer of
indatraline, also using (2H7)-indatraline as internal stan-
dard, was investigated (based on three different sample
series prepared as those containing indatraline). Linear-
ity was determined at six different concentration levels
(i.e., 5 pmol L−1–1 nmol L−1, triplicates). Accuracy and
precision were determined for QC samples at three
different concentration levels (i.e., 10, 100 pmol L−1
and 1 nmol L−1, hexaplicates).
Additionally, on each day an MS Binding Assay was
performed, also individual matrix blanks, zero samples, and
matrix standards were prepared and investigated to establish a
calibration function in a range from 5 pmol L−1 to 1 nmol L−1
(six concentration levels in triplicates). Furthermore, accuracy
and precision were examined by analysis of QCs (10,
100 pmol L−1 and 1 nmol L−1, hexaplicates).
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Cell culture and expression of hNET
The mammalian pRc/CMV expression vector containing
the complementary DNA (cDNA) coding for hNET was
kindly provided by Prof. Dr. Harald H. Sitte (Center for
Physiology and Pharmacology, Institute of Pharmacolo-
gy, Medical University of Vienna). HEK293 cells were
cultured at 37 °C and 8 % CO2 in DMEM containing
10 % (m/v) fetal bovine serum, 100 U mL−1 penicillin,
and 100 μg mL−1 streptomycin (culture medium). The
plasmid linearized with KpnI was employed for stable
transfection. About 6×105 HEK293 cells per 21 cm2
culture dish were plated in the culture medium 2 days
before transfection. On the third day, a mixture of
15 μL FuGENE6 (Roche, Mannheim, Germany) and
40 μg linearized pRc/CMV hNET DNA was added to
these cells. Two days later, the medium was exchanged
using for further cultivation “selection medium”
[DMEM supplemented with 10 % (m/v) fetal bovine
serum, 100 U mL−1 penicillin, 100 μg mL−1 streptomy-
cin, and 500 μg mL−1 geneticin]. Under these condi-
tions, cells were cultured till an appropriate confluence
was obtained in a 145-cm2 culture dish. After that, these
cells were detached (see below) and split in the selec-
tion medium for a dilution of ≤1 cell per 100 μL.
Therefrom, aliquots of 100 μL were transferred in a
96-well culture dish. Single colonies of stably
transfected cells were further cultivated in the selection
medium and tested for their expression of hNET using a
[3H]MPP+ uptake assay (for details, see supplementary
material). The clone with the highest ratio of total
uptake vs nonspecific uptake was used for hNET bind-
ing experiments.
hNET membrane preparation
HEK293 cells stably expressing hNET were cultivated in a
selection medium, as described above. After detaching the
cells by repeated aspiration and discharge of 10 mL
phosphate-buffered saline (PBS, 137 mmol L−1 NaCl,
2.7 mmol L−1 KCl, 8 mmol L−1 Na2HPO4, 1.75 mmol L
−1
KH2PO4, pH 7.4) per 145 cm
2 culture dish, the cell suspen-
sion was transferred to 50-mL tubes and centrifuged for 5 min
at 1600 rpm at 4 °C (Biofuge Stratos, Heraeus, Hanau, Ger-
many). The resulting pellet was washed twice with 10 mL
PBS buffer per 145 cm2 culture dish via resuspension and
centrifugation as described above. Finally, the pellet was
resuspended in 0.32 mol L−1 sucrose with a Polytron PT A7
(Kinematica, Littau-Luzern, Switzerland) and frozen in ali-
quots at -80 °C. On the day of the assay, an aliquot (1.0 mL) of
the membrane preparation was thawed, diluted in 20mL assay
buffer (50 mmol L−1 HEPES, 120 mmol L−1 NaCl,
5 mmol L−1 KCl, pH 7.4), and centrifuged (20 min,
20,000 rpm, 4 °C, Sorvall Evolution, SS-34 rotor, Thermo
Fisher Scientific, Dreieich, Germany). The resulting pellet
was resuspended in ice-cold assay buffer to yield a final
protein concentration of approximately 40–60 μg mL−1 (ac-
cording to Bradford after incubation with 100 mmol L−1 so-
dium hydroxide and bovine serum albumin as standard [31]).
MS Binding Assays—standard setup
hNET membrane preparations and marker were incubated in
assay buffer in polypropylene 96-deep-well plates at 37 °C in
a shaking water bath. Incubation was terminated by filtration.
Therefore, aliquots of the binding samples were transferred by
means of a 12-channel pipette onto 96-well glass fiber filter
plates (AcroPrep Advance, glass fiber, 1.0 μm, 350 μL, Multi
Well Plate Vacuum Manifold, Pall, Dreieich, Germany),
which had been pretreated for 1 h with 200 μL of a 0.5 %
(m/v) polyethyleneimine solution. Membrane fragments with
the bound marker remaining on the filter were washed five
times with 150 μL ice-cold 150 mmol L−1 ammonium acetate
buffer (pH 7.4). Afterwards, the filter plates were dried for 1 h
at 50 °C and cooled down to room temperature. Subsequently,
the bound marker was liberated via elution with acetonitrile
containing 1.33 nmol L−1 (2H7)-indatraline (3×75μL, 30 s for
every aspiration step). After addition of 75 μL of ammonium
bicarbonate buffer (5 mmol L−1, pH 10.0) per well, the plates
were centrifuged (10 min, 2500 rpm, 4 °C; Biofuge Stratos,
Heraeus, Hanau, Germany), sealed with aluminum foil, and
the samples analyzed according to the validated LC-MS/MS
method.
Matrix samples for method development and validation
were generated as hNET binding samples (protein according
to Bradford in a range from 0.5 to 5 μg per well, total
incubation volume 250 μL, aliquot transferred to the filter
plate 200 μL) but in the absence of (1R,3S)-indatraline.
MS Binding Assays—saturation experiments
hNET membrane preparations (approximately 2.0 μg protein
per well) and (1R,3S)-indatraline (15 concentration levels in a
range from 50 pmol L−1 to 30 nmol L−1, six replicates per
concentration level) were incubated in polypropylene 96-well
plates (2.2 mL per well; SARSTEDT, Nümbrecht, Germany;
total incubation volume 2.0 mL) for 2 h. Incubation was
basically terminated by filtration of the binding samples
through a glass fiber filter plate as described for the standard
setup. In contrast to the latter, however, two aliquots of
1800 μL per incubation replicate were each transferred to
the same wells of the filter plate (i.e., two of the hexaplicate
incubation samples were combined to obtain three replicates
on the filter plate, each generated from 3600 μL of the respec-
tive binding samples per filter well). The remainingmembrane
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fragments retained on the filter were further treated as de-
scribed for the standard setup.
Nonspecific binding was determined in the same way but
in the presence of 10 μmol L−1 desipramine. Employing this
modified setup, nonspecific binding could directly be deter-
mined at marker concentrations ≥500 pmol L−1. Nonspecific
binding for marker concentrations <500 pmol L−1was extrap-
olated from the experimental data (as described below in
“Data analysis”).
MS Binding Assays—competition experiments
The described standard setup was also used for competitive
experiments. The total incubation volume was 250 μL, and an
aliquot of 200 μL therefrom was transferred to the filter plate.
(1R,3S)-Indatraline was employed as marker in a concentra-
tion of 2.4 nmol L−1. For affinity characterization, desipra-
mine was incubated in the presence of the marker and the
target (approximately 2.5 μg per well) at least at seven con-
centrations in a range from 50 pmol L−1 to 1 μmol L−1.
Nonspecific binding was determined in an additional ex-
periment in a range of 2.5 to 20 nmol L−1 of (1R,3S)-
indatraline as described above (see saturation experiments).
The corresponding nonspecific binding for the employed
marker concentration, i.e., 2.4 nmol L−1, was extrapolated
from the respective experimental data (as described below in
“Data analysis”).
Data analysis
LC-ESI-MS/MS data for method development were obtained
using Analyst 1.4.2, and data for validation as well as for
binding experiments were obtained using Analyst 1.6.1. Cal-
ibration functions were generated by linear regression using
Prism 5.0 (GraphPad Software, San Diego, CA, USA).
In saturation experiments, the equilibrium dissociation con-
stant (Kd) and the maximum amount of binding sites (Bmax)
were calculated from specific binding using the nonlinear
regression tool “one site – specific binding” of Prism 5.0.
Specific binding was defined as the difference between total
and nonspecific binding.
For determination of the inhibitory constants (Ki) of desip-
ramine in competitive experiments, the nonlinear regression
tool “one site – Fit Ki” of Prism 5.0 was used. Therefore, the
corresponding specific binding, calculated as the difference of
total binding and nonspecific binding, was plotted on a per-
centage basis of a respective binding sample in the absence of
any inhibitor, which was set to 100 %, vs the employed log
concentration of the test compound, whereby 0%was equal to
the nonspecific binding.
Nonspecific binding could be experimentally determined at
a marker concentration ≥500 pmol L−1 (saturation experi-
ments) and ≥2.5 nmol L−1 (competition experiments). At
lower concentrations, nonspecific binding was calculated by
extrapolation (linear regression) of the respective experimen-
tal data using Prism 5.0.Marker depletion was negligible in all
experiments (≤10 %).
For statistical comparisons, data were examined by means
of F test and t test (two sites, α=0.05 as far as not indicated
otherwise in both cases).
Results and discussion
Method development
As the LC-MS method to be developed should be used for
quantification of indatraline in MS Binding Assays for DAT,
NET, and SERT, an LLOQ at least in the low picomolar range
was a key requirement. To achieve this task, we tried to benefit
from the high performance of an API 5000 triple quadrupole
mass spectrometer equipped with a pneumatically assisted
electrospray ionization source. To allow reliable and robust
quantification of the analyte in the matrix resulting from the
binding assays, (2H7)-indatraline was employed as internal stan-
dard. Furthermore, the method to be developed was expected to
be fast enough to enable a considerable throughput and avoid
any sample preparation.
ESI-MS/MS
As ESI-MS/MS mass transitions for indatraline and (2H7)-
indatraline have not been described so far, the first aim was to
find and optimize the potentials for the [M+H]+ species of
indatraline and (2H7)-indatraline in a Q1 scan. Afterwards, a
product ion scan was performed to identify the most intensive
product ions of the [M+H]+ parent ions of indatraline (m/z 292.2)
and (2H7)-indatraline (m/z 299.2), respectively. The five most
intensive fragments observed were m/z 261.0, 225.9, 191.0,
189.2, and 115.1 for indatraline as well as m/z 268.0, 232.9,
198.2, 195.3, and 119.2 for (2H7)-indatraline, respectively
(Fig. 2). For the most prominent mass transitions observed for
indatraline (m/z 292.2/261.0) and for (2H7)-indatraline (m/z
299.2/268.0), which are presumably the result of a loss of a
methylamine moiety, as it is described for other methylamine
derivatives in literature [32] and also for sertraline, a
tetrahydronaphthalene analogue of indatraline [33], an optimi-
zation of the mass spectrometer’s compound-dependent param-
eters was performed and the optimized parameters resulting
therefrom used for further method development. In detail, we
found an optimal declustering potential (DP) of 61 V and en-
trance potential (EP) of 10 V for both compounds [indatraline
and (2H7)-indatraline], a collision cell exit potential (CXP) of
32 V for indatraline and 30 V for (2H7)-indatraline, and a
collision energy (CE) of 19 V for indatraline and 17 V for
(2H7)-indatraline.
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LC
It was intended to establish a fast isocratic LC method
based on an RP stationary phase with a mobile phase
containing a high fraction of organic solvent, which
should ensure high intensities and as a consequence high
sensitivity under ESI conditions [34], but at the same time
polar matrix components resulting from the binding sam-
ples should be separated by HPLC to avoid a respective
suppression of the analyte signal.
In preliminary experiments with an RP18 stationary phase,
the influence of the pH value (pH 3.0-11.0) of the aqueous
component of the mobile phase on retention time and intensity
of indatraline in LC-ESI-MS/MS chromatograms recording
m/z 292.2/261.0 was studied. Furthermore, suppression of the
analyte signal was investigated in post column infusion ex-
periments using the same RP18 column and different acidic or
basic mobile phases (5 mmol L−1 ammonium formate, pH 4.0,
or 5 mmol L−1 ammonium bicarbonate, pH 10.0) in combi-
nation with acetonitrile at ratios of 20:80 and 10:90. The most
important observations resulting from these experiments were
the following. First, reasonable retention of indatraline (i.e.,
k≥1) employing such a high fraction of organic solvent in the
mobile phase, in our case between 80 and 90 % acetonitrile,
could only be obtained at pH values ≥8.5 of the aqueous
component (see ESM Fig. S2). Secondly, intensities in the
absence of the matrix were highest at the lower range of the
investigated pH values, whereas intensities in the presence of
the matrix were highest in the upper range of the investigated
pH values. Thirdly, suppression of the analyte signal could be
largely avoided at pH 10.0 when capacity factors (k) were
>0.75 (see ESM Fig. S3).
These results prompted us to focus on a basic mobile phase
in a pH range from 8.5 to 11.0 employing 5 mmol L−1 am-
monium bicarbonate as additive for further method develop-
ment. So, indatraline matrix standards (500 pmol L−1) were
employed to study this pH range at a mobile phase composi-
tion of 5 mmol L−1 ammonium bicarbonate and acetonitrile
10:90 at a flow rate of 600 μL min−1 using a 50×2.0 mm,
3 μm YMC Triart C18 column. The results from these exper-
iments showed a slight decrease of k as a consequence of an
increasing pH value of the aqueous mobile phase component
(Fig. 3a). Additionally, it could be observed that signal inten-
sity is hardly influenced by the presence of the matrix (Fig. 3b)
but increases slightly with pH up to 10.0 and then drops
markedly at a pH value above 10.5. Therefore, 5 mmol L−1
ammonium bicarbonate pH 10.0 was employed as aqueous
component of the mobile phase (in combination with the other
parameters mentioned above). This led to an acceptable inten-
sity and was a good compromise regarding retention and
chromatographic cycle time. Using the flow injection analysis
(FIA) option of Analyst 1.4.2 Quantitative Optimization tool
for these chromatographic parameters in the next step, the
source-dependent parameters of the mass spectrometer were
optimized. The most appropriate source-dependent parame-
ters were as follows: a temperature (T) of 550 °C, an ion spray
voltage (IS) of +3500 V, a curtain gas (CUR) of 20 psi, a
nebulizing gas (GS1) of 60 psi, an auxiliary gas (GS2) of
60 psi, and a collision gas (CAD) of 5 psi for the mass
transition m/z 292.2/261.0. In the end, these resulting optimal
values were used for further method development.
Next, we tried to improve the signal intensity and also peak
shape by investigating different sample solvents for the sam-
ples to be generated from theMSBinding Assays. In the setup
Fig. 2 Product ion scan with the
five most prominent
fragmentation products of the
respective [M+H]+ parent ions of
indatraline (m/z 292.2; black) and
(2H7)-indatraline (m/z 299.2; red)
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of the MS Binding Assays established so far, the binding
experiment is terminated by vacuum filtration over a 96-well
filter plate. Subsequently, liberation and elution of the target
boundmarker from the membrane fragments remaining on the
filter is achieved with methanol [11, 12]. Therefore, we con-
sidered a combination of methanol and 5 mmol L−1 ammoni-
um bicarbonate, pH 10.0, as most convenient as sample
milieu. Unfortunately, however, signals representing the mass
transition of indatraline (m/z 292.2/261.0) as well as the mass
transition resulting from the corresponding M+2 isotopologue
of indatraline (m/z 294.2/263.0), at a retention time similar to
the one of indatraline, were observed even in corresponding
solvent blanks. These signals, which were small but neverthe-
less distinctly visible and clearly differing in their isotopic
pattern from indatraline (data not shown), could be assigned to
the use of methanol in combination with certain consumables,
such as deep-well plates or reservoirs for multichannel pi-
pettes, consisting of polypropylene (the longer the contact
with these materials, the higher the signals).
Due to this problem, we tried to use acetonitrile instead of
methanol as eluent, which is also known to denature proteins
[35, 36], for liberation of the bound marker. Therefore, differ-
ent ratios of the ammonium bicarbonate buffer and acetonitrile
(i.e., 40:60, 30:70, 25:75, 20:80, 10:90 and pure acetonitrile)
were investigated as possible sample milieu regarding their
influence on peak intensity and peak shape. The results can be
summarized as follows: first, rather broad peaks could be
detected in pure acetonitrile; secondly, peak heights increased
with increasing amount of ammonium bicarbonate buffer. As
the marker is dissolved in the pure organic solvent (i.e.,
acetonitrile) after elution from the filter plate, addition of
buffer leads to a dilution of the analyte in the sample. There-
fore, we decided to use a ratio of 25% ammonium bicarbonate
buffer and 75 % acetonitrile as a compromise to gain intensity
but to avoid a marked dilution of the eluted analyte.
Additionally, we examined the possibility to gain higher
intensities as a consequence of higher sample injection vol-
umes in a range from 10 to 100 μL. A linear increase of peak
heights could be observed by raising the injection volume
from 10 μL up to 60 μL, which was, however, accompanied
by a rise of back pressure immediately after injection likely to
be caused by the higher viscosity of the sample solvent in
comparison to the mobile phase. To achieve a robust method
suitable even for routine application with large sample num-
bers, we restricted the injection volume to 45 μL, in which
case back pressure rose only by approximately 10 bar.
In the end, the developed method for quantification of
indatraline is characterized as follows: a YMC Triart C18
column (50×2.0 mm, 3 μm) with a YMC Triart C18
precolumn (10×2.0 mm, 3 μm) as stationary phase, a com-
position of acetonitrile and ammonium bicarbonate buffer
(5 mmol L−1, pH 10.0) in a ratio of 90:10 as mobile phase,
and a composition of acetonitrile and ammonium bicarbonate
buffer (5 mmol L−1, pH 10.0) in a ratio of 75:25 as sample
milieu is used; temperature amounts to 20 °C, flow rate to
600 μL min−1, and injection volume to 45 μL.
This resulting HPLC method was characterized by a chro-
matographic cycle time of only 1.5 min, whereby the eluent
for the first 0.6 min was directed to waste to protect the mass
spectrometer from the matrix. It is also noteworthy that we
defined a system suitability parameter for the final HPLC
method, in this case the retention time of the analyte, which
had to be in a range of 0.82±0.08 min, as the pH value of the
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Fig. 3 Influence of aqueous phase pH on retention and intensity of
indatraline. pH values in a range of 8.5 to 11.0 (x) are plotted against a
k and b intensity, defined as peak height (m/z 292.2/261.0), of
500 pmol L−1 indatraline in absence (black) and presence of binding
sample matrix (grey, means±SD, n=3). Chromatographic conditions:
YMC Triart C18 (50×2.0 mm, 3 μm) with respective precolumn,
5 mmol L−1 ammonium bicarbonate (pH values as indicated), and aceto-
nitrile (10:90, v/v) as a mobile phase at a flow rate of 600 μL min−1 at
20 °C and injection volume of 10 μL; for sample solvent, the mobile
phase was used
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aqueous component of the mobile phase had an influence on
the analytes k.
Binding assay development
For the development of hNETMSBinding Assays employing
(1R,3S)-indatraline as marker, we basically followed the setup
recently established for hSERT and mGAT1 MS Binding
Assays [11, 12]; a basic scheme of the workflow is shown in
Fig. 4. As several parameters, i.e., incubation and washing
buffer, filter material, and employed inhibitor for nonspecific
binding, affect the final matrix of the samples, we investigated
these parameters for matrix samples generated in preliminary
binding experiments with respect to signal intensity and
signal-to-noise level observed in multiple reaction monitoring
(MRM) chromatograms to optimize sensitivity of our quanti-
fication method (see supplementary material). The following
setup could be shown to provide conditions suitable for the
intended purpose and was selected for the assays.
For incubation, we employed a HEPES-based buffer
(50 mmol L−1 HEPES, 120 mmol L−1 NaCl, and
5 mmol L−1 KCl, pH 7.4) instead of the commonly used Tris
buffer [11] to avoid the potential reactive primary amino
function of Tris in respect of further assay applications (such
as combinatorial chemistry approaches employing aldehydes;
see for example [37]). As washing with the HEPES buffer
after termination of incubation by filtration caused an unfa-
vorable signal-to-noise ratio and low peak height, we
employed an isoosmotic 150 mmol L−1 ammonium acetate
buffer (pH 7.4) for this purpose. Employing this buffer for
washing instead of the incubation buffer did not change spe-
cific binding of indatraline towards hNET significantly.
For filtration, we employed glass fiber filter plates with a
pore size of 1.0 μm, presoaked in 0.5 % (m /v)
polyethyleneimine for 1 h, as they showed a low filter binding
of the MS marker and almost no matrix effect and enabled a
short filtration time.
Finally, desipramine, a highly potent norepinephrine reup-
take inhibitor, was employed as competitor in a concentration
of 10 μmol L−1 to determine nonspecific binding, as it neither
affected indatraline’s analyte peak area nor its peak shape.
LC-ESI-MS/MS method validation
The established method was validated in a range from
5 pmol L−1 to 5 nmol L−1 according to the FDA guidance
for bioanalytical method validation [38] regarding selectivity,
calibration standard curve, lower limit of quantification
(LLOQ), intra- and inter-batch precision as well as accuracy,
and stability.
A representative LC-ESI-MS/MS chromatogram of a ma-
trix blank demonstrating selectivity for mass transitions of
indatraline and the internal standard is shown in Fig. 4a. It
exhibits no interfering signals at the mass transitions m/z
292.2/261.0 and m/z 299.2/268.0 at the retention time of
analyte and internal standard. Linear calibration functions
were obtained in a range from 5 pmol L−1 to 5 nmol L−1,
employing a 1/x2weighting (r2≥0.9912, y-intercept ≤8.7 % of
the LLOQ; see results in Table 1). For 5 pmol L−1 indatraline
matrix standards (six series of hexaplicate samples), signal-to-
noise ratios of ≥11.60, concentrations of 83.9–114.6 % of the
nominal concentrations (calculated according to the corre-
sponding calibration functions), and RSDs ≤8.7 %were found
(see Table 1), showing that all these parameters are nicely in
agreement with the recommendations of the Center for Drug
Evaluation and Research (CDER) guidance for the LLOQ.
Corresponding chromatograms of a matrix blank, a
5 pmol L−1matrix standard, and a 1 nmol L−1matrix standard
in the presence of 1 nmol L−1 internal standard are shown in
Fig. 5a–c.
Also, the requirements for accuracy and precision were met
perfectly as indicated by the results shown in Table 1. Thereby,
the intra-batch accuracies and precision were 89.4–106.5 %
(accuracies of all concentration levels of the respective series)
and 1.7–8.9 % (RSD), respectively. Inter-batch accuracy was
found to be 93.3–102.7 % (accuracies of all concentration
levels) and precision, calculated as RSD, 2.9–6.1 %.
Due to the fact that there are no data published for the
stability of aqueous solutions of indatraline, we compared a
Fig. 4 Basic workflow for the developed MS Binding Assays consisting of incubation (blue), separation (light blue), liberation via elution (green), and
quantification via LC-MS/MS
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Table 1 Validation of indatraline quantification by LC-ESI-MS/MS with an API 5000 employing (2H7)-indatraline as internal standard
Sample (n) Intra-series Inter-series
Series 1b Series 2b Series 3b Series 4b Series 5b Series 6b
M Acc RSD M Acc RSD M Acc RSD M Acc RSD M Acc RSD M Acc RSD M Acc RSD
5 pmol L−1 Cal (6) 4.876 97.8 7.7 4.824 96.5 7.7 4.985 99.7 8.6 4.771 95.4 5.5 4.911 98.2 8.7 5.017 100.3 7.4 4.872 97.4 7.4
10 pmol L−1 Cal (6) 10.70 107.0 4.3 10.89 108.9 5.1 10.29 102.9 3.7 11.15 111.5 2.7 10.58 105.7 4.9 10.12 101.2 7.5 10.61 106.1 5.6
25 pmol L−1 Cal (3) 23.35 93.4 0.2 23.39 93.5 7.3 22.70 90.8 4.2 23.69 94.8 10.5 22.33 89.3 1.7 23.27 93.1 5.2 23.12 92.5 5.5
50 pmol L−1 Cal (3) 47.56 95.1 3.6 48.51 96.9 1.3 47.30 94.6 5.0 45.87 91.8 1.3 47.60 95.2 3.9 47.63 95.2 4.6 47.40 94.8 3.5
100 pmol L−1 Cal (3) 101.2 101.2 4.7 97.38 97.4 1.2 99.86 99.9 2.0 101.3 101.3 2.5 96.80 96.8 2.2 102.5 102.5 2.8 99.84 99.8 3.2
250 pmol L−1 Cal (3) 235.4 94.2 2.1 236.4 94.6 3.4 241.0 96.4 1.7 234.9 94.0 2.3 242.8 97.1 0.9 237.0 94.8 1.2 237.9 95.2 2.2
500 pmol L−1 Cal (3) 481.2 96.3 3.0 471.7 94.3 1.9 491.0 98.2 3.1 479.2 95.8 1.7 489.3 97.9 1.4 487.5 97.5 5.4 483.3 96.7 3.0
1000 pmol L−1 Cal (3) 1019 101.9 2.3 1051 105.1 5.7 1039 103.9 1.9 1055 105.5 1.0 1037 103.7 1.3 1068 106.8 1.3 1045 104.5 2.8
2500 pmol L−1 Cal (3) 2452 98.1 1.8 2432 97.3 1.6 2509 100.4 4.8 2409 96.4 0.7 2532 101.3 0.5 2439 97.6 1.3 2462 98.5 2.7
5000 pmol L−1 Cal (3) 5463 109.3 2.5 5506 110.1 2.3 5522 110.5 0.9 5450 109.0 0.8 5511 110.2 0.4 5471 109.4 3.8 5487 109.7 1.9
10 pmol L−1 QC (6) 10.20 102.0 4.3 9.522 95.2 7.2 10.55 105.5 3.2 10.17 101.7 5.6 10.63 106.3 6.2 10.65 106.5 2.0 10.27 102.7 6.1
25 pmol L−1 QC (6) 23.34 93.4 2.8 23.40 93.6 5.4 22.82 91.3 4.2 23.75 95.0 7.8 23.69 94.8 6.1 22.89 91.6 5.1 23.31 93.3 5.3
100 pmol L−1 QC (6) 95.96 96.0 2.5 95.06 95.1 3.2 99.16 99.2 5.5 95.02 95.0 4.7 97.24 97.2 3.7 98.72 98.7 3.7 96.86 96.9 4.1
500 pmol L−1 QC (6) 469.3 93.9 3.1 447.1 89.4 2.8 473.6 94.7 2.0 457.1 91.4 4.5 476.2 95.3 4.6 487.0 97.4 8.9 468.4 93.7 5.4
1000 pmol L−1 QC (6) 987.0 98.7 2.8 989.0 98.9 3.7 1008 100.8 3.6 984.1 98.4 2.6 988.3 98.8 1.7 1010 101.0 2.3 994.4 99.4 2.9
1000 pmol L−1 SStd newa (6) 954.1 95.4 1.7 949.2 94.9 5.4 986.1 98.6 5.2 955.8 95.6 2.3 990.4 99.0 2.2 1003 100.3 3.5 973.7 97.3 4.5
1000 pmol L−1 SStd olda (6) 991.2 99.1 2.9 941.0 94.1 3.0 1000 100.0 1.6 1013 101.3 6.8 978.8 97.9 1.9 1020 102.0 2.5 990.6 99.1 4.3
MMean of calculated concentrations (pmol L−1 ), Acc accuracy (%), RSD relative standard deviation (%), Cal calibration standard,QC quality control sample, SStd solvent standard, n number of replicates
a Solvent standard of a freshly prepared stock solution (new) and an 8-month-old stock solution (old)
bResulting calibration functions: series 1, y=0.9410x−0.00004913 (r2 =0.9932); series 2, y=0.9503x+0.00043570 (r2 =0.9914); series 3, y=0.9420x−0.00027150 (r2 =0.9937); series 4, y=0.9846x−
0.00036170 (r2 =0.9912); series 5, y=0.9792x−0.00006100 (r2 =0.9932); series 6, y=0.9804x−0.00027900 (r2 =0.9935)
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10 mmol L−1 aqueous stock solution which was stored for
8 months at room temperature with a freshly prepared
10 mmol L−1 aqueous stock solution of indatraline. For this
purpose, we prepared 1 nmol L−1 solvent standards of both
stock solutions, both supplemented with 1 nmol L−1 (2H7)-
indatraline (stock solution also stored at room temperature for
8 months), and analyzed themwith the described LC-ESI-MS/
MSmethod. The peak area ratios (i.e., area of the analyte/area
of the internal standard) as well as the analyte peak areas
found for both series, the samples prepared from the new
and the old stock solution, showed no significant differences
(n=36, α=0.01).
Additionally, we investigated the capability of our devel-
oped LC-ESI-MS/MSmethod for the quantification of the cis-
configured diastereomer of indatraline in a range of
5 pmol L−1 to 1 nmol L−1 (again using (2H7)-indatraline as
internal standard; see Fig. 5d). Calibration curves, LLOQ
(again 5 pmol L−1), and intra- and inter-batch accuracy and
precision fulfilled again the requirements of the CDER guide-
line (for further information, see ESMTable S1). Accordingly,
the developed LC-ESI-MS/MS method is suitable for quanti-
fication of all four stereoisomeric forms (enantiomers and
diastereomers) of 3-(3,4-dichlorophenyl)-1-methylamino-
2,3-dihydro-1H-indene as marker in MS Binding Assays.
Application of the LC-ESI-MS/MS method to saturation
experiments
For the intended saturation experiments employing (1R,3S)-
indatraline as marker for hNET, the following already men-
tioned aspects had to be considered:
It was reasonable to assume that the concentrations of
(1R,3S)-indatraline bound to hNETare even below the LLOQ
of the established quantification method (i.e., 5 pmol L−1) in
binding samples, especially when very low marker concentra-
tions (i.e., about 0.1 Kd) combined with very low target
concentrations (i.e., of approximately 0.1 Kd) are applied,
the latter of which is necessary when the actual Kd value for
(1R,3S)-indatraline binding towards hNET is very low, i.e., in
the picomolar range (see also “Introduction”). Therefore, we
decided to modify our standard setup for the intended
Fig. 5 MRM chromatograms of indatraline, (
2H7)-indatraline, and cis-
configured diastereomer of indatraline in presence of hNET binding
sample matrix. For quantification, the mass transition m/z 292.2/261.0
for indatraline (black) and cis-configured diastereomer (blue), and m/z
299.2/268.0 for (2H7)-indatraline (red) were used. a Blank, b 5 pmol L
−1
indatraline (LLOQ), c 1 nmol L−1 indatraline together with 1 nmol L−1 of
(2H7)-indatraline, and d 1 nmol L
−1 cis-configured diastereomer together
with 1 nmol L−1 of (2H7)-indatraline. All chromatograms were recorded
at an API 5000 employing a YMC Triart C18 (50×2 mm, 3 μm) and
5mmol L−1 ammonium bicarbonate pH 10.0 with acetonitrile (10:90, v/v)
as mobile phase at a flow rate of 600 μL min−1 at 20 °C. The injection
volume was 45 μL; the eluents of the first 0.6 min were sent to waste to
protect the mass spectrometer
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saturation experiments to ensure a reliable quantification of
the bound marker even below our LLOQ of 5 pmol L−1. A
rather simple but efficient way to enable this task in MS
Binding Assays is an increase of the incubation volume, while
the volume of the final sample, containing the bound and
subsequently liberated marker, is kept as low as possible, the
approval of which has already been taken for the performance
of MS Binding Assays addressing hSERT [11]. Increasing the
ratio of incubation volume to final sample volume to a factor
of 12 (3.6 mL binding sample to 300 μL final sample) enabled
us to quantify even 400 fmol L−1 bound (1R,3S)-indatraline
(1/12 of the LLOQ) in the binding samples.
Following this modified procedure, we characterized the
binding of (1R,3S)-indatraline towards hNET in saturation
experiments employing a wide concentration range of the
marker, namely from 50 pmol L−1 to 30 nmol L−1. Varying
the employed marker concentrations to this large extent was
considered to be sufficient to allow an accurate assessment of
the Kd value of (1R,3S)-indatraline towards hNET, indepen-
dent of where in the broad range it had to be expected, i.e.,
from middle picomolar to low nanomolar concentrations,
would actually be. In Fig. 6a, total as well as nonspecific
binding of (1R,3S)-indatraline towards hNET of a representa-
tive saturation experiment is shown. It is noteworthy that this
modified setup enabled also the quantification of nonspecifi-
cally bound (1R,3S)-indatraline down to nominal marker con-
centrations of 500 pmol L−1. At even lower concentrations, we
extrapolated the respective data points for nonspecific binding
based on the experimentally determined nonspecifically
bound marker, which is possible due to an assumed linear
correlation of nonspecific binding with nominal marker con-
centration [39, 40]. From these data for total and nonspecific
binding, specifically bound (1R,3S)-indatraline at hNET (de-
fined as the difference of total and nonspecific binding) was
calculated and plotted vs the employed nominal marker con-
centration. Finally, these plots were analyzed by means of
nonlinear regression (i.e., “one site – specific binding”) to
obtain a saturation isotherm, which gave information about
the respective affinity of (1R,3S)-indatraline towards hNET
(Kd) and the maximum amount of binding sites (Bmax); see for
example Fig. 6b. From these saturation isotherms, a Kd value
of 805±71.4 pmol L−1 and a Bmax value of 82.82±
12.31 pmol mg−1 protein (mean±SEM, n=5; 82.8±
34.2 pmol mg−1 protein, CL 95 %) were calculated, being in
good agreement with the already published results, i.e., a Ki
value of 2 nmol L−1 for indatraline obtained in [3H]nisoxetine
binding experiments addressing rNET [15, 13].
Finally, it is worth mentioning that also the results obtained
for the individually prepared matrix blanks, zero samples,
calibration standards, and QCs of this modified setup, i.e.,
starting with an incubation volume of 4.0 mL and using
3.6 mL of the binding sample to generate a final sample
volume of 300 μL, were in agreement with recommendations
for “application of validated method to routine drug analysis”
of the FDA guidance for bioanalytical method validation [38]
regarding selectivity, linearity, LLOQ, accuracy (85–115 %),
and precision (RSD ≤15 %) (see also “Method validation”).
This demonstrated that the modified setup employed in satu-
ration experiments had no influence on the analytical reliabil-
ity of our developed quantification method.
Competitive experiments
In the next step, competition experiments as the main appli-
cation of reporter ligand-based binding assays should be
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Fig. 6 Saturation experiment of (1R,3S)-indatraline binding towards
hNET. a Means±SD (n=3) of total binding of (1R,3S)-indatraline to-
wards hNET at nominal marker concentrations from 50 pmol L−1 to
30 nmol L−1 (black spheres) and nonspecific binding in presence of
10 μmol L−1 desipramine in a range of 0.5–30 nmol L−1 (grey triangles)
of a representative saturation experiment (performed as described in the
experimental section). b Specific binding and saturation isotherm (black)
derived from the experiment shown in a. Data points for nonspecific
binding below nominal marker concentrations of 0.5 nmol L−1 were
extrapolated as described in the experimental section
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implemented. To this end, we used our standard setup (i.e.,
250 μL total incubation volume per well) that has been shown
to allow a reasonable throughput as it is required for charac-
terization of test compounds. In this case, the marker sub-
stance, (1R,3S)-indatraline, was employed at a nominal con-
centration of 2.4 nmol L−1 to ensure that even low percentages
of specifically bound marker, which will occur at higher
competitor concentrations, can be quantified reliably in the
corresponding competition samples. As nonspecific binding
at 2.4 nmol L−1 (1R,3S)-indatraline was typically below our
LLOQ of 5 pmol L−1, we pursued the same approach as
already described in “saturation experiments.” That means
nonspecific binding was experimentally determined in a range
from 2.5 to 20 nmol L−1 (1R,3S)-indatraline in the presence of
10 μmol L−1 desipramine and the corresponding value for
2.4 nmol L−1 (employed marker concentration in competition
experiments) was extrapolated. As an example, we investi-
gated the well-known NET inhibitor desipramine. For the
determination of its inhibitory constant (Ki) concentrations
in a range from 50 pmol L−1 to 1 μmol L−1, desipramine
was incubated in the presence of target and marker. After
incubation, separation of nonbound from bound marker,
and, finally, after elution of the target bound marker, the
concentration of (1R,3S)-indatraline in the corresponding
samples was quantified employing the established LC-ESI-
MS/MS method. An inhibition curve for desipramine gen-
erated from a representative experiment is shown in
Fig. 7. The affinity calculated for desipramine at hNET
was 4.45±0.32 nmol L−1 (mean±SEM, n=3) being in
excellent accordance with literature, in which affinities
for desipramine towards NET of 1.6±0.2 nmol L−1
(rNET) [20] and 4.1±1.2 and 13.9±1.5 nmol L−1
(hNET) [41] based on results from radioligand binding
assays are reported.
Conclusion
In summary, the present study describes the first highly sen-
sitive method for quantification of the triple reuptake inhibitor
indatraline so far. The LC-ESI-MS/MS method developed to
quantify indatraline in MS Binding Assays is selective, fast
(chromatographic cycle time of 1.5 min), and robust and
avoids any sample preparation. According to the CDER guid-
ance of the FDA, it could be demonstrated that reliable results
regarding calibration standard curve and intra- and inter-batch
accuracy as well as precision in a range from 5 pmol L−1
(LLOQ) to 5 nmol L−1 are obtained. The established method
could also be applied to quantify the cis-configured diastereo-
mer of indatraline with similar results for the investigated
validation parameters.
The developed LC-ESI-MS/MS was successfully used in
MS-based binding assays employing (1R,3S)-indatraline as a
nonlabelled marker for hNET. With the established MS Bind-
ing Assays, the binding of (1R,3S)-indatraline towards hNET
was characterized for the first time. The established setup
(based on a 96-well microtiter plate format) of theMSBinding
Assays in combination with the developed LC-ESI-MS/MS
method proved to be sensitive enough to characterize even the
affinity of (1R,3S)-indatraline towards hNET (Kd of
805 pmol L−1) in saturation experiments under the conditions
common to radioligand binding assays (marker concentration
from 0.1 Kd to 10 Kd, target concentration ≤0.1 Kd), though it
was very high. Besides this, the established MS Binding
Assays were also demonstrated to be well suited to investigate
test compounds for their affinity towards NET in competition
experiments and represent therefore a promising substitute for
the widespread [3H]nisoxetine radioligand binding assays. It
should be emphasized, however, that the scope of the ap-
proach presented in this study is distinctly more far reaching
as it may additionally be applied to the other two monoamine
transporters DAT and SERT without any further analytical
efforts and will, besides (1R,3S)-indatraline, also allow to
employ the other indatraline stereoisomers as nonlabelled
markers.
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Fig. S1 Structures of respective nonlabelled species radioligands employed in literature for 
the affinity characterization (Ki-value) of Indatraline  
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[3H]MPP+ Uptake experiments 
HEK293 cells stably transfected with hNET as described in “Cell culture and expression of 
hNET” were cultivated as described in “hNET membrane preparation”. After washing with 
PBS for the second time, the resulting pellet was resuspended carefully in uptake buffer 
(10 mmol L-1 HEPES, 120 mmol L-1 NaCl, 3 mmol L-1 KCl, 2 mmol L-1 CaCl2, 2 mmol L-1 
MgCl2 and 20 mmol L-1 glucose, pH 7.3) resulting in 6 x 106 cells mL-1.  
3 x 105 cells were added to uptake buffer which contained [3H]MPP+ (80-85 Ci mmol-1) and 
MPP+ in a ratio of 1:100, the sample for nonspecific uptake also included 100 nmol L-1 
Indatraline, both series were prepared in triplicates, the resulting samples had a final 
concentration of 1nmol L-1 labelled MPP-+ per sample and a sample volume of 250 µL. After 
10 min of incubation at 22 °C uptake was terminated via filtration and subsequently washing 
five times with 5 mL of ice cold incubation buffer, for that we used a Brandel M-24 harvester 
and Whatman GF/C filters to collect the cells after uptake. Glass fiber pieces with the cells 
containing labelled MPP+ were transferred to scintillation vials and cells lysed by adding 
3 mL of the scintillation cocktail. Each sample was measured for 4 min with a Packard 
TriCarb 2300.  
Counts for total and nonspecific uptake of the respective hNET clone were compared to each 
other and the clones having at least a ratio of one to ten (nonspecific uptake to total uptake) 
were further tested using this [3H]MPP+ uptake experiment (n = 3). Finally, the clone having 
the highest ratio of total uptake vs nonspecific uptake in three individual experiments, was 
used for hNET binding experiments. 
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Preliminary LC-ESI-MS/MS experiments 
 
pH dependent retention profile 
 
 
Fig. S2 pH-dependence profile of Indatraline retention. pH of the aqueous phase (x) is plotted 
against the k factor (y) using a YMC Triart C18 (50 x 2.0 mm, 3 µm) with respective 
pre-column and a mobile phase composition of a 5 mmol L-1 ammonium formate 
buffer (pH 3.0 – 7.5, red triangles) or 5 mmol L-1 ammonium bicarbonate (pH 7.5 –
 11.0, blue triangles) and acetonitrile (10:90, v/v) at a flow rate of 600 µL min-1 
(temperature was set to 20 °C and injection volume to 10 µL), for sample solvent the 
mobile phase was used  
  
Post-column infusion experiments 
Fig. S3 Chromatogram of post-co
infused (5 µL min-1) after
HPLC system. Chromatog
ammonium bicarbonate p
200 µL min-1 at 20 °C on 
recorded using an API 20
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Table S1 Validation parameters for cis-configured isomers using (2H7)-Indatraline as 
internal standard 
 
Sample (na) Intra-series Inter-series 
 Series 1b Series 2c Series 3d    
 M Acc RSD M Acc RSD M Acc RSD M Acc RSD 
5 pmol L-1  
Cal cis (3) 4.475 89.5 0.6 4.553 91.1 4.5 4.619 92.4 7.4 4.549 91.0 4.6 
10 pmol L-1  
Cal cis (3) 10.15 101.5 5.3 10.11 101.1 8.6 10.70 107.0 3.8 10.32 103.2 6.0 
50 pmol L-1  
Cal cis (3) 44.81 89.6 3.2 46.92 93.8 6.5 51.85 103.7 7.1 47.86 95.7 8.4 
100 pmol L-1 
Cal cis (3) 105.0 105.0 2.5 101.6 101.6 1.9 96.24 96.2 4.2 101.0 101.0 4.6 
500 pmol L-1 
Cal cis (3) 522.6 104.5 0.6 511.4 102.3 2.6 466.4 93.3 2.0 501.5 100.0 5.4 
1000 pmol L-1 
Cal cis (3) 993.9 99.4 1.8 1014 101.4 2.4 1102 110.2 1.2 1037 103.7 5.1 
10 pmol L-1  
QC cis (6) 9.658 96.6 4.5 10.67 106.7 7.6 9.968 99.7 9.5 10.10 101.0 7.6 
100 pmol L-1  
QC cis (6) 966.8 96.7. 4.8 99.17 99.2 4.5 99.97 100.0 6.7 98.60 98.6 5.8 
1000 pmol L-1  
QC cis (6) 1029 102.9 2.6 980.1 98.0 3.4 1018 101.8 9.2 1009 100.9 6.0 
 
M Mean of calculated concentrations (pmol L-1), Acc accuracy (%), RSD (%), Cal calibration standard, 
QC quality control sample 
a
 n number of replicates. b--d resulting calibration functions: 
series 1: y=1.016x+0.0001106 (r²=0.9906) 
series 2: y=1.064x+0.0003057 (r²=0.9934) 
series 3: y=0.984x–0.0000546 (r²=0.9944) 
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MS Binding Assay development 
The standard of our MS Binding Assays has workflow as follows: incubation, separation of 
target-bound from free marker via filtration employing a vacuum manifold in combination 
with 96-well filter plates and liberation via protein denaturation [references 5 and 6 of main 
paper]. As all mentioned parameters, i.e. incubation buffer, filtration system, eluent for 
protein denaturation, etc., affect the matrix of the binding samples, we investigated these 
regarding signal intensity of the analyte peak and signal-to-noise ratio, to increase the 
sensitivity of the developed quantification method.  
Instead of the commonly used Tris based buffer which was used successfully used as 
incubation buffer in different radioligand binding studies and also in MS Binding Assays 
[references 11, 15, 19, 24 and 25 of main paper] we employed an analogous HEPES based 
buffer (50 mmol L-1 HEPES, 120 mmol L-1 NaCl and 5 mmol L-1 KCl, pH 7.4) to be more 
flexible for further assay applications.  
In the next step, different kinds of 96-well filter plates (AcroPrep Advance, 350 µL, Pall, 
Dreireich, Germany) for separation of bound from nonbound marker were examined. Various 
filter materials, i.e. glass fiber, polytetrafluorethylene, hydrophilic polypropylene, and 
polyethersulfone, with different pore sizes in a range of 0.2 to 1.0 µm were tested. 
Unfortunately, hydrophilic polypropylene and polytetrafluorethylene as well as smaller pore 
sizes were not appropriate for our purpose due to a long filtration time and a higher hold up 
volume of organic solvents. Those based on polyethersulfone and glass fiber showed a 
markedly high nonspecific binding of Indatraline (i.e. approximately 10 %), therefore we 
investigated different pre-treatments (i.e. incubation buffer, water, 0.1 – 0.5 % (m/v) 
polyethyleneimine) to reduce this undesired nonspecific binding. In the case of glass fiber 
filter plates nonspecific binding could be reduced significantly (i.e. far less than 1 %) 
employing 0.5 % (m/v) polyethylene imine, but for polyethersulfone based filters nonspecific 
binding could only be reduced to approximately 5 %. 
Additionally, we investigated the effect of different washing buffers, such as assay buffer, a 
0.9 % (m/v) NaCl solution, 25 mmol L-1 ammonium acetate, 120 mmol L-1 NaCl and 
5 mmol L-1 KCl buffer adjusted to pH 7.4, as well as a 150 mmol L-1 ammonium acetate 
buffer adjusted to pH 7.4, respectively, on intensity (peak height), signal-to-noise ratio of the 
analyte signal in corresponding MRM chromatograms and specific binding of the marker 
(nominal concentrations in a range from 2.5 nmol L-1 to 25 nmol L-1). Using the incubation 
buffer also as washing buffer has the advantage that the binding properties are not influenced 
8 
 
during wash process, but in our case it also revealed two disadvantages, i.e. a rather high 
noise level and an intensity lower as that obtained using the other investigated washing 
buffers. The 0.9 % NaCl solution and the isoosmotic replacement of Tris by ammonium 
acetate led to an improved signal-to-noise ratio and also signal intensity, but best results 
concerning a more sensitive quantification method, i.e. a noise level as low as possible next to 
a peak height as high as possible, were found using the 150 mmol L-1 ammonium acetate 
buffer, pH 7.4. Also, it can be stated that all tested washing buffers showed no significant 
difference compared to the incubation buffer in specific binding, thus we can assume that 
there is no influence on affinity of Indatraline towards hNET resulting from the wash process 
presumed that the washing buffer is ice cold and the filtration process takes only a few 
seconds. 
Finally, the chromatographic influence of high concentrations of Desipramine, as it was 
intended to use for the determination of nonspecific binding and as displacer in kinetic 
studies, was investigated. For this reason we prepared hNET binding sample matrix (like it is 
described for validation matrix samples) in absence and presence of 10 µmol L-1 Desipramine, 
these samples were treated as described in the standard setup and eluted with acetonitrile 
containing Indatraline and (2H7)-Indatraline. Comparing the resulting analyte areas and as a 
consequence the calculated concentrations, there was no significant influence of Desipramine 
on our quantification (samples without Desipramine, n = 36; samples with Desipramine, 
n = 18, α = 0.05), and also the peak shape was not influenced. Thus, it can be stated that the 
application of high concentrations of Desipramine in our binding assay for the determination 
of nonspecific can be made. 
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3.2.3 Third Publication: 
MS Binding Assays for the Three Monoamine Transporters Using the Triple 
Reuptake Inhibitor (1R,3S)-Indatraline as Native Marker 
 
The human monoamine transporters hDAT, hNET, and hSERT are the most promising targets 
for the treatment of depressions. Additional screening tools addressing these targets for the 
identification of new drugs curing the above mentioned diseases are therefore required. Due 
to their efficiency and sample throughput MS Binding Assays are well suited to fulfill this task. 
The previously developed highly sensitive LC-ESI-MS/MS method for the quantification of the 
triple reuptake inhibitor indatraline in biological matrices had already enabled its application to 
MS Binding Assays addressing hNET in saturation and competitive experiments. As a next 
step the developed MS Binding Assays were applied to different targets (i.e. hDAT, hNET, and 
hSERT) and also performed with additional markers (i.e. all stereoisomers of indatraline). First, 
the affinities of both enantiomers of indatraline, i.e. (1R,3S)- and (1S,3R)-indatraline, as well 
as of the racemic cis-configured diastereomer towards hDAT, hNET, and hSERT were 
investigated, confirming (1R,3S)-indatraline to be the eutomer for all three monoamine 
transporters (i.e. hDAT, hNET, and hSERT) and the racemic cis-configured diastereomer to 
be highly selective for hSERT. A saturation isotherm and consequently a determination of the 
distomers, (1S,3R)-indatraline, Kd-value towards all three targets as well as of the 
cis-configured diastereomer towards hDAT was unfortunately not possible. Kinetic studies 
employing the eutomer, (1R,3S)-indatraline, were performed next and the dissociation rate 
constant (koff) as well as the dissociation half life (t1/2) could be successfully determined. It is 
worth noting, that within the performed dissociation experiments an allosteric effect of 
clomipramine on the dissociation of the hSERT-(1R,3S)-indatraline complex could also be 
identified. A reliable determination of the association rate constant (kon) for the formation of 
target-(1R,3S)-indatraline complexes was for neither of the employed target, i.e. hDAT, hNET, 
or hSERT, possible due to its extreme fast progress.  
Finally, the characterization of (1R,3S)-indatraline binding properties, i.e. affinities and 
dissociation kinetics, allowed its application as marker in competitive MS binding experiments 
addressing hDAT, hNET, and hSERT. In these experiments almost 40 known inhibitors 
including transporter substrates and narcotics were investigated concerning their affinities and 
also their selectivities for the three monoamine transporters. The results obtained by the 
employed MS Binding Assays were verified by comparison with those obtained in established 
radioligand binding assays employing [125I]RTI-55 as marker, revealing an excellent correlation 
between our and literature data for all three monoamine transporters which proves the validity 
of the developed MS Binding Assays as a screening tool for hDAT, hNET, and hSERT. 
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Introduction
Mental disorders have become a global problem, decreasing
the quality of life for millions of people; they are expected to
create a significant economic burden on the order of several
trillion dollars over the next 20 years.[1] In 2010, approximately
40% of all mental disorders were diagnosed as depression.[1b]
Unfortunately, a sufficient therapeutic response can only be re-
alized in two out of three cases with currently available
drugs.[2] It is currently believed that the main mechanism
behind the genesis of emotional disorders is an imbalance in
the monoaminergic neurotransmitter systems consisting of
dopamine (DA), norepinephrine (NE), and serotonin (5-HT).[3]
Therefore, these systems are the focus for the development of
suitable medications. Most of the drugs in current use for the
treatment of depression amplify the effect of DA, NE, and 5-HT.
In general, this can be achieved by inhibiting enzymes that
catalyze the degradation of monoamines, e.g. , monoamine ox-
idase inhibitors (MAOIs), or by inhibiting monoamine trans-
porters, i.e. , the dopamine transporter (DAT), the norepineph-
rine transporter (NET), and the serotonin transporter (SERT), re-
sulting in an increased residence time of the monoamines in
the synaptic cleft. Monoamine transporter inhibitors, especially
those that selectively inhibit one transporter type (i.e. , mainly
selective SERT inhibitors), are preferred in therapy because of
their improved side effect profile relative to MAOIs; they are
therefore the current mainstay in the treatment of depres-
sion.[4] Nevertheless, results of the Global Burden of Diseases, In-
juries, and Risk Factors Study 2010 (GBD 2010) clearly demon-
strate a substantial remaining need for new antidepressants.[1b]
A fundamental task in the early stage of the development of
new antidepressive drugs is to characterize the affinity of test
compounds for targets such as hDAT, hNET, and hSERT. A
common method for this involves competitive radioligand
binding assays, which use a ligand labeled with a radioisotope
(usually tritium) that has high affinity for the desired target.
Despite all the advantages in simplicity, robustness, and sensi-
tivity of radioligand binding assays, this technique also has
some substantial drawbacks associated with the use of radio-
activity : security issues, legal restrictions, problems with waste
management, and expenses in ligand radiolabeling.
To overcome these obstacles, our research group recently in-
troduced MS Binding Assays, which follow the conventional
setup of radioligand binding assays, but use a native (i.e. , non-
labeled) marker instead of a radioligand that is quantified by
mass spectrometry.[5] Two basic requirements for the use of
a marker in MS Binding Assays are the following: First, the
marker should possess physicochemical properties that allow
good atmospheric ionization, thereby enabling its highly sensi-
tive quantification by LC–ESI-MS/MS. Second, the marker
should exhibit suitable affinity (Kd) for its target. This means
that the stability of the target–marker complex formed [de-
fined by a sufficiently low dissociation rate constant of the
complex (koff)] should be high enough to avoid substantial loss
of specifically bound marker during separation by filtration
and subsequent washing steps. For this purpose the koff value
of the target–marker complex should not exceed 10¢2 s¢1 if
We herein present label-free, mass-spectrometry-based binding
assays (MS Binding Assays) for the human dopamine, norepi-
nephrine, and serotonin transporters (hDAT, hNET, and hSERT).
Using this approach both enantiomers of the triple reuptake
inhibitor indatraline as well as its cis-configured diastereomer
were investigated toward hDAT, hNET, and hSERT in saturation
experiments. The dissociation rate constants for (1R,3S)-indatra-
line binding at hDAT, hNET, and hSERT were determined in
kinetic studies. These experiments revealed an allosteric effect
of clomipramine on the dissociation of (1R,3S)-indatraline from
hSERT. Finally, a comprehensive set of known monoamine
transport inhibitors and substrates was studied in competition
experiments at hDAT, hNET, and hSERT, using (1R,3S)-indatraline
as nonlabeled marker. The results are in excellent agreement
with those reported for radioligand binding assays. Therefore,
the established MS Binding Assays are a promising alternative
to the latter for the characterization of new monoamine re-
uptake inhibitors at DAT, NET, and SERT.
[a] S. H. Grimm, Dr. G. Hçfner, Prof. Dr. K. T. Wanner
Department Pharmazie—Zentrum fìr Pharmaforschung
Ludwig-Maximilians-Universitt Mìnchen
Butenandtstr. 7, 81377 Munich (Germany)
E-mail : Klaus.Wanner@cup.uni-muenchen.de
Supporting information for this article is available on the WWW under
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the separation step is to be performed by filtration.[6] Accord-
ing to Equation (1):
Kd ¼ koff=kon ð1Þ
the required Kd value, which is associated with a sufficiently
low koff, should be in the high picomolar to low nanomolar
range (provided that the association rate constant, kon, is inde-
pendent of the target used, but collision-limited, as can be as-
sumed).[6] However, with increasing marker affinity, the analyti-
cal demand on the sensitivity of the LC–MS quantification
method also increases. An estimate of the required sensitivity
of the quantification method can be derived from the Kd value
of the marker according to the rules generally accepted for
radioligand binding assays (i.e. , investigating the marker at
nominal concentrations in a range from at least 0.1 Kd to 10 Kd,
at a target concentration up to 0.1 Kd).
[6, 7] From this, a quantifi-
cation of at least 0.0091 Kd bound marker, which results from
binding samples employing a marker as well as target concen-
tration of or slightly below 0.1 Kd (see Supporting Information),
should be feasible employing the quantification method.
Our previously developed LC–ESI-MS/MS method for the
quantification of indatraline and its cis-configured diastereomer
(Figure 1) reaches a lower limit of quantification (LLOQ) of
5 pm in the final sample.[5b] However, even if the achieved sen-
sitivity is very high, it could still be insufficient for saturation
experiments designed to characterize highly affine markers
with very low Kd values, as the resulting concentration of
bound marker in binding samples with very low target concen-
trations (i.e. , up to 0.1 Kd) combined with low marker concen-
trations (i.e. , 0.1 Kd) might be still below the above-mentioned
LLOQ. To overcome this obstacle, we modified our setup by in-
creasing the incubation volume to 4.0 mL instead of the stan-
dard 250 mL setup. With the target concentration kept con-
stant, this results in a 16-fold higher target amount in the
4.0 mL binding sample than in the 250 mL binding sample.[5b]
Consequently, the amount of bound marker is also increased
in the 4.0 mL setup. To quantify the resulting bound marker
concentration in the 4.0 mL binding sample, we transferred
3.6 mL of the binding sample for filtration (for the standard
setup, 200 mL of the 250 mL binding sample were subjected to
filtration), while the final sample volume, resulting from libera-
tion by elution of the bound marker, was kept constant for
both setups at 300 mL (i.e. , the modified setup having a 4.0 mL
incubation volume, and the standard setup having a 250 mL in-
cubation volume).[5b] The resulting twelvefold higher concen-
tration of bound marker in the final sample (i.e. , 3.6 mL bind-
ing sample resulting in a final sample volume of 300 mL) ena-
bled us to quantify 400 fm bound marker in the corresponding
binding samples (i.e. , one twelfth the LLOQ) with this modified
setup.[5b] Summarizing these considerations, Kd values down to
at least 100 pm can be assumed to be reliably determinable by
following the above-mentioned setup, as the minimum of
quantifiable marker in binding samples (400 fm) is distinctly
below 0.0091 Kd.
The aim of the present study was to establish MS Binding
Assays for all human monoamine transporters: hDAT, hNET,
and hSERT. For this purpose, saturation experiments were per-
formed to investigate the affinities of the stereoisomers of in-
datraline [(1R,3S)-indatraline, (1S,3R)-indatraline, and the cis-
configured diastereomer; Figure 1] toward their respective tar-
gets. Based on the results of these saturation experiments, the
stereoisomer with the most appropriate affinities toward hDAT,
hNET, and hSERT, being in the range from 100 pm (see discus-
sion above concerning sensitivity) to low nanomolar (see dis-
cussion above concerning koff), was selected as marker and fur-
ther investigated in kinetic studies (i.e. , dissociation and associ-
ation experiments). Finally, competitive MS binding experi-
ments based on the chosen marker were performed for hDAT,
hNET, and hSERT to demonstrate the efficiency of MS Binding
Assays as a promising substitute for corresponding competi-
tive radioligand binding assays commonly used to characterize
the affinities of test compounds for these targets.
Results and Discussion
Available information regarding indatraline’s affinity and
potency at monoamine transporters
Until now, no studies characterizing the binding affinities of
the pure indatraline enantiomers toward monoamine trans-
porters have been reported (except for our previous study re-
garding the binding of (1R,3S)-indatraline [(1R,3S)-1] at
hNET),[5b] whereas the racemate has been characterized in com-
petitive radioligand binding assays, showing affinities in the
high picomolar to low nanomolar range.[8] There is one study
in which the potencies of both indatraline enantiomers were
individually investigated in uptake experiments.[9] In this study
an appreciable difference in potency was noted between the
enantiomers, (1R,3S)-1 and (1S,3R)-1, showing (1R,3S)-1 to be
the eutomer, with inhibitory potencies (IC50 values) of 0.17 nm
Figure 1. Native markers used in saturation experiments: (1R,3S)-1, (1S,3R)-1,
the cis-configured diastereomer rac-(1R,3R)-2, and the internal standard used
for LC–MS quantification, rac-(1R,3S)(2H7)-1.
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for [3H]DA uptake inhibition, 0.60 nm for [3H]NE uptake inhibi-
tion, and 1.0 nm for [3H]5-HT uptake inhibition. The distomer
(1S,3R)-1 exhibited IC50 values of 8.6 nm for [
3H]DA uptake in-
hibition, 5.3 nm for [3H]NE uptake inhibition, and 5.2 nm for
[3H]5-HT uptake inhibition.[9] Based on these data, eudismic
ratios of 5 ([3H]5-HT uptake inhibition), 9 ([3H]NE uptake inhibi-
tion), and 51 ([3H]DA uptake inhibition) were calculated.[9] The
latter results, however, must be critically scrutinized given the
low enantiomeric purity (95% ee) and the use of native rat
brain preparations, which are considered to be inhomogene-
ous, as in addition to the required monoamine transporter
type, they also contain other monoamine transporter types;
that these assays may therefore lack the necessary selectivity.[9]
In contrast to indatraline, its cis-configured diastereomer rac-
(1R,3R)-2 was reported to be SERT-selective in uptake experi-
ments[9] as well as in radioligand binding experiments using
[125I]RTI-55.[8l] The results of these two studies are, however,
distinctly different concerning the degree of affinity and in-
hibitory potency of rac-(1R,3R)-2. Bogeso et al. found IC50
values for [3H]5-HT uptake inhibition in the picomolar range,
and for [3H]DA and [3H]NE uptake inhibition in the low nano-
molar range,[9] whereas the radioligand binding experiments
of Froimowitz et al. revealed affinities in the low nanomolar
range for SERT, and in the high nanomolar range for DAT and
NET.[8l]
In summary, the few reliable and to some extent contradic-
tory data in the literature concerning the binding properties of
indatraline’s stereoisomers at the monoamine transporters do
not allow a substantiated selection of the stereoisomer most
suitable as a marker in MS Binding Assays for the biogenic
amine neurotransmitter transporters DAT, NET, and SERT (see
the Introduction).
Saturation experiments
We intended to initially characterize the affinities of the avail-
able indatraline stereoisomers for hDAT, hNET, and hSERT
(except for (1R,3S)-1 toward hNET, which was previously pub-
lished)[5b] in saturation experiments using the MS Binding
Assays recently published (Figure 2).[5b] From the aforemen-
tioned study, samples of the enantiomers of indatraline with
high enantiomeric purities of >99.75% ee [(1R,3S)-1] and
>99.67% ee [(1S,3R)-1] (determined according to the pub-
lished HPLC method)[10] were available to us. Unfortunately,
only the racemate of the cis-configured indatraline diastereo-
mer was available, as attempts to separate the compound by
crystallization after the formation of diastereomers using vari-
ous acids (e.g. , tartaric acid, mandelic acid, and dibenzoyl tarta-
ric acid), an approach recently applied to indatraline, have so
far been unsuccessful.
Due to the assumed high affinity of the eutomer (1R,3S)-
1 for all three monoamine transporters, and the cis-configured
diastereomer rac-(1R,3R)-2 toward hSERT, the same approach
was used as previously applied to characterize the binding of
(1R,3S)-1 at hNET in saturation experiments.[5b] As discussed
above, an increased incubation volume of 4.0 mL was used in-
stead of 250 mL, of which 3.6 mL (instead of 200 mL) were sub-
jected to filtration, which, in relation to an unchanged final
sample volume of 300 mL, resulted in a twelvefold higher
marker concentration in the final sample, thus enabling quan-
tification of even 400 fm bound marker (one twelfth the LLOQ)
in the binding samples.
Using this setup, increasing concentrations of (1R,3S)-1 (for
binding to hDAT and hSERT) and of rac-(1R,3R)-2 (for binding
to hSERT) from 50 pm to 30 nm were incubated with the corre-
sponding targets as previously described. Nonspecific binding
was determined directly at nominal marker concentrations
500 pm in the presence of 100 mm 1-[1-(benzo[b]thiophen-2-
yl)cyclohexyl]piperidine (BTCP, 6) for hDAT or 10 mm clomipra-
mine (10) for hSERT, whereas nonspecific binding for the lower
nominal marker concentrations was calculated by extrapolation
after linear regression of the experimental data obtained for
higher nominal marker concentrations (500 pm). In the end,
specific binding (defined as the difference between total bind-
ing and nonspecific binding) was plotted versus the nominal
marker concentration. The resulting saturation isotherms were
analyzed by nonlinear regression, revealing the Kd and Bmax
values listed in Table 1. We could confirm high-affinity binding
of (1R,3S)-1 toward all monoamine transporters, characterized
by Kd values of 1.7 nm at hDAT, 0.81 nm at hNET,
[5b] and
0.41 nm at hSERT, as well as high affinity of rac-(1R,3R)-2 for
hSERT, with a Kd value of 0.42 nm. Representative saturation
isotherms showing binding of (1R,3S)-1 at hDAT, hNET,[5b] and
hSERT are shown in Figure 3.
Figure 2. Basic workflow for MS Binding Assays: incubation, separation, and liberation steps followed by LC–MS/MS quantification (reproduced from ref. [5b]
with kind permission. Copyright 2015, Springer-Verlag Berlin Heidelberg).[5b]
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We also examined binding of the indatraline stereoisomers
at the transporters for which a lower affinity in saturation ex-
periments was assumed, namely binding of the distomer
(1S,3R)-1 toward all three monoamine transporters, as well as
binding of rac-(1R,3R)-2 toward hDAT and hNET. Due to the ex-
pected markedly higher Kd values in these cases, the target
concentration could also be distinctly enhanced in the corre-
sponding saturation experiments, while still maintaining
a target concentration at a magnitude up to 0.1 Kd (see above).
As the amount of bound marker resulting under these condi-
tions (i.e. , higher target concentration; see discussion in the In-
troduction concerning target concentrations in various setups)
was assumed to be sufficiently high for quantification with the
established LC–MS method with an LLOQ of 5 pm in the final
sample, we decided to revert to our standard setup for binding
experiments at an incubation volume of 250 mL instead of
4.0 mL for these investigations (see above modified setup for
saturation experiments for markers with high-affinity values).
However, when marker binding was studied in the concentra-
tion range from 100 pm to 500 nm for rac-(1R,3R)-2 and from
500 pm to 500 nm for (1S,3R)-1, no data were obtained to
allow the calculation of a saturation isotherm for (1S,3R)-1 bind-
ing to any of the monoamine transporters, or for rac-(1R,3R)-2
to hDAT. We did not further enhance the concentrations of
(1S,3R)-1 or rac-(1R,3R)-2 in saturation experiments, as in gen-
eral, binding characterized by Kd values in the higher nanomo-
lar range cannot be reliably determined in filtration-based
binding experiments (see Introduction).[6] At least the experi-
ments concerning the binding of rac-(1R,3R)-2 at hNET yielded
a satisfying saturation isotherm characterized by a Kd value of
49 nm (Table 1).
Taken together, the obtained Kd values confirm (1R,3S)-1 to
be a nonselective high-affinity ligand for the three monoamine
transporters hDAT, hNET, and hSERT, with Kd values in the high
picomolar to low nanomolar range and in a ratio of 4:2:1
(hDAT/hNET/hSERT). They also confirm rac-(1R,3R)-2 as a highly
selective high-affinity ligand for hSERT (Table 1). As (1R,3S)-
1 proved to be the only stereoisomer with an affinity for DAT
and NET sufficiently high to be suitable as a marker in filtra-
tion-based binding assays, we decided to use this compound
as a marker in competitive experiments for these targets. For
competitive experiments with hSERT (1R,3S)-1 also seemed
better suited, as it was available as a pure enantiomer, in con-
trast to rac-(1R,3R)-2, which, although possessing high affinity
for this transporter as well, was only available as the racemate.
Therefore, only the kinetics of (1R,3S)-1 binding to hDAT, hNET,
and hSERT was investigated in the next step.
Dissociation studies
At first, the dissociation rate constant (koff) and the correspond-
ing half-life of the target–marker complex (t1/2) were deter-
mined by the displacer technique by following our standard
setup (250 mL incubation volume). A prerequisite for dissocia-
tion experiments in general is a sufficient amount of target–
marker complexes formed at the beginning of the dissociation
experiments (i.e. , appropriate occupancy of the target by the
marker), leading to concentrations of the remaining non-disso-
ciated target–marker complexes after the various time steps
that are sufficiently high for reliable quantification. Therefore,
we allowed unhindered binding of (1R,3S)-1 to hDAT, hNET,
and hSERT for 2 h at 37 8C at concentrations of (1R,3S)-
1 (17.5 nm for hDAT, 25 nm for hNET, and 7.5 nm for hSERT)
leading to nearly complete saturation of the target. After equi-
librium was reached, the displacer [100 mm BTCP (6) for hDAT,
10 mm desipramine (12) for hNET, and 10 mm clomipramine
(10) for hSERT] was added to initiate dissociation, which was
terminated by filtration after various time increments ranging
Table 1. Kd and Bmax values for stereoisomers of indatraline obtained in saturation experiments toward hDAT, hNET, and hSERT.
Compound Kd [nm] (Bmax [pmolmg
¢1])[a] Kd ratio
[b]
hDAT hNET hSERT hDAT/hNET/hSERT
(1R,3S)-1 (1R,3S)-indatraline 1.70.1 (10132) 0.810.07[5b] (8312) 0.410.04[c] (333) 4:2:1
(1S,3R)-1 (1S,3R)-indatraline ND ND ND ND
rac-(1R,3R)-2 cis-configured diastereomer of indatraline ND 496 (9018) 0.420.07 (428) ND:117:1
[a] Kd and Bmax values were determined in three individual experiments, unless otherwise indicated, by MS Binding Assays (meansSEM, n=3). ND: no
data could be obtained in a concentration range from 100 pm to 500 nm [rac-(1R,3R)-2] and 500 pm to 500 nm [(1S,3R)-1] , precluding the calculation of
a saturation isotherm. [b] Ratios were calculated using mean Kd values. [c] Kd and Bmax values of four individual experiments (meanSEM, n=4).
Figure 3. Specific binding of (1R,3S)-1 at hDAT, hNET, and hSERT at nominal
marker concentrations of 50 pm to 30 nm. Specific binding was determined
as the difference between total binding and nonspecific binding (from ex-
perimental data in the range of 0.5–30 nm and from extrapolated data for
nominal marker concentrations <0.5 nm). Data points represent means of
triplicates of an individual saturation experiment (performed as described in
the Experimental Section).
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from 30 s to 2 h. After further processing according to our
standard setup, the concentration of remaining bound marker
was determined in the final sample using the developed LC–
ESI-MS/MS method. Due to the fact that nonspecific binding of
(1R,3S)-1 was found to be constant over the course of the dis-
sociation experiment, total binding was used for data analysis.
Based on these data, corresponding dissociation curves were
generated, and koff and t1/2 values were calculated by nonlinear
regression. Thereby dissociation rate constants (koff) of 4.8Õ
10¢3 s¢1 for the hDAT–(1R,3S)-1 complex, 1.4Õ10¢3 s¢1 for the
hNET–(1R,3S)-1 complex, and 5.4Õ10¢3 s¢1 for the hSERT–
(1R,3S)-1 complex were obtained (Table 2).
Surprisingly, the rank order of the calculated koff values was
not in agreement with expectations, as they did not parallel
the Kd values obtained in saturation experiments. This is gener-
ally the case, as Kd and koff values are related by Equation (1),
Kd=koff/kon,
[6] in which kon is mostly collision-limited and thus
independent of the target used.[6] For (1R,3S)-1 we had found
the affinity to be highest for hSERT over hDAT and hNET in sat-
uration experiments (see Saturation experiments above). As
a consequence, the koff value should have been the lowest and
not the highest for this transporter, as was found (see Table 2,
koff for displacer approach). One explanation for this discrepan-
cy might be positive or negative allosteric (i.e. , modulatory)
effect mediated by one or more of the chosen displacers, on
marker dissociation. This phenomenon was reported for some
monoamine transporter radioligand binding assays (i.e. , with
[3H]GBR12935, [3H]nisoxetine, or [3H]citalopram).[11] Unfortu-
nately, these allosteric effects cannot be predicted based on
published data, as they depend on numerous factors such as
the nature of the target, the marker used, as well as the em-
ployed displacer.[11b] To rule out that modulatory effects of the
chosen displacers might affect the koff value of (1R,3S)-1 in the
dissociation experiments, we followed an alternative approach
in which dissociation is induced by diluting the equilibrated
binding samples. Accordingly, dissociation was initiated under
conditions assuring an almost 1:1000 dilution of the remaining
unbound (1R,3S)-1 and corresponding target–marker com-
plexes (see the Experimental Section for details). Following this
dilution approach, dissociation rate constants of 4.2Õ10¢3 s¢1
for hDAT, 1.8Õ10¢3 s¢1 for hNET, and 0.88Õ10¢3 s¢1 for hSERT
were observed (see Table 2, koff for dilution approach, and
Figure 4).
The results for hDAT and hNET were not significantly differ-
ent from those obtained with the displacer method; the koff
value for hSERT, however, obtained with the dilution approach
was significantly lower than that obtained with the displacer
approach (t-test, a=0.05, see Figure 5). As the rank order of
koff values observed in the dilution approach is in agreement
with that of Kd values determined in saturation experiments,
and the koff values obtained for hDAT and hNET do not signifi-
cantly differ between both approaches, a negative allosteric
effect of clomipramine (10) enhancing the dissociation of the
hSERT–(1R,3S)-1 complex can be assumed.
Association studies
Subsequently, we also intended to get an estimate of the asso-
ciation rate constants (kon) for (1R,3S)-1 toward the monoamine
transporters, to which end kobs should be determined in associ-
ation experiments which is related to kon according to Equa-
tion (2) (with L as the marker concentration):[6]
kobs ¼ kon ¡ Lþ koff ð2Þ
As previous MS Binding Assays investigating the association
of the highly affine and selective serotonin reuptake inhibitor
(S)-fluoxetine [(S)-15] to hSERT showed that equilibrium was
nearly reached within a few minutes, we used a nominal
(1R,3S)-1 concentration as low as possible for the association
experiments with the monoamine transporters in order to
keep kobs as small as possible as a consequence of the above-
mentioned Equation (2). Therefore, we chose a nominal marker
Table 2. Kinetic rate constants and dissociation half-life of (1R,3S)-indatra-
line [(1R,3S)-1] binding at hDAT, hNET, and hSERT.[a]
hDAT hNET hSERT
koff [s
¢1][b] 4.80.1Õ10¢3 1.40.1Õ10¢3 5.40.2Õ10¢3
t1/2 [s]
[b] 1453 52838 1294
koff [s
¢1][c] 4.20.5Õ10¢3 1.80.2Õ10¢3 0.880.17Õ10¢3
t1/2 [s]
[c] 17325 36457 861179
kon [m
¢1 s¢1][d] 2.30.3Õ107 2.40.5Õ107 2.10.4Õ107
[a] Results are the meanSEM of three individual experiments unless
otherwise indicated. [b] Dissociation experiments performed by displacer
approach as described in the Experimental Section (hNET: n=4). [c] Dis-
sociation experiments performed by dilution approach as described in
the Experimental Section. [d] Association experiments performed as de-
scribed in the Experimental Section (hDAT: n=6, hNET: n=7).
Figure 4. Dissociation kinetics of complexes between (1R,3S)-1 and hDAT,
hNET, and hSERT targets at a nominal marker concentration of 5 nm at 37 8C.
Before dissociation experiments were started, unhindered binding of 5 nm
(1R,3S)-1 was allowed for 2 h at 37 8C to guarantee an equilibrium state.
After separation by centrifugation, dissociation was initiated by dilution (at
least 1:1000) of the remaining unbound (1R,3S)-1 and corresponding target–
marker complexes (t=0 s). Data points represent total binding (meansSD,
n=3) of an individual experiment (performed as described in the Experi-
mental Section).
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concentration of 500 pm, resulting in concentrations of bound
marker that could just be quantified reliably under conditions
of our standard setup by means of the established LC–MS
method (LLOQ 5 pm), even after the shortest incubation
period of 20 s. The results of representative association experi-
ments are shown in Figure 6. It is clearly visible that the ob-
served association is almost complete within two minutes.
Thus, association is indeed too rapid under the conditions
chosen to provide exact data in conventional filtration-based
binding assays. Nevertheless, kon values of 2.3Õ10
7
m
¢1 s¢1
(hDAT), 2.4Õ107m¢1 s¢1 (hNET), and 2.1Õ107m¢1 s¢1 (hSERT)
(Table 2) were calculated from the determined koff and kobs
values and the marker concentrations used. Although these as-
sociation rate constants are only rough estimates, their magni-
tude is in agreement with association being collision-limited
which has typically a kon value of 10
7
m
¢1 s¢1.[6]
Summary of kinetic studies
Several conclusions can be drawn from the kinetic experiments
performed. First, by using the dilution-based dissociation tech-
nique, the dissociation rate constants of the individual target–
(1R,3S)-1 complexes could be reliably determined, with a rank
order of koff values being in accord with the rank order of Kd
values observed in saturation experiments. Second, the ob-
tained dissociation rate constants for (1R,3S)-1 binding to
hDAT, hNET, and hSERT are clearly low enough to permit the
use of filtration as a separation technique without significant
loss of specific marker binding. Third, an allosteric effect of clo-
mipramine (10) causing accelerated dissociation of the hSERT–
(1R,3S)-1 complex was identified. Fourth, association experi-
ments revealed that association under the chosen conditions
was too rapid for a reliable and exact determination of kon in
a filtration-based MS Binding Assays. Notably, however, the
same applies to conventional radioligand binding assays.
Competitive experiments
(1R,3S)-Indatraline [(1R,3S)-1] proved to be the only stereoiso-
mer with high affinity for hDAT and hNET. Thus, it was chosen
to serve as a marker in competitive experiments for these tar-
gets. Compound (1R,3S)-1 was also selected as a marker for
competitive binding experiments with hSERT, as it could be
used as a pure enantiomer, whereas the cis-configured diaste-
reomer rac-(1R,3R)-2, with high affinity for this transporter as
well, was only available as a racemate. Competitive MS Binding
Assays with fixed (1R,3S)-1 concentrations and varying concen-
trations of test compounds were performed, again following
the standard setup (250 mL incubation volume) by which a rea-
sonable throughput was warranted. This setup was used to
study a series of known monoamine transporter inhibitors and
substrates covering a wide range of affinities and selectivities
(Figure 7). In each case, these compounds were used at a mini-
mum of seven concentrations in a range spanning at least
three orders of magnitude. Unfortunately, nonspecific binding
resulting from the marker concentrations used in competitive
binding experiments was typically below the LLOQ. Hence, an
additional experiment was performed in which nonspecific
binding of (1R,3S)-1 in a range from 2.5 to 20 nm was deter-
mined as described above (see Kinetic studies in the Experi-
mental Section). Therefrom, the extent of nonspecific binding
at nominal marker concentrations used in competitive MS
Binding Assays was extrapolated.
Competition curves were then established by plotting the
percentage value of the resulting specific binding (y-axis), de-
fined as difference of total binding and extrapolated nonspecif-
ic binding, versus the logarithm of the test compound used
(x-axis) and analyzed by nonlinear regression. Representative
Figure 5. Dissociation kinetics of hSERT–(1R,3S)-1 complexes at 37 8C at
a nominal marker concentration of 7.5 nm (by displacer approach with clo-
mipramine (10)) or 5 nm (by dilution approach). The incubation system was
allowed to reach equilibrium [pre-incubation of (1R,3S)-1 at 7.5 nm (displacer
approach) and 5 nm (dilution approach) for 2 h at 37 8C] before the respec-
tive dissociation experiment was started. Dissociation was initiated by
adding 10 (grey squares), resulting in a final concentration of 10 mm in the
binding sample, or by dilution (at least 1:1000) of the remaining unbound
(1R,3S)-1 and corresponding target–marker complexes obtained after separa-
tion by centrifugation (black circles) (t=0 s). Data points represent total
binding (meansSD, n=3) of an individual experiment (performed as
described in the Experimental Section).
Figure 6. Association kinetics showing the formation of the various target–
(1R,3S)-1 complexes (i.e. , hDAT, hNET, and hSERT) at a nominal marker con-
centration of 500 pm. Data points represent total binding (meansSD,
n=3) of an individual experiment (performed as described in the Experi-
mental Section).
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competition curves are shown for sertraline (27) in Figure 8.
The competition curves yielded IC50 values from which the cor-
responding Ki values of the test compounds could be calculat-
ed. The pKi values (meansSEM, n=3–7) derived from these
MS Binding Assays for the three transporters hDAT, hNET, and
hSERT using (1R,3S)-1 as marker are summarized in Table 3 (see
also Figure S1 in the Supporting Information for further
details).
To verify the results obtained we compared them with data
reported for corresponding radioligand binding assays. Un-
Figure 7. Structures of known inhibitors, including substrates 3–34 used in competitive experiments.
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fortunately, there are only few studies that are based on con-
sistent heterologous expression systems for all three mono-
amine transporters and that were carried out under consistent
conditions. Most reports describe studies based on animal
brain tissue preparations, which hardly allow a selective char-
acterization of individual monoamine transporters (this is par-
ticularly true for DAT binding assays, lacking highly selective
DAT ligands; see the discussion below). However, there is an
[125I]RTI-55 binding assay published by Eshleman et al. that also
used membrane preparations of HEK293 cells expressing hDAT,
hNET, and hSERT as respective target source and under consis-
tent conditions. This offered the opportunity to compare the
binding data of at least ten test compounds covering a broad
affinity range and diverse selectivities with these from our
study (see Table 3).[12]
Although even small differences in the performance of the
binding assays (the nature of the chosen marker, the composi-
tion of the incubation buffer, temperature, etc.) may affect the
resulting Ki values, an excellent correlation of our results with
those of Eshleman et al.[12] was observed for all three transport-
ers. In detail, the straight lines resulting from linear regression
for the compared pKi values determined by us with those re-
ported by Eshleman et al.[12] (Figure 9) were characterized by
the following equations and coefficients of determination (R2):
y=1.048x¢0.1569, R2=0.8970 (hDAT); y=1.099x¢1.028, R2=
0.9830 (hNET); and y=1.131x¢0.6675, R2=0.9726 (hSERT). The
observed agreement in pKi values along with an almost equal
rank order of potency verifies the reliability, and thus rele-
vance, of our developed MS Binding Assays as a label-free al-
ternative to radioligand binding assays addressing the studied
monoamine transporters.
Furthermore, several important insights can be gained from
these data. First, several DAT inhibitors that are claimed to be
highly selective, i.e. , 3-a-bis-(4-fluorophenyl)methoxytropane
(3),[13] BTCP (6),[14] JHW007 (18),[15] and LR1111 (19)[16] did not
show this selectivity in our MS Binding Assays (Table 3). This
fact becomes most evident by the corresponding Ki ratios for
Figure 8. Representative competition curves for sertraline (27) obtained with
hDAT, hNET, and hSERT resulting from individual competitive MS binding ex-
periments (performed as described in the Experimental Section). Data points
represent specific binding of (1R,3S)-1 in the presence of sertraline at various
concentrations in a single experiment (meansSD, n=3). The top level of
the competition curves was constrained to 100%, which is equivalent to
specific binding of (1R,3S)-1 in the absence of inhibitor, and the bottom
level to 0%, equivalent to nonspecific binding.
Figure 9. Graphical correlation of pKi values for various competitors deter-
mined in MS Binding Assays (x-axes) and in [125I]RTI-55 radioligand binding
assays (y-axes).[12] Data points represent mean values from MS Binding
Assays (n=3–7) and the converted mean value of published Ki values
(n=3–8) of radioligand binding assays. Shown are the correlations of pKi
values for ten compounds at a) hDAT (y=1.048x¢0.1569, R2=0.8970),
b) hNET (y=1.099x¢1.028, R2=0.9830), and c) hSERT (y=1.131x¢0.6679,
R2=0.9726).
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hDAT and hNET (Table 3), being 1:2 (3), 1:1 (6), 1:2 (18), and 1:1
(19). This discrepancy may be due to the fact that the radioli-
gands used in the corresponding studies, i.e. ,
[3H]WIN35428,[13,15] [3H]BTCP,[14] and [3H]JHW007,[15] label bind-
ing sites at DAT slightly different from those addressed by
(1R,3S)-1. Furthermore, the published data were obtained from
radioligand binding and transport assays using brain tissue
preparations, thus not ruling out that other targets apart from
the desired one may also be addressed by the radioligand or
the radiolabeled substrate to some extent. Second, rac-(3R,4R)-
4-(2-benzhydryloxyethyl)-1-(4-fluorobenzyl)piperidin-3-ol [rac-
(3R,4R)-4] ,[17] one of the most potent and selective DAT inhibi-
tors described so far, could be confirmed as such, showing
high affinity for hDAT (pKi : 7.43) and the highest selectivity for
this transporter characterized by a ratio of Ki values of 1:7:36
(hDAT/hNET/hSERT; Table 3). Determination of the affinity of
both enantiomers, [(3R,4R)-4] and [(3S,4S)-4] , in competitive
MS binding assays confirmed that the eutomer, [(3R,4R)-4] ,[17]
possesses even higher selectivity for hDAT (Ki ratios of 1:9:84,
hDAT/hNET/hSERT; Table 3).
Third, investigating the g-aminobutyric acid (GABA) trans-
porter (GAT) inhibitor NNC05-2090 (22), which, in contrast to
most of the other known GAT inhibitors (GAT inhibitors are
widely studied in our group), is devoid of a carboxylic acid
function, affinities for this compound for hDAT (pKi : 5.92),
hNET (pKi : 6.07), and hSERT (pKi : 6.45; Table 3) were found to
be in the range of the potencies observed at the GATs [i.e. ,
pIC50 values of 4.7 (hGAT-1), 5.7 (BGT-1), 5.6 (hGAT-2), and 4.9
(hGAT-3)] .[18] During the course of this project a study by Jin-
zenji et al. was published that also compared the uptake inhib-
ition of compound 22 at monoamine and GATs. Also according
to their results, 22 shows higher inhibitory potencies at DAT
Table 3. Affinity (pKi) and selectivity (Ki ratios hDAT/hNET/hSERT) values of various inhibitors toward hDAT, hNET, and hSERT obtained by competitive MS
Binding Assays supplemented with published data from Eshleman et al.[12]
Compound pKi Ki ratio
hDAT hNET hSERT
MS[a] RB[b] MS[a] RB[b] MS[a] RB[b] MS[c]
3 3-a-bis-(4-fluorophenyl)methoxytropane 7.520.04 7.220.02 5.710.05 1:2:65
rac-(3R,4R)-4 rac-(3R,4R)-4-(2-benzhydryloxyethyl)-1-(4-fluorobenzyl)piperidin-3-ol 7.430.09 6.580.03 5.860.04 1:7:36
(3R,4R)-4 d-84 7.450.08 6.520.09 5.520.04 1:9:84
(3S,4S)-4 d-83 6.970.05 6.470.08 5.960.05 1:3:10
5 amitriptyline 5.020.07 6.920.07 7.590.09 363:5:1
6 BTCP 7.490.10 7.490.08 6.710.08 1:1:6
rac-7 rac-bupropion 5.590.12 5.58 5.080.09 4.68 4.830.10 4.46 1:3:6
8 chlorpromazine 5.360.07 7.490.07 6.980.14 123:1:3
rac-9 rac-citalopram 4.270.03 5.450.05 8.080.05 6373:425:1
(S)-9 (S)-citalopram 4.270.06 4.990.08 8.320.13 10484:2024:1
10 clomipramine 5.370.05 7.020.07 9.090.13 5994:121:1
11 cocaine 6.130.05 6.43 6.200.05 5.80 6.560.10 6.40 3:2:1
12 desipramine 5.160.05 4.84 8.350.03[5b] 7.86 6.800.11 7.26 1760:1:44
13 doxepin 4.150.07 6.990.10 6.560.03 684:1:3
14 duloxetine 6.010.06 8.250.08 9.410.03 2520:15:1
rac-15 rac-fluoxetine 5.050.04 5.18 6.010.05 5.81 8.310.07 8.94 1782:196:1
(R)-15 (R)-fluoxetine 4.880.14 6.160.06 8.300.04 1048:141:1
(S)-15 (S)-fluoxetine 4.600.08 5.990.06 8.500.01 2397:324:1
16 GBR12909 7.430.11 7.100.04 6.400.04 1:2:10
17 imipramine 4.590.04 4.59 6.980.05 6.67 8.350.06 8.48 5656:24:1
18 JHW007 7.190.09 6.820.05 6.100.02 1:2:12
19 LR1111 7.150.02 7.220.09 6.240.09 1:1:10
20 maprotiline 6.120.04 7.270.09 4.980.09 13:1:195
rac-21 rac-nisoxetine 5.670.03 5.77 7.890.06 7.49 6.550.06 7.14 165:1:22
22 NNC05-2090 5.920.03 6.070.00 6.450.10 3:2:1
23 nortriptyline 5.300.10 5.40 7.970.12 8.13 6.830.03 7.48 454:1:13
24 paroxetine 5.670.06 6.470.06 8.910.03 1787:282:1
25 PCP 5.920.07 6.010.02 5.720.09 1:1:2
rac-(2R,2R)-26 rac-(2R,2R)-reboxetine 4.790.08 8.440.15 6.530.07 3928:1:71
27 sertraline 6.610.05 6.230.05 8.720.08 128:303:1
rac-28 rac-talopram 4.490.06 7.890.07 6.130.13 2570:1:75
rac-29 rac-tianeptine <4.00 <4.00 <4.00 ND
30 dopamine 4.710.02 5.19 5.320.08 4.55 3.310.05 2.96 4:1:96
31 l-norepinephrine 3.810.04 4.24 4.320.06 3.80 2.790.02 2.83 3:1:32
32 serotonin 3.640.05 3.26 4.190.11 3.44 5.850.06 5.46 160:47:1
33 ASP+ iodide 4.490.05 5.470.12 4.610.15 9:1:8
34 MPP+ iodide 3.830.01 5.020.14 4.230.11 14:1:6
[a] MS binding: Affinity values (pKi ; meanSEM, n=3–7) were determined in competitive MS Binding Assays using (1R,3S)-indatraline [(1R,3S)-1] as marker.
[b] Radioligand binding: Affinity values of Eshleman et al. determined in [125I]RTI-55 binding experiments (n=3–8) ;[12] reported mean Ki values were con-
verted into pKi values. [c] Ki ratios showing selectivity were calculated with the mean Ki values of respective pKi values determined in MS Binding Assays.
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(pIC50 : 5.4), NET (pIC50 : 5.1), and SERT (pIC50 : 5.3) in [
3H]DA,
[3H]NE, and [3H]5-HT transport assays (based on CHO cells
stably expressing the corresponding rat monoamine transport-
ers) as compared with the inhibitory potencies at the four GAT
subtypes in [3H]GABA transport assays [based on murine trans-
porters stably expressed in CHO cells, pIC50 values: 4.5 (GAT-1),
4.3 (GAT-2), 4.6 (GAT-3), and 5.0 (BGT-1)] .[19]
Conclusions
The MS Binding Assays performed in this study allowed the
first direct investigation of the binding of (1R,3S)-indatraline,
(1S,3R)-indatraline, and the cis-configured diastereomer to
hDAT, hNET, and hSERT. Saturation experiments confirmed
(1R,3S)-indatraline to have high and nearly equal affinity for
the three monoamine transporters, and the cis-configured dia-
stereomer of indatraline to be highly SERT selective. Further-
more, it was demonstrated that the determination of Kd values
down to 0.40 nm is feasible based on LC–MS quantification of
a nonlabeled marker. After characterization of the binding ki-
netics of (1R,3S)-indatraline toward hDAT, hNET, and hSERT, this
stereoisomer was used as a marker in competitive binding ex-
periments. In this way, a comprehensive series (nearly 40 com-
pounds) of selective and nonselective inhibitors as well as sub-
strates were assayed for their affinities to all three targets. With
respect to affinity, selectivity, and rank order of potency, the
observed results were in excellent agreement with those ob-
tained in [125I]RTI-55 binding assays for all ten compounds also
studied in the latter setup, clearly demonstrating the reliability
of the data obtained in competitive experiments with our MS
Binding Assays. After having processed almost 10000 samples
during this study, it may be stated that with the developed
setup, a throughput similar to that typical for conventional
radioligand binding assays was reached, and that the estab-
lished LC–MS-based quantification is characterized by remark-
able robustness. Regarding LC–MS quantification it is worth
mentioning that the MS Binding Assays described herein are
based on a single method that enables quantification of the
marker addressing three different targets (hDAT, hNET, and
hSERT) and, furthermore, characterization of binding of all in-
datraline stereoisomers at these targets. The sensitivity of the
developed MS-based quantification method (LLOQ of 5 pm) is
close to that achieved by liquid scintillation counting in com-
parable radioligand binding assays (see the Supporting Infor-
mation for a comparison). Thus, the MS Binding Assays de-
scribed herein are a powerful substitute for radioligand bind-
ing assays addressing hDAT, hNET, and hSERT.
Experimental Section
Chemicals : The hydrochloride of NNC05-2090 (22) was purchased
from Abcam (Cambridge, UK). The hydrochloride of sertraline (27)
was purchased from abcr GmbH (Karlsruhe, Germany), the hydro-
chlorides of rac-bupropion (rac-7), chlorpromazine (8), dopamine
(30), and serotonin (32) were from Alfa Aesar (Karlsruhe, Germany).
The sodium salt hydrate of rac-tianeptine (rac-29) was provided by
AK Scientific, Inc. (Union City, USA). The hydrochlorides of rac-ni-
soxetine (rac-21) and rac-(2R,2R)-reboxetine [rac-(2R,2R)-26] were
purchased from Biotrend (Cologne, Germany). The hydrobromide
of rac-citalopram (rac-9), the hydrochloride of paroxetine (24), and
U-0521 [1-(3,4-dihydroxyphenyl)-2-methylpropan-1-one] were ob-
tained from Enzo Life Science (Lçrrach, Germany). Ascorbic acid,
the hydrochlorides of amitriptyline (5), doxepin (13), and imipra-
mine (17) were purchased from Fagron (Barsbìttel, Germany).
ASP+ iodide (33), MPP+ iodide (34), the hydrochlorides of BTCP
(6), clomipramine (10), cocaine (11), desipramine (12), duloxetine
(14), (R)-fluoxetine [(R)-15] , (S)-fluoxetine [(S)-15] , maprotiline (20),
l-norepinephrine (31), and pargyline were provided from Sigma–
Aldrich (Taufkirchen, Germany). The oxalate of (S)-citalopram [(S)-9]
was obtained from TCI (Eschborn, Germany). The hydrochloride of
3-a-bis-(4-fluorophenyl)methoxytropane (3), the dihydrochloride of
GBR12909 (16), the hydrochlorides of JHW007 (18) as well as rac-
talopram (rac-28) were purchased from Tocris (Wiesbaden-Norden-
stadt, Germany). The hydrochloride of rac-fluoxetine (rac-15) was
bought from VWR (Darmstadt, Germany). Dr. Theo Rein (Max
Planck Institute of Psychiatry, Munich, Germany) kindly provided
the hydrochloride of nortriptyline (23). The oxalates of rac-(3R,4R)-
4-(2-benzhydryloxy)ethyl)-1-(4-fluorobenzyl)piperidin-3-ol [rac-
(3R,4R)-4] and LR1111 (19) were synthesized in house. The oxalates
of the enantiomers (3R,4R)-4-(2-benzhydryloxy)ethyl)-1-(4-fluoro-
benzyl)piperidin-3-ol, also known as d-84,[17] (>99.8% ee), [(3R,4R)-
4] , and (3S,4S)-4-(2-benzhydryloxy)ethyl)-1-(4-fluorobenzyl)piperi-
din-3-ol, also known as d-83,[17] (98.5% ee), [(3S,4S)-4] were separat-
ed and analyzed for enantiomeric purity in house. The hydrochlo-
ride of phencyclidine (PCP, 25) was a donation of Emeritus Prof.
Fritz Eiden (LMU Mìnchen, Department of Pharmacy, Germany). All
LC–MS-grade solvents (CH3CN, H2O) were purchased from VWR
Prolabo (Darmstadt, Germany). Water for incubation and washing
buffer was obtained in house by distillation of demineralized water
(prepared by reverse osmosis) and subsequent filtration using
0.45 mm filter material. Additives for LC–MS ((NH4)HCO3, (NH4)OH
solution 25%, all of LC–MS quality), were purchased from Fluka
(Taufkirchen, Germany). HPLC-grade (NH4)OAc and HEPES were pur-
chased from VWR Prolabo. The hydrochloride of indatraline [rac-
(1R,3S)-1] ,[10] the deuterochloride of rac-(1R,3S)(2H7)-indatraline [rac-
(1R,3S)(2H7)-1] ,
[20] and the hydrochloride of the cis-configured dia-
stereomer [rac-(1R,3R)-2][9] were synthesized in house according to
published methods. The hydrochlorides of the pure enantiomers
(1R,3S)-indatraline [(1R,3S)-1] and (1S,3R)-indatraline [(1S,3R)-1] pos-
sessed an enantiomeric purity of >99.75% ee and >99.67% ee, re-
spectively, determined according to the method previously de-
scribed.[10] The specific rotation of (1S,3R)-indatraline [(1S,3R)-1] hy-
drochloride (mp: 178–179 8C) amounted to [a]D21=¢16.5 (c=0.46,
CH3OH, determined with a PerkinElmer 241 C polarimeter, Perki-
nElmer, Rodgau, Germany).
LC–ESI-MS/MS : LC–ESI-MS/MS was performed following our previ-
ously described method including all aspects of the validated
method:[5b] YMC Triart C18 column (50 mmÕ2.0 mm, 3 mm) with
a YMC Triart C18 pre-column (10 mmÕ2.1 mm, 3 mm) as stationary
phase, CH3CN and (NH4)HCO3 buffer (5 mm, pH 10.0) at a ratio of
90:10 (v/v) as mobile phase, flow rate of 600 mLmin¢1, temperature
of 20 8C for chromatography, CH3CN and (NH4)HCO3 buffer (5 mm,
pH 10.0) at a ratio of 75:25 (v/v) as sample solvent, injection
volume 45 mL. Each day an assay was performed with individual
matrix blanks, zero samples, matrix standards for generating a cali-
bration function (six concentrations in a range of 5 pm to
1000 pm), and quality control samples (QCs) at three concentra-
tions (10, 100, and 1000 pm) were prepared, each at least in tripli-
cate, and analyzed with the markers (1R,3S)-(1), (1S,3R)-1, or rac-
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(1R,3R)-2, respectively, in combination with rac-(1R,3S)(2H7)-1 as
internal standard (see below).
Cell culture and expression of hDAT, hNET, and hSERT: The mam-
malian pRc/CMV expression vector containing the cDNA coding for
hDAT was kindly provided by Prof. Dr. Harald H. Sitte (Center for
Physiology and Pharmacology, Institute of Pharmacology, Medical
University of Vienna). Stable transfection of HEK293 cells was per-
formed as previously described using KpnI for linearization of the
plasmid.[5b] Single colonies of stably transfected cells were further
cultivated in selection medium containing geneticin and tested for
their expression using a [3H]MPP+ uptake assay like described.[5b]
HEK293 cell lines stably expressing hNET and hSERT (HEK-hNET and
HEK-hSERT) were established as described recently.[5b, c]
hDAT, hNET, and hSERT membrane preparations : Membrane
preparations of HEK293 cells stably expressing one of the mono-
amine transporters (i.e. , hDAT, hNET, or hSERT) were prepared as
described previously,[5b] with a final protein concentration of ~10–
30 mgmL¢1 (hDAT), 20–60 mgmL¢1 (hNET), and 10–50 mgmL¢1
(hSERT) determined according to the Bradford method after incu-
bation with 100 mm NaOH and using bovine serum albumin as
standard.[21]
General procedure for MS binding experiments : The standard
setup for MS binding followed the procedure previously described
for MS Binding Assays addressing hNET:[5b] membrane preparations
and marker were incubated in triplicates in the assay buffer
(50 mm HEPES, 120 mm NaCl, 5 mm KCl, pH 7.4) in polypropylene
96-well plates (1.2 mL well volume, total sample volume: 250 mL,
Sarstedt, Nìmbrecht, Germany) at 37 8C in a shaking water bath for
2 h. Incubation was terminated by filtration after transfer of the
binding samples (aliquot of 200 mL per well) by means of a 12-
channel pipette onto 96-well glass fiber filter plates (AcroPrep Ad-
vance, glass fiber, 1.0 mm, 350 mL, Multi-Well Plate Vacuum Mani-
fold, Pall, Dreieich, Germany), which had been pretreated for 1 h
with 200 mL of a 0.5% (w/v) polyethyleneimine (PEI) solution. Mem-
brane fragments with the bound marker remaining on the filter
were washed (5Õ150 mL) with ice-cold wash buffer (150 mm
(NH4)OAc buffer, pH 7.4). Afterward, the filter plates were dried for
1 h at 50 8C and cooled to room temperature before liberation of
the bound marker by elution with CH3CN containing 1.33 nm rac-
(1R,3S)(2H7)-1 (3Õ75 mL, 30 s for every aspiration step). To obtain
the final sample milieu, (NH4)HCO3 buffer (75 mL, 5 mm, pH 10.0)
were added per well. Finally, the plates were centrifuged (10 min,
2500 rpm, 4 8C; Biofuge Stratos, Heraeus, Hanau, Germany), sealed
with aluminum foil, and the samples were analyzed by the LC–ESI-
MS/MS method described.[5b]
Saturation experiments : For saturation experiments two different
setups were used. The standard setup was used for the characteri-
zation of the distomer, (1S,3R)-1, toward all three targets and rac-
(1R,3R)-2 toward hDAT and hNET (see General procedure for MS
binding experiments above). For affinity determination of the euto-
mer (1R,3S)-1 toward hDAT and hSERT, and rac-(1R,3R)-2 toward
hSERT, a modified setup, as described recently, was used:[5b] Mem-
brane preparations and increasing concentrations of the marker
(six replicates per concentration) were incubated in polypropylene
96-well plates (2.2 mL well volume, total sample volume 2.0 mL,
Sarstedt, Nìmbrecht, Germany) at 37 8C in a shaking water bath for
2 h. Incubation was terminated by filtration (glass fiber filter plate
including pre-treatment as described above) after transfer of
1800 mL of two incubation replicates to the same wells of the filter
plate (i.e. , two of the six replicate incubation samples were com-
bined to obtain three replicates on the filter plate, each generated
from 3600 mL of the respective binding samples per filter well). The
remaining membrane fragments with bound marker were treated
exactly as described above (washing, drying, elution, centrifuga-
tion, and analysis), yielding samples in the same final volume
(300 mL) as they were obtained following the General procedure for
MS binding experiments (above). For determination of total binding
in saturation experiments, the following concentration ranges of
marker and amounts of target were used: (1R,3S)-1 in a range from
50 pm to 30 nm, and the distomer (1S,3R)-1 in a range from
500 pm to 500 nm in the presence of ~0.5–1.5 mg protein per well
for hDAT, and 1.0–2.0 mg protein per well for hNET, and 1.5–2.5 mg
protein per well for hSERT; rac-(1R,3R)-2 toward hSERT in a range
from 50 pm to 30 nm toward hDAT and hNET in a range from
100 pm to 500 nm in the presence of ~1.0–1.5 mg protein per well
for hDAT, and 1.0–2.5 mg protein per well for hNET, and 1.5–2.5 mg
protein per well for hSERT. Nonspecific binding was determined in
the same way as total binding, but in the presence of a competitor
in vast excess (100 mm BTCP (6) for hDAT, 10 mm desipramine (12)
for hNET, and 10 mm clomipramine (10) for hSERT). Using the stan-
dard setup (250 mL incubation volume) nonspecific binding could
be determined at nominal marker concentrations 2.5 nm. With
the modified setup nonspecific binding could be determined at
marker concentrations 500 pm. In both cases an extrapolation
from the experimental data for nonspecific binding of lower
marker concentrations based on linear regression was performed
(see Data analysis below).
Kinetic studies : Dissociation experiments by the displacer ap-
proach were performed by pre-incubating (1R,3S)-1 at a nominal
concentration of 17.5 nm for hDAT, 25 nm for hNET, and 7.5 nm for
hSERT with the respective target (~0.5–1.0 mg protein per well for
hDAT, 0.5–3.0 mg protein per well for hNET, and 0.5–1.5 mg protein
per well for hSERT) at 37 8C in a shaking water bath for 2 h (in
a total incubation volume of 225 mL). After pre-equilibration, disso-
ciation was initiated by adding 25 mL of a solution of the respective
competitor to the incubation sample (i.e. , 225 mL), to yield a final
concentration of 100 mm BTCP (6) (hDAT), 10 mm desipramine (12)
(hNET), and 10 mm clomipramine (10) (hSERT), and terminated after
a defined time schedule (30 s–2 h, 16 dissociation time periods,
samples for each time period were prepared in triplicate) by filtra-
tion as described above (see General procedure for MS binding ex-
periments). For determination of the dissociation rate constant by
dilution, unhindered binding of 5 nm (1R,3S)-1 for 2 h at 37 8C in
bulk was allowed to pre-equilibrate (incubation volume 10 mL and
~35–40 mg protein for hDAT, 100–120 mg protein for hNET, and 40–
60 mg for hSERT). Pre-equilibration was terminated by centrifuga-
tion (20 min, 20000 rpm, 4 8C, Sorvall Evolution, SS34 rotor), and
the resulting pellet (including residual solvent <200 mg) was re-
suspended in 20 mL assay buffer at 37 8C (providing a dilution of
at least 1:1000). Again, dissociation was stopped by filtration after
defined time intervals (30 s–2 h, 16 dissociation time periods, sam-
ples for each time period were prepared in triplicate) of the respec-
tive batch. To this end, 400 mL of the dilution experiment bulk
sample were transferred to the filter plate and treated as described
above under General procedure for MS binding experiments. Associa-
tion experiments were performed by adding the target material
(same protein amount as described for dissociation experiments by
the displacer approach) to the incubation buffer containing
500 pm (1R,3S)-1. After a defined time schedule (20 s–2 h, 16 asso-
ciation time periods, samples for each time period were prepared
in triplicate) association was stopped by filtration (transfer of
a 200 mL aliquots of the binding samples making up a total
volume of 250 mL, to the filter plate) as described above in General
procedure for MS binding experiments. Additionally, nonspecific
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binding was determined in dissociation experiments at the respec-
tive marker concentration used, i.e. , 17.5 nm for hDAT, 25 nm for
hNET, and 7.5 nm for hSERT for the displacer approach, and of
5 nm using the dilution approach in the presence of the displacer,
i.e. , 100 mm BTCP (6) (hDAT), 10 mm desipramine (12) (hNET), and
10 mm clomipramine (10) (hSERT) according to the General proce-
dure for MS binding experiments. For association experiments non-
specific binding at a marker concentration of 500 pm was deter-
mined as follows: four different concentrations (i.e. , 2.5, 5, 10, and
20 nm) of (1R,3S)-1 were incubated in the presence of 100 mm
BTCP (6) (hDAT), 10 mm desipramine (12) (hNET), and 10 mm clo-
mipramine (10) (hSERT) according to the General procedure for MS
binding experiments. The obtained experimental data were used for
extrapolation of nonspecific binding at 500 pm (1R,3S)-1.
Competitive experiments : In all competitive studies the standard
setup (see General procedure for MS binding experiments) was used,
employing a nominal marker concentration of 1.75 nm (1R,3S)-
1 for hDAT, 2.4 nm for hNET, and 0.75 nm for hSERT. For affinity
characterization of the test compounds, a minimum of seven con-
centrations covering a range of at least three orders of magnitude
were incubated in the presence of the marker and the respective
target (~0.5–1.0 mg protein per well for hDAT, 1.0–2.5 mg protein
per well for hNET, 0.5–2.0 mg protein per well for hSERT). Due to
their low stability, native substrates, i.e. , dopamine (30) and l-nor-
epinephrine (31), were incubated in an incubation buffer supple-
mented with 100 mm pargyline, 10 mm U-0521, and 10 mm ascorbic
acid. Nonspecific binding was determined in an additional experi-
ment in a range of 2.5 nm to 20 nm as described above for associa-
tion experiments (see Kinetic studies).
Data analysis : LC–ESI-MS/MS data were obtained using Ana-
lyst 1.6.1. Calibration functions were generated by linear regression
with a 1/x2 weighting with Prism 5.0 (GraphPad Software, San
Diego, CA, USA). For saturation experiments, specific binding was
defined as the difference between total and nonspecific binding,
which was determined for lower nominal concentrations 2.5 nm
(standard setup) and 500 pm (modified setup), respectively, by
extrapolation (linear regression) of experimental data from nonspe-
cific binding at a marker concentration 2.5 nm (standard setup)
and 500 pm (modified setup) using Prism 5.0. Values for equilibri-
um dissociation constant (Kd) and maximum amount of binding
sites (Bmax) were calculated from specific binding isotherms using
the nonlinear regression tool ‘one site—specific binding’ of
Prism 5.0. Using the nonlinear regression tools of Prism 5.0, ‘disso-
ciation—one-phase exponential’ and ‘association kinetics—one
conc. of hot’, the corresponding rate constants for dissociation,
half-life of the target–marker complex, and association were deter-
mined. For determination of the inhibition constant (Ki) the corre-
sponding specific binding of the marker, calculated as the differ-
ence of total binding and nonspecific binding, was plotted on
a percentage basis of a respective binding sample in the absence
of inhibitor, which was set at 100%, versus the logarithm of the
concentration of the test compound used, whereby 0% was set
equal to the nonspecific binding. This plot was then analyzed with
the nonlinear regression tool ‘one site—Fit Ki’ of Prism 5.0. Marker
depletion was negligible in all experiments (10%). For statistical
comparisons data were examined by F-test and t-test (two sites,
a=0.05 in both cases).
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Resulting bound marker in saturation experiments 
 
According to the Langmuir adsorption model calculation of the isotherm resulting from saturation 
experiments is based on the following equation: 
 
 = 	
 ∗ 	

 + 	
 
 
with Bmax being the maximum amount of binding sites, L being the marker concentration, Kd being the 
affinity of the employed marker, and y being the formed target-marker complexes (which is equivalent 
to the bound marker). Therefore, the concentration of bound marker (y) for a nominal marker 
concentration (L) of 0.1 Kd at a target concentration (Bmax) of 0.1 Kd can be calculated to: 
 
 = 	
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 Figure S1. pKi values for a series of known inhibitors and substrates for hDAT (red), hNET (green), and hSERT 
(blue) obtained in competitive experiments employing the developed MS Binding Assays utilizing 
(1R,3S)-indatraline as MS marker (mean ± SEM, n = 3-7). 
  
Sensitivity of the developed LC-ESI-MS/MS method for the quantification of indatraline compared 
with the one expected in radioligand binding assays 
 
The developed MS based quantification method for indatraline had an LLOQ of 5 pmol L-1 in the final 
sample having a volume of 300 µL. This corresponds to 1.5 fmol indatraline in the sample to be analyzed. 
 
A corresponding radioligand of indatraline possessing a tritiated methylamine function (see figure S2) 
would have a specific activity of maximal 3.18 x 1015 Bq mol-1. According to the assumed maximal 
specific activity of [3H]indatraline, 1.5 fmol [3H]indatraline would result in approximately 5 Bq, which is 
equivalent to 300 dpm (decays per min). Due to our experience concerning liquid scintillation counting 
a counting efficiency of approximately 25 % can be assumed for quantification of tritium in 96 well micro 
titer plates in conventional filtration based radioligand binding assays. As a consequence, for 1.5 fmol 
[3H]indatraline (i.e. 300 dpm) in the sample to be analyzed, a signal of 75 cpm (counts per min) can be 
expected (based on our experience concerning such samples a noise level of approximately 10 cpm 
can be assumed). 
 
 
Figure S2. One stereoisomer of the employed MS marker and a corresponding radioligand. 
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4 Further Applications 
Within the scope of cooperation over 50 compounds have been subjected to the screening. 
During this screening new inhibitors for the monoamine transporters were identified. Their 
potencies as well as selectivities were subsequently determined in competitive binding 
experiments. 
Based on these results the group intern division for routine analysis started an expanded 
screening investigating over 200 potential inhibitors.  
The results (along with the corresponding structure formulas of the compounds) obtained by 
this screening are still confidential and are therefore not included in this study.  
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5 Summary of the Thesis 
The biogenic monoamines, i.e. dopamine, norepinephrine, and serotonin, are important 
neurotransmitters, which act in the human brain as well as in the periphery. They control 
different functions, such as motor activity, attention, memory, sleep, but also mood. An 
imbalance of one of these neurotransmitter systems is considered to be associated with 
different mental disorders, e.g. depression. Even though there is a large number of different 
antidepressants, approximately 35 % of all depressive patient have no or no efficient response 
to their therapy. As a consequence there is a substantial need for new antidepressants. 
Nowadays, the human monoamine transporters, i.e. hDAT, hNET, and hSERT, are the most 
important targets for the treatment of depressions. 
Binding studies are an indispensable tool in drug discovery process. They provide information 
regarding the affinity of a test compound towards a specific target. Up to now, radioligand 
binding assays are mainly employed to investigate binding affinities of potential inhibitors 
towards hDAT, hNET, and hSERT. Unfortunately, this technique has considerable 
disadvantages due to use of radioactivity. 
It was the aim of the present thesis to develop MS Binding Assays addressing hDAT, hNET, 
and hSERT, which should serve as screening tool for the identification and characterization of 
potential monoamine transporter inhibitors utilizing one single marker for all three targets. 
The marker to be selected should have high affinity, ideally in the low nanomolar range, 
towards each of the monoamine transporters, i.e. hDAT, hNET, and hSERT. This requirement 
is fulfilled by Indatraline [rac-(1R,3S)-3-(3,4-dichlorophenyl)-
1-methylamino-2,3-dihydro-1H-indene], a known triple reuptake inhibitor, and was therefore 
chosen as marker for the intended purpose. 
From uptake studies a significant difference of the inhibitory potency in regard to the employed 
enantiomer, i.e (1R,3S)- and (1S,3R)-indatraline, is known for all three monoamine 
transporters, with (1R,3S)-indatraline being the eutomer. To be able to investigate the 
individual enantiomers in MS Binding Assays, the enantiopurity of the employed enantiomers 
had to be determined. Therefore, two analytical methods were developed. First, an 1H NMR 
spectroscopy method employing a chiral shift agent was established. With this method a 
determination of enantiopurities up to 98.9 % ee for both enantiomers, i.e. (1R,3S)- and 
(1S,3R)-indatraline, was feasible. The second method was based on HPLC utilizing a 
cyclodextrine based chiral stationary phase. Thereby, even higher enantiopurities, i.e. for 
(1R,3S)-indatraline up to 99.75 % ee and for (1S,3R)-indatraline up to 99.67 %  ee, could be 
determined. Additionally, the latter method was validated according to the ICH guidance 
Q2(R1) regarding specificity, accuracy, precision, linearity, and quantitation limit. 
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In parallel, MS Binding Assays were developed. A fundamental requirement therefore was a 
highly sensitive MS method that allowed the quantification of the chosen marker in biological 
samples. For this purpose, an API 5000 triple quadrupole mass spectrometer equipped with 
an ESI source for ionization was employed. As ESI ionization is prone to ion suppression 
caused by co-eluting matrix components, an LC method was developed that separates the 
analyte from the matrix by chromatography. Therefore, several parameters such as stationary 
and mobile phase, but also the injection volume and sample milieu were optimized. To allow a 
reliable quantification of the analyte, even in presence of traces of matrix, a poly-deuterated 
analogue of indatraline, (2H7)-indatraline, was employed as internal standard.  
In the next step a suitable setup was developed for the intended MS based binding studies, 
where several parameters such as incubation buffer, filter materials, washing buffer, and 
elution solvent were investigated regarding their influence on the binding of the analyte to the 
respective target, but also on the signal intensity and the signal-to-noise ratio in the MRM 
chromatogram.  
Afterwards, using matrix samples from MS Binding Assays, the developed LC-MS/MS method 
was validated according to the FDA guideline for bioanalytical methods regarding stability of 
the employed marker solutions, selectivity, calibration standard curve, the LLOQ, accuracy as 
well as precision. It could be demonstrated that the developed LC-MS/MS method allows a 
selective, accurate and precise quantification in a range of 5 pmol L-1 to 5 nmol L-1. 
Finally, using the established setup it was possible to characterize potential markers, i.e. the 
stereoisomers of indatraline, in MS Binding Assays. The respective results of saturation 
experiments confirm (1R,3S)-indatraline to be the almost equi-affine eutomer for all three 
transporters, i.e. hDAT, hNET, and hSERT, whereas the cis-configured diastereomer was 
found to be a highly selective SERT inhibitor. (1R,3S)-indatraline, the only stereoisomer having 
sufficient affinity towards all three targets, i.e. hDAT, hNET, and hSERT, was further 
characterized in kinetic studies. 
The full characterization of the binding properties of (1R,3S)-indatraline allowed its application 
as marker in competitive MS binding experiments addressing hDAT, hNET, and hSERT. In 
these experiments the affinities and selectivities of about 90 potential inhibitors were 
determined.  
For ten compounds the results could be compared with those obtained in radioligand binding 
assays under consistent conditions. This comparison demonstrated that the results from MS 
Binding Assays are in excellent agreement with those derived from radioligand binding assays. 
Therefore, the established MS Binding Assays represent a promising substitute for the so far 
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dominating radioligand binding assays widely employed to characterize affinity at monoamine 
transporters. 
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6 List of Abbreviations 
 
5-HT   serotonin 
cAMP   cyclic adenosine monophosphate 
CDER   center for drug evaluation and research 
cDNA   complementary deoxyribonucleic acid 
CNS   central nervous system 
COMT   catechol-O-methyltransferase 
CSA   chiral shift agent 
DA   dopamine 
DAT   dopamine transporter 
DNA   deoxyribonucleic acid 
ee   enantiomeric excess 
EL   extracellular loop 
ESI   electrospray ionization 
FDA   food and drug administration 
FRET   fluorescence resonance energy transfer 
FP   fluorescence polarization 
GPCR   G protein-coupled receptors 
HEK   human embryonic kidney 
HPLC   high-performance liquid chromatography 
IC50   half maximal inhibitory concentration 
ICH   international conference on harmonization 
Kd   equilibrium dissociation constant 
Ki   inhibition constant 
kobs   observed rate constant 
koff   dissociation rate constant 
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kon   association rate constant 
LeuT   leucine transporter 
MAO   monoamine oxidase 
mGAT1  murine Ȗ-aminobutyric acid transporter subtype 1 
mRNA   messenger ribonucleic acid 
NE   norepinephrine 
NET   norepinephrine transporter 
NDRI   norepinephrine and dopamine reuptake inhibitor 
NMR   nuclear magnetic resonance 
NRI   selective norepinephrine reuptake inhibitor 
NSS   neurotransmitter-sodium symporter 
NTT   neurotransmitter transporter 
SERT   serotonin transporter 
SLC   solute carrier 
SNRI   serotonin and norepinephrine reuptake inhibitor 
SPR   surface plasmon resonance 
SSRI   selective serotonin reuptake inhibitor 
t1/2   half life of the target-marker complex 
TCA   tricyclic antidepressant 
TEAA   triethylammonium acetate 
TM   transmembrane helices/segments 
VMAT   vesicular monoamine transporters 
7 REFERENCES 37 
7 References 
 
[1] H. P. Rang, M. M. Dale, J. M. Ritter, R. J. Flower, G. Henderson, Rang and Dale's 
Pharmacology, Seventh Edition ed., Elsevier Churchill Livingstone, 2012. 
[2] J. M. Beaulieu, R. R. Gainetdinov, Pharmacol Rev 2011, 63, 182-217. 
[3] D. L. Murphy, A. M. Andrews, C. H. Wichems, Q. Li, M. Tohda, B. Greenberg, J Clin 
Psychiatry 1998, 59 Suppl 15, 4-12. 
[4] B. P. Guiard, in Psychiatric Disorders (Ed.: T. Uehara), Intech open, 2011, pp. 291-
316. 
[5] E. R. Kandel, J. H. Schwartz, Second Edition ed., Elsevier Science Publishing, 1986. 
[6] O. Civelli, J. R. Bunzow, D. K. Grandy, Q. Y. Zhou, H. H. Van Tol, Eur J Pharmacol 
1991, 207, 277-286. 
[7] T. H. Svensson, B. S. Bunney, G. K. Aghajanian, Brain Res 1975, 92, 291-306. 
[8] L. J. Siever, R. M. Cohen, D. L. Murphy, Am J Psychiatry 1981, 138, 681-682. 
[9] S. Hjorth, H. J. Bengtsson, A. Kullberg, D. Carlzon, H. Peilot, S. B. Auerbach, J 
Psychopharmacol 2000, 14, 177-185. 
[10] H. Buschmann, J. L. Díaz, J. Holenz, A. Párraga, A. Torrens, J. M. Vela, Vol. 1, 
Wiley-VCH, 2007. 
[11] J. J. Schildkraut, Am J Psychiatry 1965, 122, 509-522. 
[12] I. P. Lapin, G. F. Oxenkrug, Lancet 1969, 1, 132-136. 
[13] P. Skolnick, P. Popik, A. Janowsky, B. Beer, A. S. Lippa, Life Sci 2003, 73, 3175-
3179. 
[14] D. Spinks, G. Spinks, Curr Med Chem 2002, 9, 799-810. 
[15] R. C. Shelton, J Clin Psychiatry 2004, 65 Suppl 17, 5-10. 
[16] S. A. Montgomery, J Clin Psychiatry 1998, 59 Suppl 14, 26-29. 
[17] J. W. Jefferson, J. F. Pradko, K. T. Muir, Clin Ther 2005, 27, 1685-1695. 
[18] W. D. Horst, S. H. Preskorn, J Affect Disord 1998, 51, 237-254. 
[19] N. Nelson, J Neurochem 1998, 71, 1785-1803. 
[20] A. S. Kristensen, J. Andersen, T. N. Jorgensen, L. Sorensen, J. Eriksen, C. J. Loland, 
K. Stromgaard, U. Gether, Pharmacol Rev 2011, 63, 585-640. 
[21] J. A. Moron, A. Brockington, R. A. Wise, B. A. Rocha, B. T. Hope, J Neurosci 2002, 
22, 389-395. 
[22] A. J. Eshleman, M. Carmolli, M. Cumbay, C. R. Martens, K. A. Neve, A. Janowsky, J 
Pharmacol Exp Ther 1999, 289, 877-885. 
[23] A. Yamashita, S. K. Singh, T. Kawate, Y. Jin, E. Gouaux, Nature 2005, 437, 215-223. 
[24] S. K. Singh, A. Yamashita, E. Gouaux, Nature 2007, 448, 952-956. 
[25] H. Krishnamurthy, E. Gouaux, Nature 2012, 481, 469-474. 
[26] L. Shi, M. Quick, Y. Zhao, H. Weinstein, J. A. Javitch, Mol Cell 2008, 30, 667-677. 
[27] M. Quick, L. Shi, B. Zehnpfennig, H. Weinstein, J. A. Javitch, Nat Struct Mol Biol 
2012, 19, 207-211. 
[28] C. L. Piscitelli, H. Krishnamurthy, E. Gouaux, Nature 2010, 468, 1129-1132. 
[29] A. Penmatsa, K. H. Wang, E. Gouaux, Nature 2013, 503, 85-90. 
[30] P. Plenge, E. T. Mellerup, Pharmacol Toxicol 1997, 80, 197-201. 
[31] F. Chen, M. B. Larsen, H. A. Neubauer, C. Sanchez, P. Plenge, O. Wiborg, J 
Neurochem 2005, 92, 21-28. 
[32] P. Plenge, U. Gether, S. G. Rasmussen, Eur J Pharmacol 2007, 567, 1-9. 
[33] P. Plenge, O. Wiborg, Neurosci Lett 2005, 383, 203-208. 
[34] F. Chen, M. B. Larsen, C. Sanchez, O. Wiborg, European neuropsychopharmacology 
: the journal of the European College of Neuropsychopharmacology 2005, 15, 193-
198. 
[35] H. Koldso, K. Severinsen, T. T. Tran, L. Celik, H. H. Jensen, O. Wiborg, B. Schiott, S. 
Sinning, J Am Chem Soc 2010, 132, 1311-1322. 
[36] J. Andersen, O. Taboureau, K. B. Hansen, L. Olsen, J. Egebjerg, K. Stromgaard, A. 
S. Kristensen, J Biol Chem 2009, 284, 10276-10284. 
7 REFERENCES 38 
[37] J. Andersen, N. Stuhr-Hansen, L. Zachariassen, S. Toubro, S. M. Hansen, J. N. 
Eildal, A. D. Bond, K. P. Bogeso, B. Bang-Andersen, A. S. Kristensen, K. 
Stromgaard, Proc Natl Acad Sci U S A 2011, 108, 12137-12142. 
[38] T. Beuming, L. Shi, J. A. Javitch, H. Weinstein, Mol Pharmacol 2006, 70, 1630-1642. 
[39] L. Celik, S. Sinning, K. Severinsen, C. G. Hansen, M. S. Moller, M. Bols, O. Wiborg, 
B. Schiott, J Am Chem Soc 2008, 130, 3853-3865. 
[40] P. Porzgen, S. K. Park, J. Hirsh, M. S. Sonders, S. G. Amara, Mol Pharmacol 2001, 
59, 83-95. 
[41] M. A. Cooper, Nat Rev Drug Discov 2002, 1, 515-528. 
[42] H. G. Vogel, 2nd ed., Springer, Berlin, 2002. 
[43] L. A. de Jong, D. R. Uges, J. P. Franke, R. Bischoff, J Chromatogr B Analyt Technol 
Biomed Life Sci 2005, 829, 1-25. 
[44] J. A. Maynard, N. C. Lindquist, J. N. Sutherland, A. Lesuffleur, A. E. Warrington, M. 
Rodriguez, S. H. Oh, Biotechnol J 2009, 4, 1542-1558. 
[45] M. Hess, G. Höfner, K. T. Wanner, ChemMedChem 2011, 6, 1900-1908. 
[46] G. Höfner, K. T. Wanner, Angew Chem Int Ed Engl 2003, 42, 5235-5237. 
[47] C. Zepperitz, G. Höfner, K. T. Wanner, ChemMedChem 2006, 1, 208-217. 
[48] K. Wanner, G. Höfner, Vol. 36, Wiley-VCH, 2007. 
[49] F. W. McLafferty, Annual review of analytical chemistry 2011, 4, 1-22. 
[50] A. P. Davenport, F. D. Russel, in Current Directions in Radiopharmaceutical 
Research and Development (Ed.: S. Mather), Springer, 1996, pp. 169-179. 
[51] A. A. Lammertsma, J. E. Leysen, L. Heylen, X. Langlois, Springer, 
SpringerReference. Available at: 
http://www.springerreference.com/docs/html/chapterdbid/169194.html. Accessed 01 
July 2014., 2012. 
[52] E. C. Hulme, Receptor Ligand Interactions - A Practical Approach, Oxford University 
Press, New York, 1992. 
[53] Y. Cheng, W. H. Prusoff, Biochem Pharmacol 1973, 22, 3099-3108. 
[54] D. M. Marks, C. U. Pae, A. A. Patkar, Curr Neuropharmacol 2008, 6, 338-343. 
[55] M. Hess, 2011. 
[56] U. S. FDA, Available at: 
http://www.fda.gov/downloads/Drugs/Guidances/ucm070107.pdf, 2001. 
[57] K. P. Bogeso, A. V. Christensen, J. Hyttel, T. Liljefors, J Med Chem 1985, 28, 1817-
1828. 
[58] H. M. L. Davies, T. M. Gregg, Tetrahedron Lett 2002, 43, 4951-4953. 
[59] K. Takatsu, R. Shintani, T. Hayashi, Angew Chem Int Ed Engl 2011, 50, 5548-5552. 
[60] J. G. Taylor, C. R. Correia, Journal of Organic Chemistry 2011, 76, 857-869. 
[61] H. M. Turner, J. Patel, N. Niljianskul, J. M. Chong, Org Lett 2011, 13, 5796-5799. 
[62] W. T. Wei, J. Y. Yeh, T. S. Kuo, H. L. Wu, Chemistry 2011, 17, 11405-11409. 
[63] K. Yoo, H. Kim, J. Yun, Chemistry 2009, 15, 11134-11138. 
[64] S. Roesner, J. M. Casatejada, T. G. Elford, R. P. Sonawane, V. K. Aggarwal, Org Lett 
2011, 13, 5740-5743. 
[65] J. S. Salsbury, P. K. Isbester, Magn Reson Chem 2005, 43, 910-917. 
[66] S. M. Brodkorb, bachelor thesis “Entwicklung und Validierung einer HPLC Methode 
zur Enantiomerentrennung von 1R,3S-  und 1S,3R- Indatralin an einer dimethylierten 
β-Cyclodextrin Phase”, Ludwig-Maximilians-Universität 2012. 
8 CURRICULUM VITAE 39 
8  Curriculum Vitae 
Stefanie Heidrun Grimm 
 
Personal data 
Date of birth:   January 7, 1986 
Place of birth:   Buchen (Odenwald) 
Nationality:   German 
 
Education 
01/2011 – 02/2015 PhD studies, Ludwig-Maximilians-Univerisität Munich, 
Department of Pharmacy, Medicinal Chemistry 
Supervisor: Professor Dr. Klaus T. Wanner 
12/2010   Licensed pharmacist (Approbation) 
10/2005 – 09/2009 Studies of pharmacy, Martin-Luther-Universität, Halle-Wittenberg, 
final degree: Second State Examination 
09/2002 – 07/2005  High School, Frankenlandschule Walldürn   
    graduation: Abitur 
 
Professional experience and academic training 
01/2011 – 02/2015 Academic assistant, Ludwig-Maximilians-Univerisität Munich, 
Department of Pharmacy, Medicinal Chemistry  
05/2010 – present  Temporary pharmacist, Die Odenwald Apotheke, Buchen (Odw.) 
11/2009 – 04/2010  Internship, Novartis Consumer Health, Munich  
08/2009 – 03/2009  Internship, Martin-Luther-Universität, Halle-Wittenberg 
    Department Pharmacy, Medicinal Chemistry and Bioanalytics 
08/2008 – 09/2008  Internship, Martin-Luther-Universität, Halle-Wittenberg  
    Department Pharmacy, Molecular Cell Biology 
